



(19) **United States**

(12) **Patent Application Publication**
FROST et al.

(10) **Pub. No.: US 2012/0237519 A1**
(43) **Pub. Date: Sep. 20, 2012**

(54) **PESTVIRUS SPECIES**

Publication Classification

(75) Inventors: **MELINDA JANE FROST,**
MACQUARIE LINKS (AU);
PETER DANIEL KIRKLAND,
CAMDEN (AU); **DEBORAH**
SUSAN FINLAISON, PICTON
(AU)

(51) **Int. Cl.**
C12N 15/40 (2006.01)
C12Q 1/70 (2006.01)
G01N 33/53 (2006.01)
A61K 39/42 (2006.01)
A61K 39/12 (2006.01)
C07K 16/10 (2006.01)
C12N 15/63 (2006.01)
C12P 21/02 (2006.01)
G01N 33/569 (2006.01)
A61P 31/14 (2006.01)
C12N 1/19 (2006.01)
C12N 1/15 (2006.01)
C12N 5/10 (2006.01)
C12N 1/21 (2006.01)
C07K 14/08 (2006.01)

(73) Assignee: **MINISTER FOR PRIMARY**
INDUSTRIES FOR AND ON
BEHALF OF THE STATE OF
NEW SOUTH WALES, SYDNEY
(AU)

(21) Appl. No.: **13/472,818**

(52) **U.S. Cl.** **424/139.1;** 536/23.72; 530/350;
435/5; 435/7.92; 424/186.1; 530/387.9; 435/320.1;
435/69.3; 424/159.1; 424/218.1; 435/349;
435/254.2; 435/254.11; 435/419; 435/348;
435/325; 435/252.3; 435/366; 435/252.33;
435/252.34; 435/252.31; 435/252.35; 435/362;
435/365

(22) Filed: **May 16, 2012**

Related U.S. Application Data

(63) Continuation of application No. 12/298,026, filed on
Jan. 15, 2009, now Pat. No. 8,202,977, filed as appli-
cation No. PCT/AU2007/000521 on Apr. 20, 2007.

(57) **ABSTRACT**

The application relates to a pestivirus, designated PMC virus,
that is associated with porcine myocarditis syndrome, and the
gene and protein sequences derived therefrom. The applica-
tion further relates to detection methods, vaccine therapeu-
tics, and diagnostic methods using the PMC virus or gene/
protein sequences derived therefrom.

(30) **Foreign Application Priority Data**

Apr. 21, 2006 (AU) 2006902089

Figure 1

gtataacgac	agtagttcaa	gtgtcgttat	gcatcattgg	ccataacaaa	ttatctaatt	60
tggaataggg	acctgcgacc	tgtacgaagg	ccgagcgtcg	gtagccattc	cgactagtag	120
gactagtagaca	aataggtcaa	ctggttgagc	aggtgagtg	gctgcagcgg	ctaagecgtg	180
agtacaccgt	attcgtcaac	agggtctact	ggaaaggatc	accactagc	gatgcctgtg	240
tggacgagga	catgtccaag	ccaatgttat	cagtagcggg	ggcgttact	gagaaagctg	300
cccagaatgg	gtagttgcac	atacagctctg	ataggatgcc	ggcggatgcc	ctgtattttg	360
accagtataa	atattatccg	ttgtaaagca	tatgaatact	tttactttta	atacatatgg	420
agggagtgag	gaaggaaaaca	tgttccttag	aactgcacc	acgccgccac	caggggtgcca	480
agaaccgggt	tacacaagca	caatgagacc	aatttttggc	gaaccccatc	cacctctaca	540
caaacacagc	acgttaaaat	tgccacattg	gagggggatc	aaaacaatta	gagttaagaa	600
gagagaattg	ccaaagaagg	gcgattgtag	caactcaaca	acagctccca	cttcgggggt	660
gtacggtgaa	ttaggggctg	tgttctataa	agattacacg	ggcacgggat	accatcgtgt	720
accgctagaa	ctttgtacaa	accaagagag	gtgcgaggga	tccaagtgtg	tagggagaat	780
gacagggctc	gatggcaggt	tgtacaacgt	tttagtatgt	ccggacgatt	gtatcctctt	840
tgagagacac	tgtagaggtc	aaacagctct	cctgaaatgg	atctccaacc	ccttgacatc	900
accactttgg	gtccagagtt	gttctgacga	caaaggagca	aaacccaagg	tgaacccaaa	960
agacgacag	atgaagcaag	gaaaaatagt	gacaaaagcct	aaagagactg	aagcagatca	1020
aaaaactaga	ccaccagatg	ccacgatagt	ggttgacggg	cagaagtatc	aggtgaggaa	1080
gaaggggaaa	gcgaaacca	agactcaaga	cggtttatac	cacaacaaga	acaaaccaga	1140
agcgtccagg	aagaagcttg	agaaggcctt	gctagcatgg	gcaatattag	cctgcctatt	1200
ggtggtaccg	gtaggggtcca	ccaacgtgac	acaatggaac	ttatgggaca	ataaaagtac	1260
tacagacata	catagcgtca	tgtttctag	agggattaaa	aggagtctgc	atggaatttg	1320
ccccacacaa	atctgcaaag	ggatccctac	acatctagca	gcagactatg	aactgaaaag	1380
gattcacggg	atggtggatg	caagcccat	gaccaacttc	acatgttcta	ggctacagag	1440
acatgagtg	aacaagcatg	ggtggtgcaa	ctggtacaat	atagagccgt	ggatcaatct	1500
catgataaat	acccaaggac	tattaaacac	tggagacaat	ttcactgagt	gcgcagtcac	1560
atgcaggtat	gatgcagact	taggggtgaa	tatagtgact	caagccagga	ctactccaac	1620
tatcctgact	gactgtaaga	aagggcacaa	cttctcttc	tcaggggagg	tcagggcctc	1680
accctgcaac	tttgagttaa	ctgctgaaga	cttgctcagg	atcatggatc	acaccaactg	1740
cgagggatth	acctacttcg	gggaaggaat	cggtgacggt	tacaccgagg	tagtagagaa	1800
ggccagggtca	agtggtttca	gggctctcac	atggttgtcg	agtaagattg	aaaacaccaa	1860
gaaaaaaata	tccggagctg	aagccagtc	ttactgccca	gtggctaaga	gggtcttcaa	1920
cattatthtat	accaacaatt	gcaccccgct	tggactgcca	gataagtcaa	aaattatagg	1980
accaggaacc	tttgacatca	gtggcaggg	tgaattcata	tttccaaaac	tcccctacca	2040
cgtagatgac	ttcattctac	tgagcttaat	tgcaatgtct	gattttgctc	cagagacatc	2100
aggtataatc	tacctggctt	tgcaactacc	aatgccaaat	aatgacaaca	gggacttctg	2160
gtaggacctg	gacccaaata	aactaaacct	tactgcaact	aaatccgtgg	caagtgtggg	2220
ccctacatcg	tggaatgtgt	tagtgtaatg	ggtgtgcctc	aaaccaagtt	ggtgcttca	2280
ttccgccgaa	atcactaatc	tgataggagg	tgtcatcacc	gtggcagact	tagttatcaa	2340
gaccattgaa	gaattgctaa	atthgtggac	cgaagcaaca	gctgtggcat	ttctggctgc	2400
tctaataaaa	atthtttagag	gccagccgat	ccaagcggta	gcatggttaa	tcatcatagg	2460
gggagcacaa	gcccaaacct	gcaaccctga	atcattgtac	gcattagcga	aaaataccag	2520
cataggttca	ttaggaccag	aatcactgac	gacaaggtgg	taccaactaa	ccagcggttt	2580
caaactcact	gacagcacga	ttgaagtac	ctgtgtgggt	gctaacaatga	ggattcatgt	2640
agtgtgcca	cttgtaagtg	acagatattt	ggccataaac	caccctagag	cactgccaac	2700
aacggcgtgg	ttcaggaaaa	tacacactca	gcatgaggta	ccaagagaaa	gaatcatgag	2760
tgagtcaaaa	aggaggtaca	cttgccttg	tgttctaaa	ccagtgggtga	ggtcaaacac	2820
acaattcaac	ccaatatcta	tatctacccc	aagctttgaa	cttgaatgcc	ctaggggttg	2880
gactggggct	gtagagtgtg	cactagtctc	cccataact	ctgacaacag	agactatatt	2940
cacatacagg	aagcccaaac	cattcggact	tgaaaactgg	tgcaagtata	cagtgggtga	3000
gaaagggatc	ctgtattctt	gtaaatthgg	gggcaattca	acatgcatca	aagggcttat	3060
agttaaaggg	caacgggaag	acaaagtaag	gtaactgtgaa	tgggtgtggt	ataagttcag	3120
ttcacccaat	ggaactgcctc	agtatccact	gggattgtgt	gagaaaagaac	aatcagaagg	3180
actcagggat	tatgggtgact	tcccctgctg	caacaacggc	acttgtattg	acaaagaagg	3240
tagtgtgcaa	tgctacatag	gggataagaa	agttaccgtg	aagctgtata	atgcctcact	3300
attggccccc	atgccctgca	aacccatagt	gtataactcc	caggggcccc	cagcgcctaa	3360
gacctgcact	tataggtggg	cctcaacatt	agaaaataaa	tattatgaac	ccagggacag	3420
ctactaccag	caatacatta	taaagtcagg	gtatcaatat	tggtttgatc	tcacagcaaa	3480

ggatcatgtg	gcagactgga	tcacaaaata	ctttccaata	ataatagtgg	cettggttagg	3540
gggcagaggc	accttgtggg	tgtttgatage	ttagtgagttg	ctaactcagt	atgaggtagt	3600
aggagacgag	aacatagtagg	ctcaagctga	agccctggta	atcggaaaca	tcttgatgag	3660
tttagactta	gagataatta	gctgcttcct	tctgttgttg	atcgtggtga	aaaaacaagc	3720
tgtcaggaga	acgttggcct	tactgtttca	ttggataact	atgaaccocat	tccagtcagt	3780
aatgatcaca	gtggtctact	tcgctcggttt	ggtgagggcc	gaagagggaa	ctaaagaggg	3840
tagtacaagc	ggggccacca	tccatgtagt	tgcaatactg	ttattcctct	tgaccacac	3900
agtgaagtat	aaggacttta	acatagcaat	gatcttactt	ataacattgt	ccctgaaaag	3960
ctcatcctac	atacatacca	gcttgtatga	aattccattg	cttgtggctg	taataagtct	4020
cacatgctcc	atatacattt	ttgacttgca	ggtaaagagc	aagctagtgg	ccccactat	4080
aggataaatt	ggagttacc	tagcaatgag	agttttgtgg	ctggtaaggc	aatgactat	4140
accaaccccc	tctgtgtcca	ttagtctgat	agatccaaag	atggtcataa	tactctactt	4200
gataccccta	actattacag	tcaatcacia	ctgagacctg	gcaagttatt	gcttgaaact	4260
gggacctttt	atcctatcat	tcctaacaat	gtgggtggat	gttgtcatcc	tcctgctcat	4320
gctgccttgg	tacgaactag	taaaagtcta	ctacataaaa	aagaagaaag	aggatgtgga	4380
aacatggttc	caaaattcag	gaatatccac	ccaagaaact	tcccatacag	gatttgattt	4440
ttctagcccc	ggggagggag	tgcacacact	aatccaaaat	aataaaacca	aattttgtag	4500
gactgcttac	atgactgtac	taagggcttt	ggtgataaca	gccatcagca	gtgtctggaa	4560
accaataaatt	ttagcagAAC	tcctaataga	ggcagtgtat	tggacacaca	ttaaaatagc	4620
caaagaattg	gcggggtcaa	gcaggttcgt	tgctaggttc	attgcatcta	ttatagagtt	4680
gaattggggc	atggacgaaa	aagaagcatc	tcgggtacaaa	agattttacc	tattatcatc	4740
caaaaataca	gatctaattg	taagcacia	aatccaaaat	gagacagtaa	aatcctgggt	4800
tgaaagaaact	gaaatatttg	gaatacaaaa	agtggcaatg	gtgalaaggg	ctcattctct	4860
gagtttggag	ccaaatgccA	tcctttgctc	cgtttgtgaa	gaaaaacaaa	atcaaaaagc	4920
caaaaggccc	tgccctaaGT	gtggtagtag	aggcactcaa	ataaagtgtg	ggctgacact	4980
ggccgagttt	gaggaagaac	attacaaaaa	aatatacatc	ctcgaaggcc	aagatgaaac	5040
tcccatgagg	aaagaagaaa	gacagcaagt	aacttatgtc	tctaggggtg	ctctgtctct	5100
taggaactctt	cctatcttag	cttcaaaaaa	caaataccta	cttgtaggca	atctgggtat	5160
ggaattgcaa	gatttggaAa	gtatgggatg	gatcattcga	gggccagccg	tctgcaagaa	5220
gataatacac	catgagaaat	gcaggccttc	aataccagac	aaactcatgg	cattctctgg	5280
gattatgcct	aggggagttA	caccaagagc	cctacacagc	ttcctctgtg	ccttgcctgaa	5340
gataagacgg	ggtttttgagA	ccggctgggc	ctacacacac	cctggagggg	taagtagtgt	5400
gatgcatgtc	accgctgggt	cggatatata	tgtcaatgac	tcaataggga	ggacaaaaat	5460
ccagtgccaa	gacaaaaaca	ctacaacaga	tgagtgtgaa	tatggtgtga	aaacagactc	5520
agggtgctct	gatggagctc	ggtgctatgt	catcaaccct	gaagcaacca	acatagcagg	5580
gaccaagggg	gccatggtaC	acctgaggaa	agctggagga	gagttcaact	gcgtgactgc	5640
ccagggtacc	ccgccttct	ataatctaaa	gaacttaaaa	ggatgggtcag	gcctgcctat	5700
ctttgaagct	gccacaggaa	gagtggtagg	aagggtaaaa	gcaggaaaaa	acactgacaa	5760
tgctccaaca	accattatgt	cagggacgca	agtggcaaaa	ccatcagagt	gtgacctaga	5820
atcagtgggtg	aggaaactag	agacaatgaa	cagaggggaa	ttcaaaacaag	tgactctggc	5880
tacaggcgca	gaaagacaa	ccatgctacc	aaagctgtta	atagaatcca	taggcaggca	5940
taagagagtg	ttagtactga	tcccgttgag	agctgcagcg	gaggggtgtg	accagtaecat	6000
gagaaccaaa	cacccaagca	tatctttcaa	cttgaggata	ggggatctga	aagaaggtga	6060
catggcaact	gggatcacct	atgcctctta	tgggtacttc	tgccaaatgg	acatgcctag	6120
actggagaat	gcaatgaagg	aataccacta	tattttcttg	gatgaaatc	actgtgccac	6180
accagaacag	ttggcagtgA	tgtcaaaaat	acataggttc	ggtgaaatcag	ttagggtaat	6240
agccatgacc	gccacgccat	ccgggactgt	gagcacaaca	gggcagaaat	tcacaattga	6300
ggaggtggta	gtacctgaag	tgatgaaggg	ggaggacctt	gctgatgatt	acatcgaaat	6360
agcagggttg	aaggtgccaa	agaaagagtt	agagggtaac	gtactgactt	ttgtgcctac	6420
aagggaagatg	gcatcggaaa	cagcaaaaaa	attaaccaca	cagggataca	atgctggata	6480
ctacttcagt	ggagaagatc	catcatccct	gcggacaact	acttctaagt	caccatatac	6540
agtagttgca	accaatgccA	ttgaatccgg	ggtaacctta	ccggaccttg	atacagtaat	6600
agatacaggc	atgaagtgtg	aaaagagact	aagaatcgaa	aacaaagctc	cctacatcgt	6660
aacaggactg	aaaagaatgg	ctataacaac	gggggagcaa	gctcaaaagaa	aaggtagggt	6720
aggcagggtt	aaacctggga	ggtacttgag	aggacctgaa	aacactgcag	tgaaaagga	6780
ctatcactat	gaccttttac	aggcacagag	gtacggcatc	caagactcaa	taaacatcac	6840
caagtctttc	acggagatga	actatgattg	ggcattatat	gaggaagacc	cgttaaagat	6900
tgcccaatta	gagttgctaa	acacactcct	gatctcaagg	gatctgcag	tagtaacaaa	6960
aaatctgatg	gcccgacaaa	cacatccoga	acctatacaa	ttggcttaca	atagttttaga	7020
aacccctgta	ccggtggcat	tcccaaaagt	gaaaaatgga	gaagtcaactg	acgcacatga	7080
aacttacgag	ttgatgacct	gtaggaagct	tgagaagac	ccccctatat	acctgtatgc	7140
aacagaagaa	gaagatctcg	tagtggacat	actgggattg	aaatggccag	acgccacaga	7200
gagggctgtc	ttggaagtgc	aagacgcctt	gggccagatc	acaggtttat	ctgcagggga	7260

Figure 1 (continued)

gacagcttta	ctcatagccc	tattaggggtg	gggtgggctac	gaagccttgg	tgaagaggca	7320
cgtgctctatg	gtgacagaca	tatacacccct	agaagatgaa	aaattggaag	caactacaca	7380
cctacaattt	gccccagatg	atctgaacaa	ttcagatacc	attgagctcc	aagacttatc	7440
gaatcaccaa	atccaacaaa	ttctagaagg	tgggaaggaa	tatgtcggcc	aagcctacca	7500
attcctcagg	ttgcaagctg	agagggctgc	caactcagac	aaaggcaaga	aagcaatggc	7560
agcggcccca	ttactagccc	acaagttcct	ggaatacttg	caagagcatg	caggtgacat	7620
aaagaagtat	gtctctaggg	gggtccacac	agcattgtat	aacagcataa	aagaaagact	7680
gggtcacgaa	actgcattcg	catctctggt	tataaaatgg	attgcctttt	cctcagatgg	7740
agtcocgggg	atgattaagc	aagcagcagt	agacttggtg	gtatactata	taatcaacag	7800
gcctgagtat	caaggggata	aggagacaca	gaatgcaggt	agacaatttg	ttggctccct	7860
ttttgtttca	tgtctagcag	agtacacatt	caaaaacttc	aataaatcag	cattagaagg	7920
attgatcgag	cctgccttaa	gctatctacc	ctacgcttca	agcgcactaa	agttattcct	7980
accgactaga	cttgaaagtg	tagtgatact	gtccactact	atatacagaa	catacttatc	8040
aatcaggaaa	ggacttagtc	agggtttagc	cgggctggca	gtagctcag	cgatggagat	8100
cattgaaccag	aaccocaatca	gcgtggctat	tgcaactggca	ctaggagtgc	gagcaatagc	8160
ggcacataat	gccattgaga	gcagtgaggc	aaaaaggact	ctcctgatga	aggtctttgt	8220
taagaacttt	ttggaccaag	cagccactga	tgagcttgtg	aaagagaacc	ctgagaagat	8280
cataatggca	gtglttgagg	gcattcaaac	agctggaaat	ccattgagac	ttgtatacca	8340
tctatatgca	atgltctaca	aaggtggac	tgccgaggaa	atagctgaaa	aaaccgctgg	8400
taggaaacatt	tttgtgtaa	caatatgtga	aggattggaa	atgltaggcc	tggatgcccga	8460
ctcaaaatgg	agaaaactga	gctctaatta	tcttattgat	gcagtgaaga	aaatcattga	8520
aaaaatgact	aaaacagcaa	caagcttcc	ctacagcttt	ttgaaactct	tgcttctctg	8580
cccctctctg	tgtactaaat	cagaaagaga	tccaagaata	gggtggcccc	aaaaagacta	8640
cgactacctc	gaggtccgat	gcgcttgtgg	gtataacagg	agagctataa	aaagagactc	8700
aggacctgtg	ttatgggaga	ccttagagga	gacgggtcca	gagtagctgc	acaacagagg	8760
tgaagggggg	ctcagcaatg	tgaagactac	tagatgcttt	gtccaaggag	aggaatccc	8820
tccaattgca	ctgagggaaag	gagtaggtga	gatgttggtc	aaggggtgtt	cattcagaat	8880
agatlttgat	aaagacaaga	tactttcaac	agacaagtgg	aaggtaccac	atagggcagt	8940
tacatcaatc	tttgaggatt	ggcaggggat	tggttacaga	gaggttacc	tagggaccaa	9000
accagactat	gggggtctgg	tgcccagatc	ttgtgtaact	gtaacaaaac	aagggttaac	9060
attccttgaaa	actgccaagag	geattgcttt	cacgactgac	ctgaccatcc	agaacatcaa	9120
aatgctgata	gctacatgct	tcaagaacaa	ggtgaaggaa	ggggagatac	cagctacgat	9180
tgaaggggaa	acatggatca	acataccact	agtgaatgag	gacaccggga	ccattaacc	9240
aagcttcggg	gaaagagtga	ttcccgaacc	atatgaggag	gacccacttg	aaggcccaag	9300
tgtaatcgtt	gaaaccaggag	gcatagccat	caaccaata	ggggtcaatc	cacaatccag	9360
tacatgtgga	acagttttta	cagcagtga	ggatctgtgc	caaacagtta	gtaataaagc	9420
caagaatatac	aaaattgggt	tttcgggaag	ccaataccca	gggtccagggg	ttgcaagaa	9480
gacactgaac	cagctcatac	aagatgaaga	ccccaaaaca	ttcataattg	tttgtggctc	9540
tgacaagtca	atgtctaatc	gggcaaaaac	tgcgaggaaac	atcaagagaa	tcaccaacc	9600
aacacctgag	aaattcagag	acttgcaaaa	aaacaagaaa	ttgataattg	tgctgttagg	9660
tgatagatac	catgaagata	tagaaaagta	tgcaacttc	aagggcacct	tcttgaccag	9720
acaaaccttg	gaagcactag	caagtgcaca	agctgtagag	aaggacatga	ccaagaaaga	9780
agcagcaaga	gtattggcaa	tggaaagaaa	ggatgaaacta	gaactcccag	gggtggctgca	9840
tacagatgca	cccaaatcc	tagacattac	taaggacaac	atcacacatc	acctaatagg	9900
ggacatgcag	agtctgagag	aaagagcagg	ggagatagga	gcaaaggcca	ccactcaaat	9960
cactaagaaa	gggagtgtat	acacaatcaa	tctgagtacg	tggtgggagt	cagagagggt	10020
ggcaatcttg	gaacctttgt	tccgggaact	actatctaaa	tgcaaggccag	tggacaggga	10080
gacatataag	aattgtcatt	ttgcaacagc	agoccaaact	gccggaggaa	actgggtacc	10140
ggtagcacca	gttgtaacatc	ttggggaaat	tccggtaaag	aagaaaaaga	ctctccccta	10200
cgaggcatac	aagctcctaa	aagagatggg	tgactcggag	aaggaattcc	ataaaccagt	10260
gagcagggaa	aaacaccaat	ggatactgaa	caaagtgaaa	actggtgggtg	acctcggctt	10320
aaaaaatcta	gtatgtccag	gtaggggttg	agaaccaatc	ctaagagaga	agaagaatt	10380
caacatttac	aacaagagga	ttaccagtac	tatgttatca	gtagggataa	ggccagaaaa	10440
attgccagtg	gtaagagccc	agaccagtac	caaagaattt	catgaagcaa	taagggacaa	10500
aatagacaaa	aaagcaaac	cacagacccc	agccctacac	aaagaattgt	tggagatatt	10560
caactcaata	tgtgccatcc	ccgaacttag	aaatacctac	aaagaggttg	attgggacgt	10620
totaacctca	ggcataaata	ggaaaggtgc	agccgggtac	ttcgaaaaaa	tgaacatagg	10680
ggagatcata	gatagtgaca	aaaaatcagt	ggaacaactc	ataaagagaa	tgaatcagg	10740
gctagaattc	aactactatg	agactgcaat	accaaaaaat	gagaagaggg	cagtggtaga	10800
tgattggatg	gaaggtgact	atgtagaaga	aaaaagacca	agagtcatac	agtatcctga	10860
ggcaaagatg	agattagcta	taaccaaggt	aatgtataac	tgggtcaagc	agaagcctat	10920
agtaatccct	ggatacgaag	gtaagactcc	tttgtttcat	gttttcgaca	aggtccacaa	10980
agaatggaaa	aatttcaaca	gtccagttgc	agtcagtttt	gacactaaag	cctgggacac	11040

Figure 1 (continued)

acaagtaaca	cccaaagacc	ttctcctcat	atcagaaatc	caaaagtatt	attacaagaa	11100
agaataccat	agattcatag	ataat ttgac	cgagaaaatg	gtggaggtag	cagtggtttg	11160
tgaagacgga	aacgtctaca	taagagaagg	tcagagggga	agtgggtcaac	cagacactag	11220
cgcaggtaat	agtatgttga	atgtactgac	tatgataat	gccttctgca	aagctaactc	11280
catcccttac	tcagccttcc	acagggtagc	aaagatacat	gtgtgtggag	atgatggttt	11340
cttgataact	gagaaaagt	ttggtgaggc	ctttgcgatc	aaggggcctc	aaat ttgat	11400
ggaagcagga	aaaccacaaa	aacttatagg	tgaat ttgga	ctgaaattgg	catataaatt	11460
tgatgacatt	gaat ttgct	cgcatacacc	aataaaggtc	aggtgggctg	acaacaacac	11520
atcatacatg	cccggaagag	acacagctac	cattctagct	aaaatggcaa	cccgccttga	11580
ctctagtggg	gagaggggga	ccgagggata	cgagctggcc	gtggccttca	gtttcttact	11640
aatgtattct	tggaaacccc	tggtagaag	aatatgcctg	cttgtcatgt	ctacaattga	11700
cacaaaagaa	gctagccaaa	ataacactat	atatacattt	aggggggac	ccataggtgc	11760
ctacacagag	gtaattgggt	ataggctgga	ccaaactaaa	cagacagagt	totctaaatt	11820
ggctcagctg	aatttg tcaa	tggcaatact	tcaaataac	aataaaaaa	caaccaagag	11880
actcatcgaa	gattgtgtga	aacttggcaa	ccaaaataag	caaataattgg	tgaatgcaga	11940
ccgtttgatc	agcaagaaaa	cgggctacac	atatgagcca	acagctggcc	acactaagat	12000
aggcaagcac	tatgaagaaa	tcaacctgct	gaagatata	ccacaaaaaa	ctgtctacca	12060
aggaactgaa	aggtata					12077

Figure 1 (continued)


Figure 2

GGSEEGNMFF	RTAPTPPPGC	QEPVYTSTMR	PIFGEPHPPL	HKHSTLKLPH	WRGIKTIRVK	60
KRELPKKGDC	SNSTTAPTSG	VYVELGAVFY	KDYTGTVYHR	VPLELCTNQE	RCEGSKCVGR	120
MTGSDGRLYN	VLVCPDDCIL	FERHCRGQTV	VLKWI SNPLT	SPLWVQSCSD	DKGAKPKVKP	180
KDDRMKQGGI	VTKPKETED	QKTRPPDATI	VVDGQKYQVR	KKGKAKPKTQ	DGLYHNKNKP	240
EASRKLLEKA	LLAWAILACL	LVPVPGSTNV	TQWNLWDNKS	TTDIHSVMFS	RGIKRSLHGI	300
WPTQICKGIP	THLAADYELK	RIHGMVDASP	MINFTCCRLQ	RHEWNKHGWC	NWYNIEPWIN	360
LMNNTQGLLN	TGDNFTECAV	TCRYDADLGV	NIVTQARTTP	TILTGCKKGH	NFSFSGEVRA	420
SPCNFELTAE	DLLRIMDHTN	CEGFTYFEGE	IVDGYTEVVE	KARSSGFRL	TWLSKIENT	480
KKKIFGAEAS	PYCPVAKRVF	NIIYTNNCTP	LGLPDKSKII	GPFTDISGR	DEFIFPRLPY	540
HVDDFILLSL	IAMSDFAPET	SSIIYLALHY	LMPSNDRDF	VMDLDPNKLN	LTATKSVASV	600
VPTSVNVLGE	WVCVKPSWWP	YSAETNLIG	GVITVADLVI	KTIEELNLW	TEATAVAFIA	660
ALIKIFRGQP	IQAVAWLIII	GGAQAQTCNP	BFMYALAKNT	SIGSLGPESL	TTRWYQLTSG	720
FKLPTDSTIEV	TCVGANMRIH	VVCPLVSDRY	LAINHPRALP	TFAWFRKIHT	QHEVPRRIM	780
SESKRRYTCP	CGSKPVVRS	TQFNPI SIST	PSFELECPRG	WTGAVECTLV	SPSTLTTEI	840
FTYRKPFPFG	LENWCYTVV	EKGILYSCKF	GGNSTCIKGL	IVKQREDKV	RYCEWCYKF	900
SSPNGLPQYP	LGLCEKEQSE	GLRDYGDVFC	CNNGT CIDKE	GSVQCYIGDK	KVTVKLYNAS	960
LLAPMFCWPI	VYNSQPPAP	KTCYRWAST	LENKYEPRD	SYQQYI IKS	GYQYWFDLTA	1020
KDHVADWTK	YFPIIIVALL	GGRGTIWLVI	AYELLTQYEV	VGDENIVAQA	EALVIGNILM	1080
SLDLEIISCF	LLLLIVVKKQ	AVRRTLALLF	HWITMNPFS	VMITVYVFG	LVRAEEGTKE	1140
GSTSGPPIHV	VAILLFLLYH	TVKYKDFNIA	MILLITLSLK	SSSYIHTSLY	ETPLLVAVIS	1200
LTCSIYIFDL	QVSKLVAPT	IGIIGVTIAM	RVLWLVQRMT	IPTPSVSISL	IDPKMVIILY	1260
LISLTTITVN	NLDLASCYCLK	LGPFI LSFLT	MWVDVILLLL	MLEPWEIVKV	YLLKKKKEDV	1320
ETWFQNSGIS	TQETSPYGF	FSSPGEVHT	LPMQNKTKFC	RTAYMTVIRA	LVITAISVW	1380
KPIILABELLI	BAVYWITHIKI	AKELAGSSRF	VARFIASIE	LNWAMDEKEA	SRYKRFYLLS	1440
SKITDLMVKH	KIQNETVKSW	FEETEIFGIQ	KVAMVIRAH	LSLEPNAILC	SVCEEKQNK	1500
AKRPFCKCGS	RGTQIKCGLT	LAEFBEHYK	KIYILEGQDE	TPMRKEERQQ	VTVVSRGALF	1560
LRNLPILASK	NKYLLVGNLG	MELQDLESMG	WIIRGPAVCK	KIIHHEKCRP	SIPDKLMAFF	1620
GIMPRGVTPR	APTRFPVSL	KIRRGFETGW	AYTHPGVSS	VMHVTAGSDI	YVNSDGRTK	1680
IQCQDKNTTT	DECEYGVKTD	SGCSDGARC	VINPEATNIA	GTKGAMVHLR	KAGGEFNCVT	1740
AQGTAFYNL	KNLKGWSGLP	IFEAAATGRVV	GRVKAGKNTD	NAPTTIMSGT	QVAKPSECDL	1800
ESVVRKLETM	NRGEFKQVTL	ATGAGKTML	PKLLIESIGR	HKRVLVLIPL	RAAAEGVYQY	1860
MRTKHPISIF	NLRIGDLKEG	DMATGITYAS	YGYFCQMDMP	RLENAMKEYH	YIFLDEYHCA	1920
TPEQLAVMSK	IHRFGBSVRV	TAMTATPSGT	VSTTGQKFTI	EEVVVPEVMK	GEDLADDYIE	1980
IAGLVKPKKE	LEGNVLTFFV	TRKMASETAK	KLTTQGYNAG	YFSGEDPSS	LRTTTSKSPY	2040
IVVAINAIES	GVTLPLDITV	IDTGMKCEKR	LRIENKAPYI	VTGLKRMAIT	TGBQAQRGR	2100
VGRVKPGRYL	RGPENTAGEK	DYHYDLLQAQ	RYGIQDSINI	TKSFREMYD	WALYEEDPLK	2160
IAQLELLNTL	LISRDLFVVT	KNLMAR'THP	EPIQLAYNSL	ETPVPVAFPK	VKNGEVTDH	2220
ETYELMTCRK	LEKDPPIYLY	ATEEEDLVVD	ILGLKWPDAT	ERAVLEVQDA	LGQITGLSAG	2280
ETALLIALLG	WVGYEALVKR	HVPMVTDIYT	LEDEKLEBTT	HLQFAPDDL	NSDTIELQDL	2340
SNHQIQQILE	GGKEYVQYAY	QFLRLQAERA	ANSDKGKKAM	AAAPLLAHKF	LEYLQEHAGD	2400
IKKYGLWGVH	TALYNSIKER	LGHETAFASL	VIKWIAFSSD	GVPGMIKQAA	VDLVVYYIIN	2460
RPEYQGDKET	QNAGRQFVGS	LFVVSCLAEYT	FKNFNKSAL	GLTEPALSYL	PYASSALKLF	2520
LPTRLESVVI	LSTTIYRTYL	SIRKSSSQGL	AGLAVSSAME	IMNQNPISVA	IALLALGVGAI	2580
AAHNAIESSE	AKRTLLMKVF	VKNFLDQAAT	DELVKENPEK	IIMAVFEGIQ	TAGNPLRLVY	2640
HLYAMFYKGW	TAAEIAEKTA	GRNIFVLTIF	EGLEMLGLDA	DSKWRNLSN	YLIDAVKKLI	2700
EKMTKTATSF	TYSFLKSLLP	APFSC TKSER	DPRIGWPQKD	YDYLEVRCAC	GYNRRAIKRD	2760
SGPVLWETLE	ETGPEYCHNR	GERGLSNVKT	TRCFVQGBE	PPIALRKGVG	EMLVKGVSF	2820
IDFDKDKILS	TDKWKVPHRA	VTSIFEDWQG	IGYREAYLGT	KPDYGGVLP	SCVTVTKQGL	2880
TFLKTARGMA	FTTDLTIQNI	KMLIATCFKN	KVKEGEIPAT	IEGETWINIP	LVNEDTGTIK	2940
PSFGERVIPE	PYEEDPLEGP	SVIVETGGIA	INQIGVNPQS	STCGTVFTAV	KDLCQTVSNK	3000
AKNIKIGFSE	GQYPGPGVAK	KTLNQLIQDE	DPKPFIFVCG	SDKSMSNRAK	TARNIKRIT	3060
TTPEKFRDLA	KNKLLIIVLL	GDRYHEDIEK	YADFKGTFILT	RQTFLEALASA	KAVEKDMTKK	3120
EAARVLAMEE	KDELELPGWL	HTDAPKFLDI	TKDNITHHLI	GDMQSLRERA	GEIGAKATTQ	3180
ITKKGSVYTI	NLSTWWSER	LASLEPLFRE	LLSKCRPVDR	ETYKNCHFAT	AAQLAGGNV	3240
VPAPVVHLGE	IPVKKKTLP	YEAYKLLKEM	VDSEKEFHKP	VSREKHQWIL	NKVKTGGDLG	3300
LKNLVCPRV	GEPILREKPK	FNIYKRLITS	TMLSVGLRPE	KLPPVRAQTS	TKEFHEAIRD	3360
KIDKKANTQT	PGLHKELLEI	FNSICAIPEL	RNTYKEVDWD	VLTSGINRKG	AAGYFEKMMI	3420
GEIIDSDDKS	VEQLIKRMKS	GLEFNYYETA	IPKNEKRAVV	DDWMEGDYVE	EKRPRVIOYP	3480

EAKMRLAITK	VMYNWKQKP	IVIPGYEGKT	PLFHVFDKVI	KEWKNFNSPV	AVSFDTKAWD	3540
TQVTPKDLLL	ISEIQKYYYK	KEYHRFIDNL	TEKMVEVPVV	CEDGNVYIRE	GQRGSGQPD	3600
SAGNSMLNVL	TMIYAFCKAN	SIPYSAFHRV	AKIHVCGDDG	FLITEKSFGE	AFAIKGPQIL	3660
MEAGKPQLI	GEFGLKLAYK	FDDIEFCSHT	PIKVRWADNN	TSYMPGRDTA	TILAKMATRL	3720
DSSGERGTEG	YELAVAFSFL	LMYSWNPLVR	RICLLVMSTI	DTKEASQNT	IYTFRGDPIG	3780
AYTEVIGYRL	DQLKQTEFSK	LAQLNLSMAI	LQIYNKNTTK	RLIEDCVKLG	NQNKQILVNA	3840
DRLISKKTGY	TYEPTAGHTK	IGKHYEELNL	LKDTPQKTVY	QGTERY		3886

Figure 2 (continued)

Figure 3



Keylist :

- PCR Product
- NADL Reference Sequence gi8626649
-{...}F or R Primers [...] indicates bp locations based on NADL sequence
R indicates reverse primer
F indicates forward primer

Figure 4




Figure 5A





Figure 5B

41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60



61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80



81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99




Figure 6A




Figure 6B

41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80



81 82 83 84 85 86 87



Figure 7A




Figure 7B




Figure 8A

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20



21 22 23 24 25 26 27 28 29 30 31 32 33




Figure 8B

34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53





Figure 9



PEPPILOT of: Pasted_No.2.1 ck: 2874, 1 to 3928 March 20, 2006 15:23




Figure 10

PESTIVIRUS SPECIES

FIELD OF THE INVENTION

[0001] The present invention relates to a novel pestivirus, and gene sequences derived from the same. The invention further relates to detection methods, vaccines, therapeutics, and diagnostic methods using the sequences of the present invention.

REFERENCE TO SEQUENCE LISTING

[0002] A Sequence Listing submitted as an ASCII text file via EFS-Web is hereby incorporated by reference in accordance with 35 U.S.C. §1.52(e). The name of the ASCII text file for the Sequence Listing is 13279926.TXT, the date of creation of the ASCII text file is May 16, 2012, and the size of the ASCII text file is 110 KB.

BACKGROUND ART

[0003] Pestiviruses cause highly contagious and often fatal diseases of pigs, cattle and sheep, which are characterised by damage to the respiratory and gastrointestinal tracts and immune system and can run an acute or chronic course. Infection of the reproductive system may cause embryonic and foetal death, congenital defects and the birth of persistently infected animals. Outbreaks of the diseases associated with pestivirus infections occur in many countries and can cause large economic losses.

[0004] The Pestivirus genus of the Flaviviridae comprises three structurally, antigenically and genetically closely related member species: Classical swine fever (CSF) or hog cholera (Francki et al. 1991. Flaviviridae, In the Fifth report of the International Committee on Taxonomy of Viruses, Archiv. Virol. Suppl. 2, Springer Verlag, Vienna p. 223-233); Bovine viral diarrhoea virus (BVDV) which mainly affects cattle, and Border disease virus (BDV) which mainly affects sheep (Moennig and Plagemann (1992) Adv. Virus Res. 41: 53-98; Moormann et al., (1990) Virology 177: 184-198; Becher et al. (1994) Virology 198: 542-551). Recent studies indicate that there may be several less well recognised viruses that warrant separate taxonomic classification, perhaps as separate species (Avalos-Ramirez et al (2001) Virology 286: 456-465)

[0005] The genomes of pestiviruses consist of a positive strand RNA molecule of about 12.5 kb (Renard et al. (1985) DNA 4: 429-438; Moormann and Hulst (1988) Virus Res. 11: 281-291; Becher et al. (1994) Virology 198: 542-551). However, the positive strand RNA genomes of several cytopathogenic BVDV strains may be considerably larger (Meyers et al. (1991) Virology 180: 602-616; Meyers et al. (1992) Virology 191: 368-386; Qi et al. (1992) Virology 189: 285-292).

[0006] An inherent property of viruses with a positive strand RNA genome is that their genomic RNA is infectious, i.e. after transfection of this RNA in cells that support viral replication, infectious virus is produced. As expected, the genomic (viral) RNA of pestiviruses is also infectious (Moennig and Plagemann, (1992) Adv. Virus Res. 41: 53-98).

[0007] In 2003 an outbreak of stillbirths and pre-weaning deaths of piglets occurred on two farms in New South Wales, Australia (McOrist et al, (2004) Aust Vet J. 82: 509-511). Key features of the clinical presentation and pathology findings suggested that this disease outbreak was novel and probably due to a virus. Extensive testing for known viruses and some bacteria failed to identify an aetiological agent. To avoid

confusion with other important diseases in pigs, the term "porcine myocarditis syndrome" (abbreviated as "PMC") was ascribed to the disease, and the term "PMC virus" given to presumptive agent. Subsequently, the causative agent was identified as a novel pestivirus. The name Bungowanah is proposed for this new virus.

[0008] The present invention addresses a need in the art for methods of detecting and/or treating infections caused by the novel PMC virus.

SUMMARY OF THE INVENTION

[0009] The invention provides an isolated RNA nucleotide sequence corresponding to the PMC virus nucleotide sequence depicted in SEQ ID NO:1, or sequences substantially homologous to SEQ ID NO:1, or fragments thereof.

[0010] The invention also provides the isolated DNA nucleotide sequence of the PMC virus of SEQ ID NO:1, or sequences substantially homologous to SEQ ID NO:1, or fragments thereof.

[0011] The invention further provides polypeptides encoded by the above RNA and DNA nucleotide sequences and fragments thereof, and/or an isolated PMC virus amino acid sequence as shown in SEQ ID NO: 2 and fragments thereof.

[0012] In another aspect, the invention provides methods for detecting the presence of a PMC virus amino acid sequence in a sample, comprising the steps of:

[0013] a) contacting a sample suspected of containing a PMC virus amino acid sequence with an antibody that specifically binds to the PMC virus amino acid sequence under conditions which allow for the formation of reaction complexes comprising the antibody and the PMC virus amino acid sequence; and

[0014] b) detecting the formation of reaction complexes comprising the antibody and PMC virus amino acid sequence in the sample, wherein detection of the formation of reaction complexes indicates the presence of PMC virus amino acid sequence in the sample.

[0015] The invention also provides methods for detecting the presence of a PMC virus antibody in a sample, comprising the steps of:

[0016] a) contacting a sample suspected of containing a PMC virus antibody with an amino acid sequence under conditions which allow for the formation of reaction complexes comprising the PMC virus antibody and the amino acid sequence; and

[0017] b) detecting the formation of reaction complexes comprising the antibody and amino acid sequence in the sample, wherein detection of the formation of reaction complexes indicates the presence of PMC virus antibody in the sample.

[0018] Additionally, the invention provides an in vitro method for evaluating the level of PMC virus antibodies in a biological sample comprising the steps of:

[0019] a) detecting the formation of reaction complexes in a biological sample according to the method noted above; and

[0020] b) evaluating the amount of reaction complexes formed, which amount of reaction complexes corresponds to the level of PMC virus antibodies in the biological sample.

[0021] The invention also provides an in vitro method for evaluating the level of PMC virus polypeptides in a biological sample comprising the steps of:

- [0022]** a) detecting the formation of reaction complexes in a biological sample according to the method noted above; and
- [0023]** b) evaluating the amount of reaction complexes formed, which amount of reaction complexes corresponds to the level of PMC virus polypeptide in the biological sample.
- [0024]** The present invention further provides methods for detecting the presence or absence of PMC virus in a biological sample, which comprise the steps of:
- [0025]** a) bringing the biological sample into contact with a polynucleotide probe or primer comprising a PMC virus polynucleotide of the invention under suitable hybridising conditions; and
- [0026]** b) detecting any duplex formed between the probe or primer and nucleic acid in the sample.
- [0027]** The present invention also relates to a method for the detection of PMC virus nucleic acids present in a biological sample, comprising:
- [0028]** a) amplifying the nucleic acid with at least one primer as defined above,
- [0029]** b) detecting the amplified nucleic acids.
- [0030]** The present invention also relates to a method for the detection of PMC virus nucleic acids present in a biological sample, comprising:
- [0031]** a) hybridizing the nucleic acids of the biological sample at appropriate conditions with one or more probes as defined above,
- [0032]** b) washing under appropriate conditions, and
- [0033]** c) detecting the hybrids formed.
- [0034]** In a further aspect, the present invention provides a method for the generation of antibodies comprising the steps of:
- [0035]** a) providing a PMC virus polypeptide sequence to a subject; and
- [0036]** b) collecting the antibodies generated in the subject against the polypeptide.
- [0037]** In another aspect of the invention, there is provided a vaccine composition comprising a PMC virus polypeptide or fragment thereof. The invention also provides a vaccine composition comprising a PMC virus nucleotide or fragment thereof that encodes for a PMC virus polypeptide.
- [0038]** Pharmaceutical compositions comprising a PMC virus polypeptide that enhances the immunocompetence of the host individual and elicits specific immunity against the PMC virus are further provided by the invention.
- [0039]** The present invention also provides therapeutic compositions comprising polynucleotide sequences and/or antibodies prepared against the polypeptides of the invention. The present invention further provides therapeutic compositions comprising PMC virus nucleic acid sequences as well as antisense and ribozyme polynucleotide sequences hybridisable to a polynucleotide sequence encoding a PMC virus amino acid sequence according to the invention.
- [0040]** The present invention provides for the use of PMC virus amino acid sequences and/or antibodies according to the invention, for manufacture of a medicament for modulation of a disease associated with PMC virus. The present invention additionally provides for the use of polynucleotide sequences of the invention, as well as antisense and ribozyme polynucleotide sequences hybridisable to a polynucleotide sequence encoding a PMC virus amino acid sequence according to the invention, for manufacture of a medicament for modulation of a disease associated with PMC virus.
- [0041]** The present invention further provides a method of inducing a protective immune response in an animal or human against PMC virus comprising the steps of:
- [0042]** a) administering to said animal or human an effective amount of a composition of the invention.
- [0043]** The present invention also provides methods for enhancing an animal's immunocompetence and the activity of its immune effector cells against a PMC virus comprising the step of:
- [0044]** a) administering a composition comprising a therapeutically effective amount of a PMC virus peptide or polypeptide.
- [0045]** In addition, the present invention provides a live vector comprising the PMC virus and a heterologous polynucleotide.
- [0046]** In another aspect of the invention, there is provided a method of screening for drugs comprising the steps of:
- [0047]** a) contacting an agent with a PMC virus amino acid sequence or fragment thereof
- [0048]** b) assaying for the presence of a complex between the agent and the PMC virus amino acid sequence or fragment.
- [0049]** The present invention also provides a method of screening for ligands of the proteins of the PMC virus comprising the steps of:
- [0050]** a) contacting a ligand with a PMC virus amino acid sequence or fragment thereof and
- [0051]** b) assaying for the presence of a complex between the PMC virus amino acid sequence or fragment and a ligand.
- [0052]** In a further aspect of the invention, a test kit may be prepared for the demonstration of the presence of PMC virus comprising:
- [0053]** (a) a predetermined amount of at least one labelled immunochemically reactive component obtained by the direct or indirect attachment of the present PMC virus amino acid sequence or a specific binding partner thereto, to a detectable label;
- [0054]** (b) other reagents; and
- [0055]** (c) directions for use of said kit.
- [0056]** Additionally, the invention provides a test kit for the demonstration of the presence of PMC virus comprising:
- [0057]** (a) a predetermined amount of at least one labelled antibody to the PMC virus;
- [0058]** (b) other reagents; and
- [0059]** (c) directions for use of said kit.
- [0060]** The invention also provides a test kit for the demonstration of the presence of PMC virus comprising:
- [0061]** (a) a predetermined amount of at least one labelled polypeptide derived from the PMC virus;
- [0062]** (b) other reagents; and
- [0063]** (c) directions for use of said kit.
- [0064]** Additionally the present invention provides a test kit prepared for the demonstration of the presence of PMC virus comprising:
- [0065]** (a) a predetermined amount of at least one labelled nucleic acid sequence derived from the PMC virus;
- [0066]** (b) other reagents; and
- [0067]** (c) directions for use of said kit.
- [0068]** The present invention also provides a recombinant expression vector comprising a PMC virus nucleic acid

sequence or a part thereof as defined above, operably linked to prokaryotic, eukaryotic or viral transcription and translation control elements.

[0069] The invention further relates to the hosts (prokaryotic or eukaryotic cells) which are transformed by the above mentioned vectors and recombinants and which are capable of expressing said RNA and/or DNA fragments.

[0070] The present invention also relates to a method for the production of a recombinant PMC virus polypeptide, comprising the steps of:

[0071] a) transforming an appropriate cellular host with a recombinant vector, in which a PMC virus polynucleotide sequence or a part thereof has been inserted under the control of appropriate regulatory elements,

[0072] b) culturing said transformed cellular host under conditions enabling the expression of said insert, and,

[0073] c) harvesting said polypeptide.

[0074] According to another embodiment the present invention provides methods for preparing a PMC virus amino acid sequence, comprising the steps of:

[0075] (a) culturing a cell containing a vector as described above under conditions that provide for expression of the PMC virus amino acid sequence; and

[0076] (b) recovering the expressed PMC virus sequence.

BRIEF DESCRIPTION OF THE DRAWINGS

[0077] FIG. 1 shows the DNA sequence (SEQ ID NO: 1) of the PMC virus of the present invention;

[0078] FIG. 2 shows the protein sequence (SEQ ID NO: 2) of the PMC virus of the present invention;

[0079] FIG. 3 shows a map of the location of primers used to sequence the whole virus, the dotted lines underneath are the length of the PCR products produced and sequenced;

[0080] FIG. 4 shows an ethidium bromide stained 0.8% gel of SISPA applied to DNA and RNA of adaptor PCR (run on Corbett and Eppendorf cyclers). Arrows indicate where gel was cut to collect bands for purification and cloning (e.g. ER1=Eppendorf PCR machine, RNA preparation, gel position 1). Lane 1 Eppendorf machine RNA SISPA 10 ul of PCR product; Lane 2 Eppendorf machine DNA SISPA 10 ul of PCR product; Lane 3 Eppendorf machine RNA SISPA 40 ul of PCR product; Lane 4 Eppendorf machine DNA SISPA 40 ul of PCR product; Lane 5 Eppendorf machine Blank 40 ul of PCR control; Lane 6 Corbett machine RNA SISPA 40 ul of PCR product; Lane 7 Corbett machine DNA SISPA 40 ul of PCR product; Lane 8 Corbett machine blank 40 ul of PCR product; Lane 9 100 bp marker.

[0081] FIG. 5 (A and B) show ethidium bromide stained 1% gels of SISPA applied to DNA and RNA simultaneously to screen colonies for inserts (e.g. ER31=Eppendorf PCR machine, RNA sample position 3 colony 1). Lane 1 ER31; Lane 2 ER32; Lane 3 ER33; Lane 4 ER34; Lane 5 ER35; Lane 6 ER36; Lane 7 ER37; Lane 8 ER38; Lane 9 ER39; Lane 10 ER310; Lane 11 ER311; Lane 12 ER312; Lane 13 Marker 100 bp; Lane 14 ER41; Lane 15 ER42; Lane 16 ER43; Lane 17 ER44; Lane 18 ER45; Lane 19 ER46; Lane 20 ER47; Lane 21 ER48; Lane 22 ER49; Lane 23 ER410; Lane 24 ER411; Lane 25 ER412; Lane 26 ER51; Lane 27 ER52; Lane 28 ER53; Lane 29 ER54; Lane 30 ER55; Lane 31 ER56; Lane 32 ER57; Lane 33 Marker 100 bp; Lane 34 ER58; Lane 35 ER59; Lane 36 ER510; Lane 37 ER511; Lane 38 ER512; Lane 39 ER61; Lane 40 ER62; Lane 41 ER63; Lane 42 ER64; Lane 43 ER65; Lane 44 ER66; Lane 45 ER67; Lane 46 ER68;

Lane 47 ER69; Lane 48 ER610; Lane 49 ER611; Lane 50 ER612; Lane 51 ER71; Lane 52 ER72; Lane 53 Marker 100 bp; Lane 54 ER73; Lane 55 ER74; Lane 56 ER75; Lane 57 ER76; Lane 58 ER77; Lane 59 ER78; Lane 60 ER710; Lane 61 ER711; Lane 62 ER712; Lane 63 ER81; Lane 64 ER82; Lane 65 ER83; Lane 66 ER84; Lane 67 ER85; Lane 68 ER86; Lane 69 ER87; Lane 70 ER88; Lane 71 ER89; Lane 72 ER810; Lane 73 Marker 100 bp; Lane 74 ER811; Lane 75 ER812; Lane 76 ER91; Lane 77 ER92; Lane 78 ER93; Lane 79 ER94; Lane 80 ER95; Lane 81 Marker 100 bp; Lane 82 ER96; Lane 83 ER97; Lane 84 ER98; Lane 85 ER99; Lane 86 ER910; Lane 87 ER911; Lane 88; Lane 89 ER102; Lane 90 ER103; Lane 91 ER104; Lane 92 ER105; Lane 93 ER106; Lane 94 ER107; Lane 95 ER108; Lane 96 ER109; Lane 97 ER1010; Lane 98 ER1011; Lane 99 ER1012.

[0082] FIG. 6 (A and B) show ethidium bromide stained 1% gels of PCR carried out to screen of colonies for DNA (Eppendorf cycler). Lane 1 ED21=Eppendorf machine, DNA gel cut out 2, colony 1; Lane 2 ED22; Lane 3 ED23; Lane 4 ED24; Lane 5 ED25; Lane 6 ED26; Lane 7 ED27; Lane 8 ED28; Lane 9 ED29; Lane 10 ED210; Lane 11 ED211; Lane 12 ED212; Lane 13 Marker 100 bp; Lane 14 ED31; Lane 15 ED32; Lane 16 ED33; Lane 17 ED34; Lane 18 ED35; Lane 19 ED36; Lane 20 ED37; Lane 21 ED38; Lane 22 ED39; Lane 23 ED310; Lane 24 ED311; Lane 25 ED312; Lane 26 ED41; Lane 27 ED42; Lane 28 ED43; Lane 29 ED44; Lane 30 ED45; Lane 31 ED46; Lane 32 ED47; Lane 33 Marker 100 bp; Lane 34 ED48; Lane 35 ED49; Lane 36 ED410; Lane 37 ED411; Lane 38 ED412; Lane 39 ED51; Lane 40 ED52; Lane 41 ED53; Lane 42 ED54; Lane 43 ED55; Lane 44 ED56; Lane 45 ED57; Lane 46 ED58; Lane 47 ED59; Lane 48 ED510; Lane 49 ED511; Lane 50 ED512; Lane 51 ED61; Lane 52 ED62; Lane 53 ED63; Lane 54 ED64; Lane 55 ED65; Lane 56 ED66; Lane 57 ED67; Lane 58 ED68; Lane 59 ED69; Lane 60 Marker 100 bp; Lane 61 ED610; Lane 62 ED611; Lane 63 ED612; Lane 64 ED71; Lane 65 ED72; Lane 66 ED73; Lane 67 ED74; Lane 68 ED75; Lane 69 ED76; Lane 70 ED77; Lane 71 ED78; Lane 72 ED79; Lane 73 ED710; Lane 74 ED711; Lane 75 ED712; Lane 76 ED81; Lane 77 ED82; Lane 78 ED83; Lane 79 ED84; Lane 80 ED85; Lane 81 ED86; Lane 82 ED87; Lane 83 ED88; Lane 84 ED89; Lane 85 ED810; Lane 86 ED811; Lane 87 ED812.

[0083] FIG. 7 (A and B) show ethidium bromide stained 1% gels of PCR carried out to screen of colonies for RNA inserts (Corbett cycler). Lane 1 CR21=Corbett machine, RNA gel position 2, colony 1; Lane 2 CR22; Lane 3 CR23; Lane 4 CR24; Lane 5 CR25; Lane 6 CR26; Lane 7 Marker 100 bp; Lane 8 Marker 100 bp; Lane 9 CR27; Lane 10 CR28; Lane 11 CR29; Lane 12 CR210; Lane 13 CR211; Lane 14 CR212; Lane 15 CR31; Lane 16 CR32; Lane 17 CR33; Lane 18 CR34; Lane 19 CR35; Lane 20 CR36; Lane 21 CR37; Lane 22 CR38; Lane 23 CR39; Lane 24 CR310; Lane 25 CR311; Lane 26 CR312; Lane 27 Marker 100 bp; Lane 28 Marker 100 bp; Lane 29 CR41; Lane 30 CR42; Lane 31 CR43; Lane 32 CR44; Lane 33 CR45; Lane 34 CR46; Lane 35 CR47; Lane 36 CR48; Lane 37; CR49; Lane 38 CR410; Lane 39 CR411; Lane 40 CR412; Lane 41 marker 100 bp; Lane 42 marker 100 bp; Lane 43 CR51; Lane 44 CR52; Lane 45 CR53; Lane 46 CR54; Lane 47 CR55; Lane 48 CR56; Lane 49 CR57; Lane 50 CR58; Lane 51 CR59; Lane 52 CR510; Lane 53 CR511; Lane 54 PCR Blank control; Lane 55 marker 100 bp.

[0084] FIG. 8 (A and B) show ethidium bromide stained 1% gels of PCR carried out to screen colonies for DNA (Corbett cycler). Lane 1 marker 100 bp; Lane 2 CD3 1=Corbett machine, DNA gel cut out 3, colony 1; Lane 3 CD3 2; Lane 4 CD3 3; Lane 5 CD3 4; Lane 6 CD3 5; Lane 7 CD3 6; Lane 8 CD3 7; Lane 9 CD3 8; Lane 10 CD3 9; Lane 11 CD3 10; Lane 12 CD3 11; Lane 13 CD3 12; Lane 14 CD4 1; Lane 15 CD4 2; Lane 16 CD4 3; Lane 17 CD4 4; Lane 18 CD4 5; Lane 19 CD4 6; Lane 20 marker 100 bp; Lane 21 marker 100 bp; Lane 22 CD4 7; Lane 23 CD4 8; Lane 24 CD4 9; Lane 25 CD4 10; Lane 26 CD4 11; Lane 27 CD4 12; Lane 28 CD5 1; Lane 29 CD5 2; Lane 30 CD5 3; Lane 31 CD5 4; Lane 32 CD5 5; Lane 33 CD5 6; Lane 34 CD5 7; Lane 35 CD5 8; Lane 36 CD5 9; Lane 37 CD5 10; Lane 38 CD5 11; Lane 39 CD5 12; Lane 40 marker 100 bp; Lane 41 marker 100 bp; Lane 42 CD6 1; Lane 43 CD6 2; Lane 44 CD6 3; Lane 45 CD6 4; Lane 46 CD6 5; Lane 47 CD6 6; Lane 48 CD6 7; Lane 49 CD6 8; Lane 50 CD6 9; Lane 51 CD6 10; Lane 52 CD6 11; Lane 53 CD6 12.

[0085] FIG. 9 shows an ethidium bromide stained 1.5% gel of PCR carried out to confirm authenticity of viral sequence for virus confirmation by nRT-PCR. PCR results confirmed the presence of Pestivirus in clinical specimens (lanes 3, 8 and 23) while EMCV was not present (lane 28) (lanes marked + are PCR positive). Lane 1 Marker 100 bp; Lane 2 Blank CR39 primers; Lane 3 SISPA sera CR39 primers; Lane 4 NADL +ve control CR39 primers; Lane 5 EMCV -ve control CR39 primers; Lane 6; Lane 7 Blank ER510 primers; Lane 8 SISPA sera ER510 primers; Lane 9 NADL +ve control ER510 primers; Lane 10 EMCV -ve control ER510 primers; Lane 11; Lane 12 Blank ER55 primers; Lane 13 SISPA sera ER55 primers; Lane 14 NADL +ve control ER55 primers; Lane 15 EMCV -ve control ER55 primers; Lane 16; Lane 17; Lane 18; Lane 19; Lane 20 Marker 100 bp; Lane 21 Marker 100 bp; Lane 22 Blank ER62 primers; Lane 23 SISPA sera ER62 primers; Lane 24 NADL +ve control ER62 primers; Lane 25 EMCV -ve control ER62 primers; Lane 26; Lane 27 Blank ER41 primers; Lane 28 SISPA sera ER41 primers; Lane 29 NADL +ve control ER41 primers; Lane 30 EMCV -ve control ER41 primers; Lane 31; Lane 32; Lane 33; Lane 34; Lane 35; Lane 36; Lane 37; Lane 38; Lane 39; Lane 40 marker 100 bp.

[0086] FIG. 10 shows a hydrophobicity plot of the PMC virus protein sequence.

DETAILED DESCRIPTION OF THE INVENTION

New Pestivirus

[0087] In accordance with this invention, a new pestivirus has been discovered that differs genetically from known pestiviruses. The new virus is characterised by the RNA sequence corresponding to that shown in SEQ ID NO: 1. The sequence has been deposited as Genbank reference EF100713.

[0088] The new virus is hereinafter generally referred to as PMC virus and the condition caused by infection with the PMC virus is PMC.

[0089] The PMC virus genome comprises a single open reading frame (ORF), encoding a number of genes. The genes encoded by the ORF of PMC correspond to those of other pestiviruses, being the Npro, capsid, E0, E1, E2, P7, NS2, NS3, NS4A, NS4B, NS5A and NS5B genes.

[0090] The PMC virus is approximately 40% similar to other pestiviruses on a nucleic acid sequence level. At the

protein level, PMC virus has 46-71% identity and 63-83% similarity with other pestiviruses. A comparative analysis of both the nucleic acid and deduced amino acid sequences would suggest that PMC virus is sufficiently unique to warrant consideration for classification as a new species within the pestivirus genus.

Open Reading Frames, Encoded Genes, Features of RNA Genomes

[0091] The nucleotide sequence of SEQ ID NO:1 encodes a single ORF encoding a number of different genes. The genes encoded by SEQ ID NO:1 correspond to the Npro, capsid, E0, E1, E2, P7, NS2, NS3, NS4A, NS4B, NS5A and NS5B genes of other pestiviruses.

[0092] The approximate location of the genes of PMC, based on sequence comparison with gi12657941, is indicated in Table 1.

TABLE 1

Location of proteins within PMC nucleic acid open-reading frame.	
PROTEIN	APPROXIMATE DNA POSITION
NPro	419-922
Capsid	923-1219
E0	1220-1885
E1	1886-2473
E2	2474-3604
P7	3605-3820
NS2	3821-5224
NS3	5225-7252
NS4A	7253-7441
NS4B	7442-8482
NS5A	8483-9997
NS5B	9998-12077

TABLE 2

Location of proteins within PMC protein open-reading frame.	
PROTEIN	APPROXIMATE AMINO ACID POSITION
NPro	1-167
Capsid	168-267
E0	268-489
E1	490-685
E2	686-1062
P7	1063-1134
NS2	1135-1602
NS3	1603-2278
NS4A	2279-2341
NS4B	2342-2688
NS5A	2689-3193
NS5B	3194-3886

Nucleic Acid Sequences

RNA

[0093] The invention provides an isolated RNA nucleotide sequence corresponding to the PMC virus nucleotide sequence depicted in SEQ ID NO:1, or sequences substantially homologous to SEQ ID NO:1, or fragments thereof. The invention further provides an RNA sequence comprising the complement of the PMC virus RNA genome, or fragments thereof.

[0094] The RNA sequence may also correspond to a fragment of SEQ ID NO:1. Preferably, the fragment is selected from the following locations of SEQ ID NO:1: position 419-922, 923-1219, 1220-1885, 1886-2473, 2474-3604, 3605-3820, 3821-5224, 5225-7252, 7253-7441, 7442-8482, 8483-9997, 9998-12077. Alternatively, the fragment may be selected from any one of SEQ ID NOs:3-15.

[0095] Substantial homology or identity exists when a PMC virus polynucleotide sequence or fragment thereof will hybridise to another PMC virus polynucleotide (or a complementary strand thereof) under selective hybridisation conditions.

[0096] Selective hybridisation may be under low, moderate or high stringency conditions, but is preferably under high stringency.

[0097] Typically, selective hybridisation will occur when there is at least about 55% identity over a stretch of at least about 14 nucleotides, preferably at least about 65%, more preferably at least about 75% and most preferably at least about 90%. The length of homology comparison, as described, may be over longer stretches and in certain embodiments will often be over a stretch of at least about nine nucleotides, usually at least about 20 nucleotides, more usually at least about 24 nucleotides, typically at least about 28 nucleotides, more typically at least about 32 nucleotides and preferably at least about 36 or more nucleotides.

[0098] Thus, the polynucleotide sequences of the invention preferably have at least 75%, more preferably at least 85%, more preferably at least 90% homology to the sequences shown in the sequence listings herein. More preferably there is at least 95%, more preferably at least 98%, homology. Nucleotide homology comparisons may be conducted as described below for polypeptides. A preferred sequence comparison program is the GCG Wisconsin Bestfit program.

[0099] In the context of the present invention, a homologous sequence is taken to include a nucleotide sequence which is at least 60, 70, 80 or 90% identical, preferably at least 95 or 98% identical at the nucleic acid level over at least 20, 50, 100, 200, 300, 500 or 819 nucleotides with the corresponding nucleotide sequences set out in SEQ ID NO:1. In particular, homology should typically be considered with respect to those regions of the sequence that encode contiguous amino acid sequences known to be essential for the function of one or more of PMC virus proteins, rather than non-essential neighbouring sequences.

[0100] PMC virus polynucleotide sequence fragments of the invention will preferably be at least 15 nucleotides in length, more preferably at least 20, 30, 40, 50, 100 or 200 nucleotides in length. Generally, the shorter the length of the polynucleotide sequence, the greater the homology required to obtain selective hybridisation. Consequently, where a polynucleotide sequence of the invention consists of less than about 30 nucleotides, it is preferred that the percentage identity is greater than 75%, preferably greater than 90% or 95% compared with the polynucleotide sequences set out in the sequence listings herein. Conversely, where a polynucleotide sequence of the invention consists of, for example, greater than 50 or 100 nucleotides, the percentage identity compared with the polynucleotide sequences set out in the sequence listings herein may be lower, for example greater than 50%, preferably greater than 60 or 75%.

[0101] Nucleic acid sequences according to the present invention which are homologous to the sequences as represented by a SEQ ID NO: 1 can be characterized and isolated

according to any of the techniques known in the art, such as amplification by means of sequence-specific primers, hybridization with sequence-specific probes under more or less stringent conditions, serological screening methods or via the LiPA typing system.

DNA

[0102] The DNA of the new PMC virus also is provided. The DNA sequence is preferably derived from the RNA sequences described above. Most preferably, the DNA sequence is that shown in SEQ ID NO: 1 or fragments thereof.

[0103] The invention also provides DNA fragments hybridisable with the genomic RNA of PMC. The DNA or DNA fragment sequence may be derived from the cDNA sequence of the PMC virus or fragments thereof. The DNA, cDNA or fragments thereof may be in the form of recombinant DNAs.

[0104] The DNA sequence may also be a fragment of SEQ ID NO:1. Preferably, the fragment is selected from the following locations of SEQ ID NO:1: position 419-922, 923-1219, 1220-1885, 1886-2473, 2474-3604, 3605-3820, 3821-5224, 5225-7252, 7253-7441, 7442-8482, 8483-9997, 9998-12077.

Variant Nucleic Acids

[0105] Nucleic acid sequences and fragments, which would include some deletions or mutations which would not substantially alter their ability to hybridizing with the genome of PMC virus, are also provided by the present invention. Such variants are to be considered as forming obvious equivalents of the RNA, DNA or fragments referred to above.

[0106] Other preferred variant nucleic acid sequences of the present invention include sequences which are redundant as a result of the degeneracy of the genetic code compared to any of the above-given nucleic acid sequences of the present invention. These variant nucleic acid sequences will thus encode the same amino acid sequences as the nucleic acid sequences they are derived from. Preferably, the RNAs of these variants, and the related cDNAs derived from said RNAs, are hybridisable to corresponding parts of the RNA and cDNA of PMC virus.

[0107] Also included within the present invention are sequence variants of the DNA sequence of SEQ ID NO: 1 or corresponding RNA sequence or fragments thereof, containing either deletions and/or insertions of one or more nucleotides, especially insertions or deletions of 1 or more codons.

[0108] Also included are substitutions of some non-essential nucleotides by others (including modified nucleotides and/or inosine).

[0109] Particularly preferred variant polynucleotides of the present invention also include sequences which hybridise under stringent conditions with any of the nucleic acid sequences of the present invention. Thus, sequences which show a high degree of homology (similarity) to any of the nucleic acid sequences of the invention as described above are preferred. Particularly preferred are sequences which are at least 80%, 85%, 90%, 95% or more homologous to said nucleic acid sequences of the invention. Preferably, said sequences will have less than 20%, 15%, 10%, or 5% variation of the original nucleotides of said nucleic acid sequences.

Probes and Primers

[0110] Primer and probes are further provided, which can be made starting from any RNA or DNA sequence or

sequence fragment according to the invention. Preferably, such probes or primers are between about 5 to 50 nucleotides long, more preferably from about 10 to 25 nucleotides. Probes and primers of the present invention may be used in PCR, sequencing reactions, hybridisation reactions and other applications known to the skilled person.

[0111] The present invention also relates to an oligonucleotide primer comprising part of SEQ ID NO: 1, said primer being able to act as a primer for specifically amplifying the nucleic acid of the PMC virus. Preferably, the primer is a single stranded DNA oligonucleotide sequence capable of acting as a point of initiation for synthesis of a primer extension product which is complementary to the nucleic acid strand to be copied. The specific length and sequence of the primer used will depend on the complexity of the required DNA or RNA targets, as well as on the conditions of primer use, such as temperature and ionic strength. The fact that amplification primers do not have to match exactly with corresponding template sequence to warrant proper amplification is amply documented in the literature (Kwok et al., 1990).

[0112] The amplification method used can be either polymerase chain reaction (PCR; Saiki et al., 1988), ligase chain reaction (LCR; Landgren et al., 1988; Wu & Wallace, 1989; Barany, 1991), nucleic acid sequence-based amplification (NASBA; Guatelli et al., 1990; Compton, 1991), transcription-based amplification system (TAS; Kwok et al., 1989), strand displacement amplification (SDA; Duck, 1990; Walker et al., 1992) or amplification by means of Q β replicase (Lizardi et al., 1988; Lomeli et al., 1989) or any other suitable method to amplify nucleic acid molecules using primer extension. During amplification, the amplified products can be conveniently labelled either using labelled primers or by incorporating labelled nucleotides. Labels may be isotopic (³²P, ³⁵S, etc.) or non-isotopic (biotin, digoxigenin, etc.). The amplification reaction is repeated between 20 and 70 times, advantageously between 25 and 45 times.

[0113] The present invention also relates to an oligonucleotide probe comprising part of SEQ ID NO:1, with said probe being able to act as a hybridisation probe for the PMC virus. Preferably, the probe can be used for specific detection and/or classification into types and/or subtypes of PMC virus. Preferably, the probe is a single stranded sequence-specific oligonucleotide sequence which has a sequence that is complementary to the target sequence of the PMC virus to be detected.

[0114] Those skilled in the art will recognise that the stringency of hybridisation will be affected by such conditions as salt concentration, temperature, or organic solvents, in addition to the base composition, length of the complementary strands and the number of nucleotide base mismatches between the hybridising nucleic acids. Stringent temperature conditions will generally include temperatures in excess of 30° C., typically in excess of 37° C., and preferably in excess of 45° C. Stringent salt conditions will ordinarily be less than 1000 mM, typically less than 500 mM, and preferably less than 200 mM. However, the combination of parameters is much more important than the measure of any single parameter. An example of stringent hybridisation conditions is 65° C. and 0.1 \times SSC (1 \times SSC=0.15 M NaCl, 0.015 M sodium citrate pH 7.0).

[0115] Optionally, the probe of the invention is labelled and/or attached to a solid substrate. The solid substrate can refer to any substrate to which an oligonucleotide probe can

be coupled, provided that it retains its hybridization characteristics and provided that the background level of hybridization remains low. Usually the solid substrate will be a microtiter plate, a membrane (e.g. nylon or nitrocellulose) or a microsphere (bead). Prior to application to the membrane or fixation it may be convenient to modify the nucleic acid probe in order to facilitate fixation or improve the hybridization efficiency. Such modifications may encompass homopolymer tailing, coupling with different reactive groups such as aliphatic groups, NH₂ groups, SH groups, carboxylic groups, or coupling with biotin or haptens.

[0116] The probes of the invention may include also an isolated polynucleotide attached to a label or reporter molecule and may be used to isolate other polynucleotide sequences, having sequence similarity by standard methods. For techniques for preparing and labelling probes see, e.g. Sambrook et al., (1989) or Ausubel et al., (2001).

[0117] Oligonucleotides according to the present invention and used as primers or probes may also contain or consist of nucleotide analogues such as phosphorothioates (Matsukura et al., 1987), alkylphosphorates (Miller et al., 1979) or peptide nucleic acids (Nielsen et al., 1991; Nielsen et al., 1993) or may contain intercalating agents (Asseline et al., 1984). The introduction of these modifications may be advantageous in order to positively influence characteristics such as hybridization kinetics, reversibility of the hybrid-formation, biological stability of the oligonucleotide molecules, etc.

[0118] Recombinant DNAs containing fragments of the DNA sequence of PMC virus are also provided by the present invention, and may be used as, for example, probes. Preferably, the plasmid used to generate the recombinant DNA is a plasmid amplifiable in prokaryotic or eukaryotic cells and carrying said fragments. For example, using cloned DNA containing a DNA fragment of PMC virus as a molecular hybridization probe, either by marking with radionucleotides or with fluorescent reagents, PMC virus RNA may be detected directly, for example, in blood, body fluids and blood products.

Nucleic Acid Arrays

[0119] PMC virus polynucleotide sequences (preferably in the form of probes) may also be immobilised to a solid phase support for the detection of PMC virus. Alternatively the PMC virus polynucleotide sequences will form part of a library of DNA molecules that may be used to detect simultaneously a number of different genes from PMC virus. In a further alternate form of the invention, PMC virus polynucleotide sequences together with other polynucleotide sequences (such as from other bacteria or viruses) may be immobilised on a solid support in such a manner permitting identification of the presence of PMC virus and/or any of the other polynucleotide sequences bound onto the solid support.

[0120] Techniques for producing immobilised libraries of DNA molecules have been described in the art. Generally, most prior art methods describe the synthesis of single-stranded nucleic acid molecule libraries, using for example masking techniques to build up various permutations of sequences at the various discrete positions on the solid substrate. U.S. Pat. No. 5,837,832 describes an improved method for producing DNA arrays immobilised to silicon substrates based on very large scale integration technology. In particular, U.S. Pat. No. 5,837,832 describes a strategy called "tiling" to synthesize specific sets of probes at spatially defined locations on a substrate that may be used to produce the

immobilised DNA libraries of the present invention. U.S. Pat. No. 5,837,832 also provides references for earlier techniques that may also be used. Thus polynucleotide sequence probes may be synthesised in situ on the surface of the substrate.

[0121] Alternatively, single-stranded molecules may be synthesised off the solid substrate and each pre-formed sequence applied to a discrete position on the solid substrate. For example, polynucleotide sequences may be printed directly onto the substrate using robotic devices equipped with either pins or pizo electric devices.

[0122] The library sequences are typically immobilised onto or in discrete regions of a solid substrate. The substrate may be porous to allow immobilisation within the substrate or substantially non-porous, in which case the library sequences are typically immobilised on the surface of the substrate. The solid substrate may be made of any material to which polypeptides can bind, either directly or indirectly. Examples of suitable solid substrates include flat glass, silicon wafers, mica, ceramics and organic polymers such as plastics, including polystyrene and polymethacrylate. It may also be possible to use semi-permeable membranes such as nitrocellulose or nylon membranes, which are widely available. The semi-permeable membranes may be mounted on a more robust solid surface such as glass. The surfaces may optionally be coated with a layer of metal, such as gold, platinum or other transition metal. A particular example of a suitable solid substrate is the commercially available BiaCore™ chip (Pharmacia Biosensors).

[0123] Preferably, the solid substrate is generally a material having a rigid or semi-rigid surface. In preferred embodiments, at least one surface of the substrate will be substantially flat, although in some embodiments it may be desirable to physically separate regions for different polymers with, for example, raised regions or etched trenches. It is also preferred that the solid substrate is suitable for the high density application of DNA sequences in discrete areas of typically from 50 to 100 μm, giving a density of 10000 to 40000 dots/cm².

[0124] The solid substrate is conveniently divided up into sections. This may be achieved by techniques such as photo-etching, or by the application of hydrophobic inks, for example teflon-based inks (Cel-line, USA).

[0125] Discrete positions, in which each different member of the library is located may have any convenient shape, e.g., circular, rectangular, elliptical, wedge-shaped, etc.

[0126] Attachment of the polynucleotide sequences to the substrate may be by covalent or non-covalent means. The polynucleotide sequences may be attached to the substrate via a layer of molecules to which the library sequences bind. For example, the polynucleotide sequences may be labelled with biotin and the substrate coated with avidin and/or streptavidin. A convenient feature of using biotinylated polynucleotide sequences is that the efficiency of coupling to the solid substrate can be determined easily. Since the polynucleotide sequences may bind only poorly to some solid substrates, it is often necessary to provide a chemical interface between the solid substrate (such as in the case of glass) and the nucleic acid sequences. Examples of suitable chemical interfaces include hexaethylene glycol. Another example is the use of polylysine coated glass, the polylysine then being chemically modified using standard procedures to introduce an affinity ligand. Other methods for attaching molecules to the surfaces of solid substrate by the use of coupling agents are known in the art, see for example WO98/49557.

[0127] Binding of complementary polynucleotide sequences to the immobilised nucleic acid library may be determined by a variety of means such as changes in the optical characteristics of the bound polynucleotide sequence (i.e. by the use of ethidium bromide) or by the use of labelled nucleic acids, such as polypeptides labelled with fluorophores. Other detection techniques that do not require the use of labels include optical techniques such as optoacoustics, reflectometry, ellipsometry and surface plasmon resonance (see WO97/49989).

[0128] Thus, the present invention provides a solid substrate having immobilized thereon at least one polynucleotide of the present invention, preferably two or more different polynucleotide sequences of the present invention. In a preferred embodiment the solid substrate further comprises polynucleotide sequences derived from genes other than the PMC virus polynucleotide sequence.

Antisense Nucleic Acids and Ribozymes

[0129] The present invention also extends to the preparation of antisense nucleotides and ribozymes that may be used to interfere with the expression of PMC virus amino acid sequences at the translational level. This approach utilises antisense nucleic acid and ribozymes to block translation of a specific mRNA, either by masking that mRNA with an antisense nucleic acid or cleaving it with a ribozyme.

[0130] Antisense nucleic acids are DNA or RNA molecules that are complementary to at least a portion of a specific mRNA molecule [See: Weintraub, (1990) *Sci. Am.*, 262:40-46; Marcus-Sekura, (1988) *Anal. Biochem.*, 172:289-295]. In the cell, they hybridise to that mRNA, forming a double-stranded molecule. The cell does not translate an mRNA complexed in this double-stranded form. Therefore, antisense nucleic acids interfere with the expression of mRNA into protein. Oligomers of about fifteen nucleotides and molecules that hybridise to the AUG initiation codon will be particularly efficient, since they are easy to synthesize and are likely to pose fewer problems than larger molecules when introducing them into infected cells. Antisense methods have been used to inhibit the expression of many genes in vitro [Hambor et al., (1988) *J. Exp. Med.*, 168:1237-1245].

[0131] Ribozymes are RNA molecules possessing the ability to specifically cleave other single-stranded RNA molecules in a manner somewhat analogous to DNA restriction endonucleases. Ribozymes were discovered from the observation that certain mRNAs have the ability to excise their own introns. By modifying the nucleotide sequence of these RNAs, researchers have been able to engineer molecules that recognise specific nucleotide sequences in an RNA molecule and cleave it [Cech, (1988) *J. Am. Med. Assoc.*, 260:3030-3034]. Because they are sequence-specific, only mRNAs with particular sequences are inactivated.

[0132] Investigators have identified two types of ribozymes, Tetrahymena-type and "hammerhead"-type. Tetrahymena-type ribozymes recognize four-base sequences, while "hammerhead"-type recognize eleven- to eighteen-base sequences. The longer the recognition sequence, the more likely it is to occur exclusively in the target mRNA species. Therefore, hammerhead-type ribozymes are preferable to Tetrahymena-type ribozymes for inactivating a specific mRNA species and eighteen base recognition sequences are preferable to shorter recognition sequences.

[0133] The PMC polynucleotide sequences described herein may thus be used to prepare antisense molecules

against, and ribozymes that cleave, mRNAs for PMC virus amino acid sequences, thus inhibiting expression of the PMC virus polynucleotide sequences.

Polypeptide Sequences

Polypeptides

[0134] The invention also covers polypeptides encoded by the above RNA and DNA nucleotide sequences and fragments thereof. The invention further provides an isolated PMC virus amino acid sequence as shown in SEQ ID NO: 2 and fragments thereof. More desirably, the PMC virus amino acid sequence is provided in substantially purified form. Further provided are polypeptide fragments having lower molecular weights and having peptide sequences or fragments in common with those shown in SEQ ID NO:2.

[0135] The term "isolated" is used to describe a PMC virus amino acid sequence that has been separated from components that accompany it in its natural state. Further, a PMC virus amino acid sequence is "substantially purified" when at least about 60 to 75% of a sample exhibits a single PMC virus amino acid sequence. A substantially purified PMC virus amino acid sequence will typically comprise about 60 to 90% W/W of a PMC virus amino acid sequence sample, more usually about 95%, and preferably will be over about 99% pure. Protein purity or homogeneity may be indicated by a number of means well known in the art, such as polyacrylamide gel electrophoresis of a protein sample, followed by visualizing a single PMC virus amino acid sequence band upon staining the gel. For certain purposes, higher resolution may be provided by using HPLC or other means well known in the art which are utilised for application.

[0136] The invention further contemplates fragments of the PMC virus amino acid sequence. A PMC virus amino acid sequence fragment is a stretch of amino acid residues of at least about five to seven contiguous amino acids, often at least about seven to nine contiguous amino acids, typically at least about nine to 13 contiguous amino acids and, most preferably, at least about 20 to 30 or more contiguous amino acids.

[0137] In a highly preferred form of the invention the fragments exhibit ligand-binding, immunological activity and/or other biological activities characteristic of PMC virus amino acid sequences. More preferably, the fragments possess immunological epitopes consistent with those present on native PMC virus amino acid sequences.

[0138] As used herein, "epitope" refers to an antigenic determinant of a polypeptide. An epitope could comprise three amino acids in a spatial conformation that is unique to the epitope. Generally, an epitope consists of at least five amino acids, and more usually consists of at least 8-10 amino acids. Methods of determining the spatial conformation of such amino acids are known in the art.

[0139] Preferred PMC virus amino acid sequences of the invention will have one or more biological properties (eg in vivo, in vitro or immunological properties) of the native full-length PMC virus amino acid sequence. Alternatively, fragments of the full-length PMC virus amino acid sequence may have one or more biological properties of one or more of the genes which the full length amino acid sequence encodes.

[0140] Preferably, the fragments of the full length PMC virus amino acid sequence SEQ ID NO:2 are chosen from the following locations in SEQ ID NO:2: 1-167, 168-267, 268-489, 490-685, 686-1062, 1063-1134, 1135-1602, 1603-2278,

2279-2341, 2342-2688, 2689-3193, 3194-3886. Alternatively, the fragment may be selected from any one of SEQ ID NOs:16-27.

[0141] Non-functional PMC virus amino acid sequences are also included within the scope of the invention since they may be useful, for example, as antagonists of PMC virus genes. The biological properties of analogues, fragments, or derivatives relative to wild type may be determined, for example, by means of biological assays.

[0142] PMC virus amino acid sequences, including analogues, fragments and derivatives, can be prepared synthetically (e.g., using the well known techniques of solid phase or solution phase peptide synthesis). Preferably, solid phase synthetic techniques are employed. Alternatively, PMC virus amino acid sequences of the invention can be prepared using well known genetic engineering techniques, as described infra. In yet another embodiment, PMC virus amino acid sequences can be purified (e.g., by immunoaffinity purification) from a biological fluid, such as but not limited to whole blood, plasma, faeces, serum, or urine from animals, including pigs, cattle, sheep, chickens, human beings, dogs, horses, and fish.

Variant Polypeptides

[0143] PMC virus amino acid sequence analogues preferably include those having an amino acid sequence wherein one or more of the amino acids is substituted with another amino acid, which substitutions do not substantially alter the biological activity of the molecule.

[0144] In the context of the invention, an analogous sequence is taken to include a PMC virus amino acid sequence which is at least 60, 70, 80 or 90% homologous, preferably at least 95 or 98% homologous at the amino acid level over at least 20, 50, 100 or 200 amino acids, with the amino acid sequence set out in SEQ ID NO:1. In particular, homology should typically be considered with respect to those regions of the sequence known to be essential for the function of the protein or proteins encoded by the PMC virus RNA, rather than non-essential neighbouring sequences.

[0145] Although homology can be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity. The terms "substantial homology" or "substantial identity", when referring to PMC virus amino acid sequences, indicate that the PMC virus amino acid sequence in question exhibits at least about 70% identity with an entire naturally-occurring PMC amino acid sequence or portion thereof, usually at least about 80% identity and preferably at least about 90 or 95% identity.

[0146] In a highly preferred form of the invention, a PMC virus amino acid sequence analogue will have 80% or greater amino acid sequence identity to the PMC virus amino acid sequence set out in SEQ ID NO:2. Examples of PMC virus amino acid sequence analogues within the scope of the invention include the amino acid sequence of SEQ ID NO:2 wherein: (a) one or more aspartic acid residues is substituted with glutamic acid; (b) one or more isoleucine residues is substituted with leucine; (c) one or more glycine or valine residues is substituted with alanine; (d) one or more arginine residues is substituted with histidine; or (e) one or more tyrosine or phenylalanine residues is substituted with tryptophan.

[0147] PMC virus amino acid sequence derivatives are also provided by the invention and include PMC virus amino acid sequences, analogues or fragments thereof which are substantially homologous in primary structure but which include chemical and/or biochemical modifications or unusual amino acids. Such modifications include, for example, acetylation, carboxylation, phosphorylation, glycosylation, ubiquitination, labelling, (e.g., with radionucleotides), and various enzymatic modifications, as will be readily appreciated by those well skilled in the art.

[0148] In one form of the invention the chemical moieties suitable for derivatisation are selected from among water soluble polymers. The polymer selected should be water soluble so that the protein to which it is attached does not precipitate in an aqueous environment, such as a physiological environment. Preferably, for therapeutic use of the end-product preparation, the polymer will be pharmaceutically acceptable. One skilled in the art will be able to select the desired polymer based on considerations such as whether the polymer/protein conjugate will be used therapeutically, and if so, the desired dosage, circulation time, resistance to proteolysis and other considerations. For the present proteins and peptides, these may be ascertained using the assays provided herein.

[0149] The water soluble polymer may be selected from the group consisting of, for example, polyethylene glycol, copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), and dextran or poly (n-vinyl pyrrolidone)polyethylene glycol, propylene glycol homopolymers, polypropylene oxide/ethylene oxide copolymers, polyoxyethylated polyols and polyvinyl alcohol. Polyethylene glycol propionaldehyde may provide advantages in manufacturing due to its stability in water.

[0150] In another form of the invention the amino acid sequences may be modified to produce a longer half life in an animal host, for example, by fusing one or more antibody fragments (such as an Fc fragment) to the amino or carboxyl end of a PMC virus amino acid sequence.

[0151] Where the PMC virus amino acid sequence is to be provided in a labelled form, a variety of methods for labelling amino acid sequences are well known in the art and include radioactive isotopes such as ^{32}P , ligands which bind to labelled antigens (eg, antibodies), fluorophores, chemiluminescent agents, enzymes and antigens which can serve as specific binding pair members for a labelled ligand. The choice of label depends on the sensitivity required, stability requirements, and available instrumentation. Methods of labelling amino acid sequences are well known in the art [See, e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989); and Ausubel, F., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., Struhl, K. *Current protocols in molecular biology*. Greene Publishing Associates/Wiley Intersciences, New York (2001)].

[0152] The PMC virus amino acid sequences of the invention, if soluble, may be coupled to a solid-phase support, e.g., nitrocellulose, nylon, column packing materials (e.g., Sepharose beads), magnetic beads, glass wool, plastic, metal,

polymer gels, cells, or other substrates. Such supports may take the form, for example, of beads, wells, dipsticks, or membranes.

[0153] The invention also provides for fusion polypeptides, comprising PMC virus amino acid sequences and fragments. Thus PMC virus amino acid sequences may be fusions between two or more PMC virus amino acid sequences or between a PMC virus amino acid sequence and a related protein. Likewise, heterologous fusions may be constructed which would exhibit a combination of properties or activities of the derivative proteins. For example, ligand-binding or other domains may be "swapped" between different fusion polypeptides or fragments. Such homologous or heterologous fusion polypeptides may display, for example, altered strength or specificity of binding. Fusion partners include immunoglobulins, bacterial beta-galactosidase, trpE, protein A, beta-lactamase, alpha amylase, alcohol dehydrogenase and yeast alpha mating factor.

[0154] Modified PMC virus amino acid sequences may be synthesised using conventional techniques, or may be encoded by a modified polynucleotide sequence and produced using recombinant nucleic acid methods. The modified polynucleotide sequence may also be prepared by conventional techniques. Fusion proteins will typically be made by either recombinant nucleic acid methods or may be chemically synthesised.

Diagnostics

[0155] In accordance with another embodiment the invention provides diagnostic and prognostic methods to detect the presence of PMC virus using PMC virus glycoproteins, proteins and other peptides and polypeptides (whether obtained in a purified state from PMC virus preparations, or by chemical synthesis) and/or antibodies derived there from and/or PMC virus polynucleotide sequences.

[0156] Diagnostic and prognostic methods will generally be conducted using a biological sample obtained from an animal, such as a pig. A "sample" refers to a sample of tissue or fluid suspected of containing a PMC polynucleotide or polypeptide from an animal, but not limited to, e.g., whole blood, blood cells, plasma, serum, milk, faecal samples, tissue and samples of in vitro cell culture constituents.

Polypeptide/Antibody-Based Diagnostics

[0157] Means are provided for the detection of proteins of PMC virus, particularly for the diagnosis of PMC or for the detection of antibodies against PMC virus or its proteins, particularly in subjects afflicted with PMC or more generally in asymptomatic carriers and in animal derived products such as meat. Such methods are also referred to as immunoassays.

[0158] The invention thus provides a method for detecting the presence of a PMC virus amino acid sequence in a sample, comprising the steps of:

[0159] a) contacting a sample suspected of containing a PMC virus amino acid sequence with an antibody that specifically binds to the PMC virus amino acid sequence under conditions which allow for the formation of reaction complexes comprising the antibody and the PMC virus amino acid sequence; and

[0160] b) detecting the formation of reaction complexes comprising the antibody and PMC virus amino acid sequence in the sample, wherein detection of the forma-

tion of reaction complexes indicates the presence of PMC virus amino acid sequence in the sample.

[0161] Particularly the invention relates to an in vitro process of diagnosis making use of an amino acid sequence encoding an envelope glycoprotein or of a polypeptide bearing an epitope of a glycoprotein from PMC virus or any other viral protein (structural or non-structural) for the detection of anti-PMC virus antibodies in serum, milk or body fluids. Preferably, the antibody used in the above methods binds to the E0, E1, E2, NS2, NS3, NS4A, NS4B and/or NS5A, NS5B proteins of PMC virus.

[0162] The invention also provides a method for detecting the presence of a PMC virus antibody in a sample, comprising the steps of:

[0163] a) contacting a sample suspected of containing a PMC virus antibody with an amino acid sequence under conditions which allow for the formation of reaction complexes comprising the PMC virus antibody and the amino acid sequence; and

[0164] b) detecting the formation of reaction complexes comprising the antibody and amino acid sequence in the sample, wherein detection of the formation of reaction complexes indicates the presence of PMC virus antibody in the sample.

[0165] A method is also provided for the detection of anti-PMC virus antibodies, comprising the steps of:

[0166] a) depositing a predetermined amount of one or several PMC virus antigens onto a solid support such as a microplate;

[0167] b) introducing increasing dilutions of a biological fluid (e.g., blood serum or plasma, milk, cerebrospinal fluid, lymphatic fluid or other body fluids) onto the antigens and incubating;

[0168] c) washing the solid support with an appropriate buffer;

[0169] d) adding specific labelled antibodies directed against the antibodies of the subject; and

[0170] e) detecting the antigen-antibody-antibody complex formed, which is then indicative of the presence of PMC virus antibodies in the biological fluid.

[0171] Preferably, the antibody used in these methods is derived from an affinity-purified polyclonal antibody, and more preferably a mAb. In addition, it is preferable for the antibody molecules used herein be in the form of Fab, Fab', F(ab')₂ or F(v) portions or whole antibody molecules.

[0172] Particularly preferred methods for detecting PMC virus based on the above methods include enzyme linked immunosorbent assays, radioimmunoassays, immunoradiometric assays and immunoenzymatic assays, including sandwich assays using monoclonal and/or polyclonal antibodies.

[0173] Three such procedures that are especially useful utilise either PMC virus amino acid sequences (or fragments thereof) labelled with a detectable label, antibody Ab₁ labelled with a detectable label, or antibody Ab₂ labelled with a detectable label. The procedures may be summarized by the following equations wherein the asterisk indicates that the particle is labelled and "AA" stands for the PMC virus amino acid sequence:

[0174] A. AA*+Ab₁=AA*Ab₁

[0175] B. AA+Ab₁*=AA Ab₁*

[0176] C. AA+Ab₁+Ab₂*=Ab₁ AA Ab₂*

[0177] The procedures and their application are all familiar to those skilled in the art and accordingly may be utilised

within the scope of the present invention. The "competitive" or "blocking" procedure, Procedure A, is described in U.S. Pat. Nos. 3,654,090 and 3,850,752. Procedure B is representative of well-known competitive assay techniques. Procedure C, the "sandwich" procedure, is described in U.S. Pat. Nos. RE 31,006 and 4,016,043. Still other procedures are known, such as the "double antibody" or "DASP" procedure.

[0178] In each instance, the PMC virus amino acid sequences form complexes with one or more antibody(ies) or binding partners and one member of the complex is labelled with a detectable label. The fact that a complex has formed and, if desired, the amount thereof, can be determined by known methods applicable to the detection of labels.

[0179] It will be seen from the above that a characteristic property of Ab₂ is that it will react with Ab₁. This is because Ab₁, raised in one mammalian species, has been used in another species as an antigen to raise the antibody, Ab₂. For example, Ab₂ may be raised in goats using rabbit antibodies as antigens. Ab₂ therefore would be anti-rabbit antibody raised in goats. For purposes of this description and claims, Ab₁ will be referred to as a primary antibody, and Ab₂ will be referred to as a secondary or anti-Ab₁ antibody.

[0180] The labels most commonly employed for these studies are radioactive elements, enzymes, chemicals that fluoresce when exposed to ultraviolet light, and others.

[0181] A number of fluorescent materials are known and can be utilised as labels. These include, for example, fluorescein, rhodamine and auramine. A particular detecting material is anti-rabbit antibody prepared in goats and conjugated with fluorescein through an isothiocyanate.

[0182] The PMC virus amino acid sequences or their binding partners can also be labelled with a radioactive element or with an enzyme. The radioactive label can be detected by any of the currently available counting procedures. The preferred isotope may be selected from ³H, ¹⁴C, ³²P, ³⁵S, ³⁶Cl, ⁵¹Cr, ⁵⁷Co, ⁵⁸Co, ⁵⁹Fe, ⁹⁰Y, ¹²⁵I, ¹³¹I, and ¹⁸⁶Re.

[0183] Enzyme labels are likewise useful, and can be detected by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques. The enzyme is conjugated to the selected particle by reaction with bridging molecules such as carbodiimides, diisocyanates, glutaraldehyde and the like. Many enzymes, which can be used in these procedures, are known and can be utilized. The preferred enzymes are peroxidase, β-glucuronidase, β-D-glucosidase, β-D-galactosidase, urease, glucose oxidase plus peroxidase and alkaline phosphatase. U.S. Pat. Nos. 3,654,090, 3,850,752 and 4,016,043 are referred to by way of example for their disclosure of alternate labelling material and methods.

[0184] In another embodiment of the invention there are provided in vitro methods for evaluating the level of PMC virus antibodies in a biological sample comprising the steps of:

[0185] a) detecting the formation of reaction complexes in a biological sample according to the method noted above; and

[0186] b) evaluating the amount of reaction complexes formed, which amount of reaction complexes corresponds to the level of PMC virus antibodies in the biological sample.

[0187] Preferably, the antibody used in the above methods binds to the E0, E1, E2, NS2, NS3, NS4A, NS4B and/or NS5A, NS5B proteins of PMC virus.

[0188] In another embodiment of the invention there are provided *in vitro* methods for evaluating the level of PMC virus polypeptides in a biological sample comprising the steps of:

[0189] a) detecting the formation of reaction complexes in a biological sample according to the method noted above; and

[0190] b) evaluating the amount of reaction complexes formed, which amount of reaction complexes corresponds to the level of PMC virus polypeptide in the biological sample.

[0191] Preferably, the polypeptide used in the above methods encodes the E0, E1, E2, NS2, NS3, NS4A, NS4B and/or NS5A, NS5B proteins of PMC virus.

[0192] Further there are provided *in vitro* methods for monitoring therapeutic treatment of a disease associated with PMC virus in an animal host comprising evaluating, as describe above, the levels of PMC virus antibodies in a series of biological samples obtained at different time points from an animal host undergoing such therapeutic treatment.

[0193] The methods for detecting polypeptides using antibodies, or immunoassays, according to the present invention may utilize antigens from the different domains of the new and unique polypeptide sequences of the present invention that maintain linear (in case of peptides) and conformational epitopes (in case of polypeptides) recognized by antibodies in the sera from subjects infected with PMC virus.

[0194] It is within the scope of the invention to use, for instance, single or specific oligomeric antigens, dimeric antigens, as well as combinations of single or specific oligomeric antigens.

[0195] The PMC virus antigens of the present invention may be employed in virtually any assay format that employs a known antigen to detect antibodies. Of course, a format that denatures the PMC virus conformational epitope should be avoided or adapted.

[0196] A common feature of all of these detection methods is that the antigen is contacted with the test specimen suspected of containing PMC virus antibodies under conditions that permit the antigen to bind to any such antibody present in the component. Such conditions will typically be physiologic temperature, pH and ionic strength, using an appropriate pre-determined quantity of antigen. The incubation of the antigen with the specimen is followed by detection of immune complexes comprised of the antigen and antibodies derived from the specimen typically by using a labelled second antibody that is directed against the immunoglobulins of the test animal species.

[0197] Design of the immunoassays is subject to a great deal of variation, and many formats are known in the art. Protocols may, for example, use solid supports, or immunoprecipitation. Assays which amplify the signals from the immune complex are also known; examples of which are assays which utilize biotin and avidin or streptavidin, and enzyme-labelled and mediated immunoassays, such as ELISA assays. Furthermore, the immunoassay may be, without limitation, in a heterogeneous or in a homogeneous format, and of a standard or competitive type.

[0198] In a heterogeneous format, the polypeptide is typically bound to a solid matrix or support to facilitate separation of the sample from the polypeptide after incubation. Examples of solid supports that can be used are nitrocellulose (e.g., in membrane or microtiter well form), polyvinyl chloride (e.g., in sheets or microtiter wells), polystyrene latex

(e.g., in beads or microtiter plates, polyvinylidene fluoride (known as Immunolon™), diazotized paper, nylon membranes, activated beads, and Protein A beads. For example, Dynatech Immunolon™ 1 or Immunolon™ 2 microtiter plates or 0.25 inch polystyrene beads (Precision Plastic Ball) can be used in the heterogeneous format. The solid support containing the antigenic polypeptides is typically washed after separating it from the test sample, and prior to detection of bound antibodies. Both standard and competitive formats are known in the art.

[0199] In a homogeneous format, the test sample is incubated with the combination of antigens in solution. For example, it may be under conditions that will precipitate any antigen-antibody complexes which are formed. Both standard and competitive formats for these assays are known in the art.

[0200] In a standard format, the amount of PMC virus antibodies in the antibody-antigen complexes is directly monitored. This may be accomplished by determining whether labelled anti-xenogeneic (e.g. anti-swine) antibodies which recognize an epitope on anti-PMC virus antibodies will bind due to complex formation. In a competitive format, the amount of PMC virus antibodies in the sample is deduced by monitoring the competitive effect on the binding of a known amount of labelled antibody (or other competing ligand) in the complex.

[0201] Complexes formed comprising anti-PMC virus antibody (or in the case of competitive assays, the amount of competing antibody) are detected by any of a number of known techniques, depending on the format. For example, unlabelled PMC virus antibodies in the complex may be detected using a conjugate of anti-xenogeneic Ig complexed with a label (e.g. an enzyme label).

[0202] In an immunoprecipitation or agglutination assay format, the reaction between the PMC virus antigens and the antibody forms a network that precipitates from the solution or suspension and forms a visible layer or film of precipitate. If no anti-PMC antibody is present in the test specimen, no visible precipitate is formed.

[0203] There currently exist three specific types of particle agglutination (PA) assays. These assays are used for the detection of antibodies to various antigens when coated to a support. One type of this assay is the haemagglutination assay using red blood cells (RBCs) that are sensitized by passively adsorbing antigen (or antibody) to the RBC. The addition of specific antigen antibodies present in the body component, if any, causes the RBCs coated with the purified antigen to agglutinate.

[0204] To eliminate potential non-specific reactions in the haemagglutination assay, two artificial carriers may be used instead of RBC in the PA. The most common of these are latex particles. However, gelatin particles may also be used. The assays utilizing either of these carriers are based on passive agglutination of the particles coated with purified antigens.

Nucleic Acid-Based Diagnostics

[0205] The present invention further provides methods for detecting the presence or absence of PMC virus in a biological sample, which comprise the steps of:

[0206] c) bringing the biological sample into contact with a polynucleotide probe or primer comprising a PMC virus polynucleotide of the invention under suitable hybridising conditions; and

[0207] d) detecting any duplex formed between the probe or primer and nucleic acid sequences in the sample.

[0208] According to one embodiment of the invention, detection of PMC virus may be accomplished by directly amplifying PMC virus polynucleotide sequences from biological sample, using known techniques and then detecting the presence of PMC virus polynucleotide sequences.

[0209] The present invention thus also relates to a method for the detection of PMC virus nucleic acids present in a biological sample, comprising:

[0210] c) amplifying the nucleic acid with at least one primer as defined above,

[0211] d) detecting the amplified nucleic acids.

[0212] Preferably, the nucleic acid is extracted and/or purified (eg from a from a tissue sample) prior to amplification.

[0213] The present invention also relates to a method for the detection of PMC virus nucleic acids present in a biological sample, comprising:

[0214] d) hybridizing the nucleic acids of the biological sample at appropriate conditions with one or more probes as defined above,

[0215] e) washing under appropriate conditions, and

[0216] f) detecting the hybrids formed.

[0217] Preferably, the hybridizing conditions are denatured conditions.

[0218] Preferably, the nucleic acid is extracted and/or purified (eg from a from a tissue sample) prior to hybridisation. More preferably, the nucleic acid sample is amplified with at least one primer as defined above, after extraction or at least prior to hybridisation. Preferably, said probes are attached to a solid substrate or detected in a liquid phase by photometric or fluorogenic detection or by other methods of visualisation such as by agarose gel electrophoresis.

[0219] The present invention also relates to a method as defined above, wherein said nucleic acids are labelled during or after amplification.

[0220] Suitable assay methods for purposes of the present invention to detect hybrids formed between the oligonucleotide probes and the nucleic acid sequences in a sample may comprise any of the assay formats known in the art, such as the conventional dot-blot format, sandwich hybridization or reverse hybridization. For example, the detection can be accomplished using a dot blot format, the unlabelled amplified sample being bound to a membrane, the membrane being incorporated with at least one labelled probe under suitable hybridization and wash conditions, and the presence of bound probe being monitored.

[0221] An alternative and preferred method is a "reverse" dot-blot format, in which the amplified sequence contains a label. In this format, the unlabelled oligonucleotide probes are bound to a solid support and exposed to the labelled sample under appropriate stringent hybridization and subsequent washing conditions. It is to be understood that also any other assay method which relies on the formation of a hybrid between the nucleic acids of the sample and the oligonucleotide probes according to the present invention may be used.

[0222] In one form of the invention, the target nucleic acid sequence is amplified by PCR and then detected using any of the specific methods mentioned above. Other useful diagnostic techniques for detecting the presence of PMC virus polynucleotide sequences include, but are not limited to: 1) allele-specific PCR; 2) single stranded conformation analysis; 3) denaturing gradient gel electrophoresis; 4) RNase protection

assays; 5) the use of proteins which recognize nucleotide mismatches, such as the *E. coli* mutS protein; 6) allele-specific oligonucleotides; and 7) fluorescent in situ hybridisation.

[0223] In addition to the above methods, PMC virus polynucleotide sequences may be detected using conventional probe technology. When probes are used to detect the presence of the PMC virus polynucleotide sequences, the biological sample to be analysed, such as blood or serum, may be treated, if desired, to extract the nucleic acids. The sample polynucleotide sequences may be prepared in various ways to facilitate detection of the target sequence; e.g. denaturation, restriction digestion, electrophoresis or dot blotting. The targeted region of the sample polynucleotide sequence usually must be at least partially single-stranded to form hybrids with the targeting sequence of the probe. If the sequence is naturally single-stranded, denaturation will not be required. However, if the sequence is double-stranded, the sequence will probably need to be denatured. Denaturation can be carried out by various techniques known in the art.

[0224] Sample polynucleotide sequences and probes are incubated under conditions that promote stable hybrid formation of the target sequence in the probe with the putative PMC virus polynucleotide sequence in the sample. Preferably, high stringency conditions are used in order to prevent false positives.

[0225] Detection, if any, of the resulting hybrid is usually accomplished by the use of labelled probes. Alternatively, the probe may be unlabelled, but may be detectable by specific binding with a ligand that is labelled, either directly or indirectly. Suitable labels and methods for labelling probes and ligands are known in the art, and include, for example, radioactive labels which may be incorporated by known methods (e.g., nick translation, random priming or kinasings), biotin, fluorescent groups, chemiluminescent groups (e.g., dioxetanes, particularly triggered dioxetanes), enzymes, antibodies and the like. Variations of this basic scheme are known in the art, and include those variations that facilitate separation of the hybrids to be detected from extraneous materials and/or that amplify the signal from the labelled moiety.

[0226] It is also contemplated within the scope of this invention that the nucleic acid probe assays of this invention may employ a cocktail of nucleic acid probes and/or primers capable of detecting PMC virus polynucleotide sequences. Thus, in one example to detect the presence of PMC virus polynucleotide sequences in a cell sample, more than one probe complementary to PMC virus polynucleotide sequences is employed and in particular the number of different probes is alternatively 2, 3, or 5 different nucleic acid probe sequences.

[0227] Additionally, the present invention provides a method for detecting viral RNA or DNA comprising the steps of:

[0228] a) immobilizing PMC virus on a support (e.g., a nitrocellulose filter);

[0229] b) disrupting the virion; and

[0230] c) hybridizing with a probe.

[0231] Preferably, the probe is labelled. More preferably, the probe is radiolabelled or fluorescent- or enzyme-labelled. Such an approach to detection of virus has already been developed for Hepatitis B virus in peripheral blood (Scotto J. et al. Hepatology (1983), 3, 379-384).

[0232] The present invention also provides a method for rapid screening of genomic DNA derived from the tissue of

subjects with PMC virus related symptoms to detect proviral PMC virus related DNA or RNA present in the tissues. Thus, the present invention also provides a method for screening the tissue of subjects comprising the steps of:

- [0233] a) extracting DNA from tissue;
- [0234] b) restriction enzyme cleavage of said DNA;
- [0235] c) electrophoresis of the fragments; and
- [0236] d) Southern blotting of genomic DNA from tissues and subsequent hybridization with labelled cloned PMC virus DNA.

[0237] Hybridization in situ can also be used.

Antigenic Polypeptide Production

[0238] Viral RNA and DNA according to the invention can be used for expressing PMC viral antigens for diagnostic purposes, as well as for the production of a vaccine against PMC virus. The methods which can be used to achieve expression of antigenic polypeptides are multifold:

- a) DNA can be transfected into mammalian cells with appropriate selection markers by a variety of techniques, such as calcium phosphate precipitation, polyethylene glycol, protoplast-fusion, etc and the resultant proteins purified.
- b) DNA fragments corresponding to genes can be cloned into expression vectors for *E. coli*, yeast or mammalian cells and the resultant proteins purified.
- c) The proviral RNA or DNA can be "shot-gunned" (fragmented) into prokaryotic expression vectors to generate fusion polypeptides. Recombinants, producing antigenically competent fusion proteins, can be identified by simply screening the recombinants with antibodies against PMC virus antigens.

[0239] Particular reference in this respect is made to those portions of the genome of PMC virus which, in the figures, are shown to belong to open reading frames and which encode the products having the polypeptide sequences shown. Preferably, the nucleic acid sequences used in the above methods encode the E0, E1, E2, NS2, NS3, NS4A, NS4B and/or NS5A, NS5B proteins of PMC. Preferably, polypeptides are provided containing sequences in common with polypeptides comprising antigenic determinants included in the proteins encoded and expressed by the PMC virus genome.

Antibodies

[0240] Antibodies to PMC Proteins

[0241] The different peptides according to this invention can also be used themselves for the production of antibodies, preferably monoclonal antibodies specific for the respective different peptides. Thus, according to the invention, PMC virus amino acid sequences produced recombinantly or by chemical synthesis and fragments or other derivatives or analogues thereof, including fusion proteins, may be used as an immunogen to generate antibodies that recognize the PMC virus amino acid sequence. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments and a Fab expression library.

[0242] Thus, the present invention provides a method for the generation of antibodies comprising the steps of:

- [0243] a) providing a PMC virus polypeptide sequence to a subject; and
- [0244] b) collecting the antibodies generated in the subject against the polypeptide.

[0245] Preferably, the polypeptide used to generate the antibody is antigenic. More preferably, the polypeptide is

chosen from the list comprising the E0, E1, E2, NS2, NS3, NS4A, NS4B and/or NS5A or NS5B proteins of PMC virus. More preferably, the protein used to generate the antibody is the E0, E2, NS2 and/or NS3 proteins or a fragment or derivative thereof. For example, in a highly preferred embodiment, a composition of the invention comprises both a PMC virus E0/E2 complex and an PMC virus NS2/NS3 complex.

[0246] A molecule is "antigenic" when it is capable of specifically interacting with an antigen recognition molecule of the immune system, such as an immunoglobulin (antibody) or T cell antigen receptor. An antigenic amino acid sequence contains at least about 5, and preferably at least about 10, amino acids. An antigenic portion of a molecule can be that portion that is immunodominant for antibody or T cell receptor recognition, or it can be a portion used to generate an antibody to the molecule by conjugating the antigenic portion to a carrier molecule for immunization. A molecule that is antigenic need not be itself immunogenic, i.e., capable of eliciting an immune response without a carrier.

[0247] An "antibody" is any immunoglobulin, including antibodies and fragments thereof, that binds a specific epitope. The term encompasses polyclonal, monoclonal, and chimeric antibodies, the last mentioned described in further detail in U.S. Pat. Nos. 4,816,397 and 4,816,567, as well as antigen binding portions of antibodies, including Fab, F(ab')₂ and F(v) (including single chain antibodies). Accordingly, the phrase "antibody molecule" in its various grammatical forms as used herein contemplates both an intact immunoglobulin molecule and an immunologically active portion of an immunoglobulin molecule containing the antibody combining site. An "antibody combining site" is that structural portion of an antibody molecule comprised of heavy and light chain variable and hypervariable regions that specifically binds antigen.

[0248] Exemplary antibody molecules are intact immunoglobulin molecules, substantially intact immunoglobulin molecules and those portions of an immunoglobulin molecule that contain the paratope, including those portions known in the art as Fab, Fab', F(ab')₂ and F(v), which portions are preferred for use in the therapeutic methods described herein.

[0249] Fab and F(ab')₂ portions of antibody molecules are prepared by the proteolytic reaction of papain and pepsin, respectively, on substantially intact antibody molecules by methods that are well-known. See for example, U.S. Pat. No. 4,342,566 to Theofilopolous et al. Fab' antibody molecule portions are also well-known and are produced from F(ab')₂ portions followed by reduction with mercaptoethanol of the disulfide bonds linking the two heavy chain portions, and followed by alkylation of the resulting protein mercaptan with a reagent such as iodoacetamide. An antibody containing intact antibody molecules is preferred herein.

[0250] The phrase "monoclonal antibody" in its various grammatical forms refers to an antibody having only one species of antibody combining site capable of immunoreacting with a particular antigen. A monoclonal antibody thus typically displays a single binding affinity for any antigen with which it immunoreacts.

[0251] For the production of hybridomas secreting said monoclonal antibodies, conventional production and screening methods can be used. These monoclonal antibodies, which themselves are part of the invention, provide very useful tools for the identification and even determination of relative proportions of the different polypeptides or proteins

in biological samples, particularly animals samples containing PMC virus or related viruses.

[0252] Adjuvants include, but are not limited to, complete Freund's adjuvant, incomplete Freund's adjuvant, saponin, mineral gels such as aluminium hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil or hydrocarbon emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (*bacille Calmette-Guerin*) and *Corynebacterium parvum*. Preferably, the adjuvant is pharmaceutically acceptable.

[0253] Further examples of adjuvants which may be effective include but are not limited to: N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, referred to as nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (CGP 19835A, referred to as MTP-PE), and RIBI, which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton (MPL+TDM+CWS) in a 2% squalene/Tween 80 emulsion.

[0254] Additional examples of adjuvants and other agents include aluminium hydroxide, aluminium phosphate, aluminium potassium sulfate (alum), beryllium sulfate, silica, kaolin, carbon, water-in-oil emulsions, oil-in-water emulsions, muramyl dipeptide, bacterial endotoxin, lipid X, *Corynebacterium parvum* (*Propionobacterium acnes*), *Bordetella pertussis*, polyribonucleotides, sodium alginate, lanolin, lysolecithin, vitamin A, saponin, immuno stimulating complexes (ISCOMs), liposomes, levamisole, DEAE-dextran, blocked copolymers or other synthetic adjuvants. Such adjuvants are available commercially from various sources, for example, Merck Adjuvant 65 (Merck and Company, Inc., Rahway, N.J.) or Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, Mich.).

[0255] Typically, adjuvants such as Amphigen (oil-in-water), Alhydrogel (aluminium hydroxide), or a mixture of Amphigen and Alhydrogel are used. Only aluminium hydroxide is approved for human use.

[0256] The proportion of immunogenic polypeptide and adjuvant can be varied over a broad range so long as both are present in effective amounts. For example, aluminium hydroxide can be present in an amount of about 0.5% of the vaccine mixture (Al₂O₃ basis). Conveniently, the vaccines are formulated to contain a final concentration of immunogen in the range of from 0.2 to 200 µg/ml, preferably 5 to 50 µg/ml, most preferably 15 µg/ml.

[0257] After formulation, the vaccine may be incorporated into a sterile container which is then sealed and stored at a low temperature, for example 4° C., or it may be freeze-dried. Lyophilisation permits long-term storage in a stabilised form.

[0258] The vaccines are conventionally administered parenterally, by injection, for example, either subcutaneously or intramuscularly. Additional formulations which are suitable for other modes of administration include suppositories and, in some cases, oral formulations. For suppositories, traditional binders and carriers may include, for example, polyalkylene glycols or triglycerides; such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5% to 10%, preferably 1% to 2%. Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magne-

sium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10% to 95% of active ingredient, preferably 25% to 70%. Where the vaccine composition is lyophilised, the lyophilised material may be reconstituted prior to administration, e.g. as a suspension. Reconstitution is preferably effected in buffer

[0259] Capsules, tablets and pills for oral administration to a patient may be provided with an enteric coating comprising, for example, Eudragit "S", Eudragit "L", cellulose acetate, cellulose acetate phthalate or hydroxypropylmethyl cellulose.

[0260] The PMC virus polypeptides of the invention may be formulated into the vaccine as neutral or salt forms. Pharmaceutically acceptable salts include the acid addition salts (formed with free amino groups of the peptide) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids such as acetic, oxalic, tartaric and maleic. Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine and procaine.

[0261] Compositions of the present invention may further comprise antigenic polypeptides that are not coupled to PMC virus polypeptides and/or biologically active molecules whose primary purpose is not to serve as an antigen but to modulate the immune response in some other aspect. Examples of biologically active molecules that modulate the immune system of an animal or human subject include cytokines.

[0262] The term "cytokine" refers to any secreted polypeptide that influences the function of other cells mediating an immune response. Some examples of cytokines include, but are not limited to, interleukin-1α (IL-1α), interleukin-1β (IL-1β), interleukin-2 (IL-2), interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-8 (IL-8), interleukin-9 (1-9), interleukin-10 (IL-10), interleukin-11 (IL-11), interleukin-12 (IL-12), interferon-α (IFN-α), interferon-β (IFN-β), interferon-γ (IFN-γ), tumour necrosis factor-α (TNF-α), tumour necrosis factor-β (TNF-β), granulocyte colony stimulating factor (G-CSF), granulocyte/macrophage colony stimulating factor (GM-CSF), and transforming growth factor-β (TGF-β).

[0263] Various procedures known in the art may be used for the production of polyclonal antibodies to PMC virus amino acid sequences, or fragment, derivative or analogues thereof.

[0264] For the production of antibody, various host animals can be immunised by injection with the PMC virus amino acid sequence, or a derivative (e.g., fragment or fusion protein) thereof, including but not limited to rabbits, mice, rats, sheep, goats, etc.

[0265] In one embodiment, the PMC virus amino acid sequences or fragment thereof can be conjugated to an immunogenic carrier, e.g., bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH).

[0266] Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet

hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (*bacille Calmette-Guerin*) and *Corynebacterium parvum*.

[0267] For preparation of monoclonal antibodies directed toward the PMC virus amino acid sequences, or fragments, analogues, or derivatives thereof, any technique that provides for the production of antibody molecules by continuous cell lines in culture may be used. These include but are not limited to the hybridoma technique originally developed by Kohler et al., (1975) *Nature*, 256:495-497, the trioma technique, the human B-cell hybridoma technique [Kozbor et al., (1983) *Immunology Today*, 4:72], and the EBV-hybridoma technique to produce human monoclonal antibodies [Cole et al., (1985) in *Monoclonal Antibodies and Cancer Therapy*, pp. 77-96, Alan R. Liss, Inc.]. Immortal, antibody-producing cell lines can be created by techniques other than fusion, such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. See, e.g., U.S. Pat. Nos. 4,341,761; 4,399,121; 4,427,783; 4,444,887; 4,451,570; 4,466,917; 4,472,500; 4,491,632; and 4,493,890.

[0268] In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals. According to the invention, swine antibodies may be used and can be obtained by using swine hybridomas or by transforming B cells with PMC virus in vitro. In fact, according to the invention, techniques developed for the production of "chimeric antibodies" [Morrison et al., (1984) *J. Bacteriol.*, 159:870; Neuberger et al., (1984) *Nature*, 312:604-608; Takeda et al., (1985) *Nature*, 314:452-454] by splicing the genes from a mouse antibody molecule specific for a PMC amino acid sequence together with genes from an antibody molecule of appropriate biological activity can be used; such antibodies are within the scope of this invention. Such chimeric antibodies are preferred for use in therapy of intestinal diseases or disorders, since the antibodies are much less likely than xenogenic antibodies to induce an immune response, in particular an allergic response, themselves.

[0269] According to the invention, techniques described for the production of single chain antibodies (U.S. Pat. No. 4,946,778) can be adapted to produce PMC virus amino acid sequence-specific single chain antibodies. An additional embodiment of the invention utilises the techniques described for the construction of Fab expression libraries [Huse et al., (1989) *Science*, 246:1275-1281] to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for a PMC virus amino acid sequence, or its derivatives, or analogues.

[0270] Antibody fragments, which contain the idiotype of the antibody molecule, can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')₂ fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragment, and the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.

Screening for Antibodies

[0271] In the production of antibodies, screening for the desired antibody can be accomplished by techniques known in the art, e.g., radioimmunoassay, ELISA, "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope

labels, for example), Western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc.

[0272] In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labelled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention. For example, to select antibodies that recognise a specific epitope of a PMC virus amino acid sequence, one may assay generated hybridomas for a product that binds to a PMC virus amino acid sequence fragment containing such epitope. For selection of an antibody specific to a PMC virus amino acid sequence from a particular species of animal, one can select on the basis of positive binding with PMC virus amino acid sequence expressed by or isolated from cells of that species of animal.

Labelling Antibodies

[0273] Advantageously, the labelling of the anti-immunoglobulin antibodies is achieved by an enzyme selected from among those which are capable of hydrolysing a substrate, which substrate undergoes a modification of its radiation-absorption, at least within a predetermined band of wavelengths. The detection of the substrate, preferably comparatively with respect to a control, then provides a measurement of the likelihood of exposure of an animal to the virus, or of the effective presence, of the disease.

[0274] Thus, preferred methods of immunoenzymatic and also immunofluorescent detections, in particular according to the ELISA technique, are provided. Titrations may be determinations by immunofluorescence or direct or indirect immunoenzymatic determinations. Quantitative titrations of antibodies on the serums studied can be made.

Epitope Bearing Fragments

[0275] Antibodies according to the present invention may be generated using polypeptide fragments (or molecules, particularly glycoproteins having the same polypeptidic backbone as the polypeptides mentioned hereinabove) bearing an epitope characteristic of a protein or glycoprotein of PMC virus. The polypeptide or molecule may further have N-terminal and C-terminal extremities respectively either free or, independently from each other, covalently bonded to amino acids other than those which are normally associated with them in the larger polypeptides or glycoproteins of the PMC virus, which last mentioned amino acids are then free or belong to another polypeptidic sequence.

Conjugation to Increase Immunogenicity

[0276] Peptide sequences of small size bearing an epitope or immunogenic determinant, (eg those which are readily generated by chemical synthesis), may require coupling or covalent conjugation to a physiologically acceptable and non-toxic carrier molecule in order to increase their in vivo immunogenic character and thus enhance the production of antibodies.

[0277] Particularly, the invention relates to antibodies generated using hybrid polypeptides containing any of the

epitope bearing-polypeptides which have been defined more specifically hereinabove, recombined with other polypeptides fragments normally foreign to the PMC virus proteins, having sizes sufficient to provide increased immunogenicity to the epitope-bearing-polypeptide. The foreign polypeptide fragments are preferably immunogenically inert and/or do not interfere with the immunogenic properties of the epitope-bearing-polypeptide.

[0278] Such hybrid polypeptides, which may contain from 5 up to 150, even 250 amino acids, usually consist of the expression products of a vector which contains a nucleic acid sequence encoding said epitope-bearing-polypeptide expressible under the control of a suitable promoter or replicon in a suitable host.

[0279] Said epitope-bearing-polypeptides, particularly those whose N-terminal and C-terminal amino acids are free, may also be generated by chemical synthesis according to techniques well known in the chemistry of proteins.

[0280] Examples of carrier molecules or macromolecular supports which can be used for making the conjugates according to the invention are natural proteins, such as tetanic toxoid, ovalbumin, serum-albumins, hemocyanins, etc. Synthetic macromolecular carriers, for example polysines or poly (D-L-alanine)-poly(L-lysine), can also be used. Other types of macromolecular carriers that can be used, which generally have molecular weights higher than 20,000, are known from the literature.

[0281] The conjugates can be synthesized by known processes such as are described by Frantz and Robertson [*Infection & Immunity*, 33, 193-198 (1981)] and by P. E. Kauffman [*Applied and Environmental Microbiology*], October 1981 Vol. 42, No. 4, pp. 611-614]. For instance, the following coupling agents can be used: glutaric aldehyde, ethyl chloroformate, water-soluble carbodiimides such as (N-ethyl-N'(3-dimethylamino-propyl) carbodiimide, HCl), diisocyanates, bis-diazobenzidine, di- and trichloro-s-triazines, cyanogen bromides and benzaquinone, as well as the coupling agents mentioned in *Scand. J. Immunol.*, 1978, vol. 8, pp. 7-23 (Avrameas, Ternynck, Guesdon).

[0282] Any coupling process can be used for bonding one or several reactive groups of the peptide, on the one hand, and one or several reactive groups of the carrier, on the other hand. Coupling is advantageously achieved between the carboxyl and amine groups carried by the peptide and the carrier in the presence of a coupling agent of the type used in protein synthesis, e.g., 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide, N-hydroxybenzotriazole, etc. Coupling between amine groups respectively borne by the peptide and the carrier can also be made with glutaraldehyde, for instance, according to the method described by Boquet et al. (1982) *Molec. Immunol.*, 19, 1441-1549, when the carrier is haemocyanin.

[0283] The immunogenicity of epitope-bearing-peptides can also be increased by oligomerisation thereof, for example in the presence of glutaraldehyde or any other suitable coupling agent. In particular, the invention relates to the water soluble immunogenic oligomers thus obtained, comprising particularly from 2 to 10 monomer units.

Vaccines

[0284] The invention also relates to vaccine compositions whose active principle is a polypeptide or fragment thereof of the present invention i.e. the hereinabove disclosed polypeptides of PMC virus, fusion polypeptides or oligopeptides, in

association with a suitable pharmaceutically or physiologically acceptable carrier. The present invention further provides immunogenic polypeptides, and more particularly protective polypeptides, for use in the preparation of vaccine compositions against PMC or related syndromes.

[0285] Thus, the present invention provides a vaccine composition comprising a PMC virus polypeptide or fragment thereof.

[0286] Preferably, the polypeptide is an antigenic polypeptide. More preferably, the vaccine further comprises a pharmaceutically acceptable carrier or diluent.

[0287] The invention also provides a vaccine composition comprising a PMC virus nucleotide or fragment thereof that encodes for a PMC virus polypeptide.

[0288] The term "vaccine" as used herein, refers to mean any composition of the invention containing PMC virus peptide or polypeptide or nucleotide sequences coding for PMC virus polypeptides having at least one antigenic determinant which, when administered to a animal, is capable of stimulating an immune response against the antigenic determinant. It will be understood that the term vaccine does not necessarily imply that the composition will provide a complete protective response. Rather a therapeutic effect will be sufficient.

[0289] The phrase "immune response" refers to any cellular process that is produced in the animal following stimulation with an antigen and is directed toward the elimination of the antigen from the animal. The immune response typically is mediated by one or more populations of cells characterized as being lymphocytic and/or phagocytic in nature.

[0290] A vaccine may generate an immune response that blocks the infectivity, either partially or fully, of an infectious agent. The administration of the vaccine of the present invention may be for either a prophylactic or therapeutic purpose. When provided prophylactically, the vaccine is provided in advance of any exposure to PMC virus or in advance of any symptom of any symptoms due to PMC virus infection. The prophylactic administration of the immunogen serves to prevent or attenuate any subsequent infection by PMC virus in a mammal or reduce the severity of infection and/or symptoms. When provided therapeutically, the vaccine is provided at (or shortly after) the onset of the infection or at the onset of any symptom of infection or disease caused by PMC virus. The therapeutic administration of the vaccine serves to attenuate the infection or disease.

[0291] The immune response generated against an introduced PMC virus peptide or polypeptide will be dictated by the amino acid constitution of the antigenic peptide or polypeptide. Such determinants may define either humoral or cell mediated antigenic regions. Without being limited to any particular mode of action, it is contemplated that the immune response generated by the PMC virus peptide or polypeptide will preferably include both humoral and cell mediated immune responses. Where a cell mediated immune response is effected it preferably leads to a T cell cascade, and more specifically by means of a cytotoxic T cell cascade.

[0292] The term "cytotoxic T cell", as used herein, refers to any T lymphocyte expressing the cell surface glycoprotein marker CD8+ that is capable of targeting and lysing a target cell which bears a major histocompatibility class I (MHC Class I) complex on its cell surface and is infected with an intracellular pathogen.

[0293] Preferably, the vaccine composition is developed to generate antibodies against the E0 and E2 envelope glycoproteins and the NS2 and NS3 non-structural proteins.

[0294] The vaccine compositions of the present invention may be used to vaccinate animals and humans against infectious diseases, preferably against PMC. The term "animal" includes: mammals such as farm animals including sheep, goats, pigs, cows, horses, llamas, household pets such as dogs and cats, and primates; birds, such as chickens, geese and ducks; fish; and reptiles such as crocodiles and alligators.

[0295] The vaccine composition according to the invention preferably contains a nucleotide sequence as described above, either as such or as a vaccine strain or in a vector or host organism, or a polypeptide as described above, in an amount effective for producing protection against a pestivirus infection. The vaccine can also be a multipurpose vaccine comprising other immunogens or nucleotides encoding these. The vaccines can furthermore contain conventional carriers, adjuvants, solubilizers, emulsifiers, preservatives etc. The vaccines according to the invention can be prepared by conventional methods.

[0296] Preferably, the active principle is a peptide containing less than 250 amino acid units, preferably less than 150, particularly from 5 to 150 amino acid residues, as deducible from the complete genome of PMC virus.

[0297] The term 'effective amount' refers to an amount of epitope-bearing polypeptide sufficient to induce an immunogenic response in the subject to which it is administered either in a single dose or as part of a series of doses. Preferably, the effective amount is sufficient to effect prophylaxis or treatment, as defined above. The exact amount necessary will vary according to the application. For vaccine applications or for the generation of polyclonal antiserum/antibodies, for example, the effective amount may vary depending on the taxonomic group or species of subject to be treated (e.g. nonhuman primate, primate, etc.), the age and general health and physical condition of the subject, the severity of the condition being treated, the capacity of the subject's immune system to synthesize antibodies, the degree of protection desired, the formulation of the vaccine, the strain of infecting PMC virus, the particular polypeptide selected and its mode of administration, and other relevant factors. It is also believed that effective amounts will be found within a relatively large, non-critical range. An appropriate effective amount can be readily determined using only routine experimentation.

[0298] By way of example, suitable dosages of the vaccine compositions are those which are effective to elicit antibodies in vivo, in the host, particularly a porcine host. Suitable doses range from 10 to 500 µg of polypeptide, protein or glycoprotein, for instance 50 to 100 µg. Other preferred ranges of proteins for prophylaxis of PMC are 0.01 to 1000 µg/dose, preferably 0.1 to 100 µg/dose. Several doses may be needed per subject in order to achieve a sufficient immune response and subsequent protection against PMC.

[0299] The immunogenic compositions are conventionally administered using standard procedures, for example, intravenously, subcutaneously, intramuscularly, intraorbitally, ophthalmically, intraventricularly, intracranially, intracapsularly, intraspinaly, intracisternally, intraperitoneally, buccal, rectally, vaginally, intranasally, orally or by aerosol administration.

[0300] Preferably, the immunogenic composition is administered parenterally, typically by injection, for example, subcutaneously or intramuscularly. However, additional formulations suitable for other methods of administration include oral formulations and suppositories or prepared for pulmo-

nary, nasal or other forms of administration. Dosage treatment may be a single dose schedule or a multiple dose schedule.

[0301] The mode of administration of the immunogenic vaccine compositions prepared in accordance with the invention will necessarily depend upon such factors as the stability of the immunogenic compositions under physiological conditions, the intensity of the immune response required etc.

[0302] The vaccine compositions of the invention may be co-administered with additional immune response enhancers or biological response modifiers including, but not limited to, the cytokines IFN-α, IFN-γ, IL-2, IL-4, IL-6, TNF, or other cytokine-affecting immune cells. In accordance with this aspect of the invention, the PMC virus peptide or polypeptide is administered in combination therapy with a therapeutically active amount of one or more of these cytokines. In addition, conventional antibiotics may be coadministered with the PMC virus peptide or polypeptide. The choice of suitable antibiotics will however be dependent upon the disease in question.

[0303] Parenteral Delivery

[0304] The compounds provided herein can be administered by any parenteral techniques such as subcutaneous, intravenous and intraperitoneal injections. Typically, such vaccines are prepared either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared. The preparation may also be emulsified, or the protein encapsulated in liposomes. The active immunogenic ingredients are often mixed with excipients and carriers, which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof.

[0305] In addition, if desired, the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine.

[0306] Oral Delivery

[0307] Contemplated for use herein are oral solid dosage forms, which are described generally in Martin, Remington's Pharmaceutical Sciences, 18th Ed. (1990 Mack Publishing Co. Easton Pa. 18042) at Chapter 89, which is herein incorporated by reference. Solid dosage forms include tablets, capsules, pills, troches or lozenges, cachets or pellets. Also, liposomal or proteinoid encapsulation may be used to formulate the present compositions (as, for example, proteinoid microspheres reported in U.S. Pat. No. 4,925,673). Liposomal encapsulation may be used and the liposomes may be derivatised with various polymers (E.g., U.S. Pat. No. 5,013,556). A description of possible solid dosage forms for the therapeutic is given by Marshall, in Modern Pharmaceutics, Chapter 10, Banker and Rhodes ed., (1979), herein incorporated by reference. In general, the formulation will include a PMC virus polypeptide or polynucleotide, and inert ingredients which allow for protection against the stomach environment, and release of the biologically active material in the intestine.

[0308] Also specifically contemplated are oral dosage forms of PMC virus polypeptides or polynucleotides. In this respect the PMC virus polypeptides or polynucleotides may be chemically modified so that oral delivery is efficacious. Generally, the chemical modification contemplated is the attachment of at least one moiety to the protein (or peptide) molecule itself, where said moiety permits (a) inhibition of

proteolysis; and (b) uptake into the blood stream from the stomach or intestine. Also desired is the increase in overall stability of the protein and increase in circulation time in the body. Examples of such moieties include: polyethylene glycol, copolymers of ethylene glycol and propylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone and polyproline. Abuchowski et al., 1981, supra; Newmark et al., *J. Appl. Biochem.*, 4:185-189 (1982). Other polymers that could be used are poly-1,3-dioxolane and poly-1,3,6-tioxocane. Preferred for pharmaceutical usage, as indicated above, are polyethylene glycol moieties.

[0309] For PMC virus polypeptides or polynucleotides the location of release may be the stomach, the small intestine (the duodenum, the jejunum, or the ileum), or the large intestine. One skilled in the art has available formulations that will not dissolve in the stomach, yet will release the material in the duodenum or elsewhere in the intestine. Preferably, the release will avoid the deleterious effects of the stomach environment, either by protection of the complex or by release of the biologically active material beyond the stomach environment, such as in the intestine.

[0310] To ensure full gastric resistance, a coating impermeable to at least pH 5.0 is essential. Examples of the more common inert ingredients that are used as enteric coatings are cellulose acetate trimellitate (CAT), hydroxypropylmethylcellulose phthalate (HPMCP), HPMCP 50, HPMCP 55, polyvinyl acetate phthalate (PVAP), Eudragit L30D, Aquateric, cellulose acetate phthalate (CAP), Eudragit L, Eudragit S, and Shellac. These coatings may be used as mixed films.

[0311] A coating or mixture of coatings can also be used on tablets, which are not intended for protection against the stomach. This can include sugar coatings, or coatings which make the tablet easier to swallow. Capsules may consist of a hard shell (such as gelatin) for delivery of dry therapeutic i.e. powder; for liquid forms, a soft gelatin shell may be used. The shell material of cachets could be thick starch or other edible paper. For pills, lozenges, molded tablets or tablet triturates, moist massing techniques can be used.

[0312] The therapeutic can be included in the formulation as fine multiparticulates in the form of granules or pellets of particle size about 1 mm. The formulation of the material for capsule administration could also be as a powder, lightly compressed plugs or even as tablets. The therapeutic could be prepared by compression.

[0313] Colorants and flavoring agents may all be included. For example, PMC virus polypeptides or polynucleotides may be formulated (such as by liposome or microsphere encapsulation) and then further contained within an edible product, such as a refrigerated beverage containing colorants and flavoring agents.

[0314] One may dilute or increase the volume of the therapeutic with an inert material. These diluents could include carbohydrates, especially mannitol, alpha-lactose, anhydrous lactose, cellulose, sucrose, modified dextrans and starch. Certain inorganic salts may be also be used as fillers including calcium triphosphate, magnesium carbonate and sodium chloride. Some commercially available diluents are Fast-Flo, Emdex, STA-Rx 1500, Emcompress and Avicell.

[0315] Disintegrants may be included in the formulation of the therapeutic into a solid dosage form. Materials used as disintegrants include but are not limited to starch including the commercial disintegrant based on starch, Explotab. Sodium starch glycolate, Amberlite, sodium carboxymethylcellulose, ultramylopectin, sodium alginate, gelatin, orange

peel, acid carboxymethyl cellulose, natural sponge and bentonite may all be used. Another form of the disintegrants are the insoluble cationic exchange resins. Powdered gums may be used as disintegrants and as binders and these can include powdered gums such as agar, Karaya or tragacanth. Alginic acid and its sodium salt are also useful as disintegrants.

[0316] Binders may be used to hold the therapeutic agent together to form a hard tablet and include materials from natural products such as acacia, tragacanth, starch and gelatin. Others include methyl cellulose (MC), ethyl cellulose (EC) and carboxymethyl cellulose (CMC). Polyvinyl pyrrolidone (PVP) and hydroxypropylmethyl cellulose (HPMC) could both be used in alcoholic solutions to granulate the therapeutic.

[0317] An antifrictional agent may be included in the formulation of the therapeutic to prevent sticking during the formulation process. Lubricants may be used as a layer between the therapeutic and the die wall and these can include but are not limited to: stearic acid including its magnesium and calcium salts, polytetrafluoroethylene (PTFE), liquid paraffin, vegetable oils and waxes. Soluble lubricants may also be used such as sodium lauryl sulphate, magnesium lauryl sulphate, polyethylene glycol of various molecular weights, and Carbowax 4000 and 6000.

[0318] Glidants that might improve the flow properties of the complex during formulation and to aid rearrangement during compression might be added. The glidants may include starch, talc, pyrogenic silica and hydrated silicoaluminate.

[0319] To aid dissolution of the therapeutic into the aqueous environment, a surfactant might be added as a wetting agent. Surfactants may include anionic detergents such as sodium lauryl sulphate, dioctyl sodium sulphosuccinate and dioctyl sodium sulfonate. Cationic detergents might be used and could include benzalkonium chloride or benzethonium chloride. The list of potential nonionic detergents that could be included in the formulation as surfactants are lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 50 and 60, glycerol monostearate, polysorbate 40, 60, 65 and 80, sucrose fatty acid ester, methyl cellulose and carboxymethyl cellulose. These surfactants could be present in the formulation of the complex either alone or as a mixture in different ratios.

[0320] Additives which potentially enhance uptake of the complex are for instance the fatty acids oleic acid, linoleic acid and linolenic acid.

[0321] Controlled release formulation may be desirable. The complex could be incorporated into an inert matrix which permits release by either diffusion or leaching mechanisms i.e., gums. Slowly degenerating matrices may also be incorporated into the formulation. Another form of a controlled release of this therapeutic is by a method based on the Oros therapeutic system (Alza Corp.), i.e. the drug is enclosed in a semipermeable membrane which allows water to enter and push drug out through a single small opening due to osmotic effects. Some enteric coatings also have a delayed release effect.

[0322] Other coatings may be used for the formulation. These include a variety of sugars which could be applied in a coating pan. The therapeutic agent could also be given in a film-coated tablet; the materials used in this instance are divided into 2 groups. The first are the nonenteric materials and include methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, methylhydroxy-ethyl cellulose, hydroxypropyl

cellulose, hydroxypropyl-methyl cellulose, sodium carboxymethyl cellulose, providone and the polyethylene glycols. The second group consists of the enteric materials that are commonly esters of phthalic acid.

[0323] A mix of materials might be used to provide the optimum film coating. Film coating may be carried out in a pan coater or in a fluidized bed or by compression coating.

[0324] Pulmonary Delivery

[0325] Also contemplated herein is pulmonary delivery of vaccine composition. The PMC virus polypeptides or polynucleotides may be delivered to the lungs of an animal while inhaling and traverses across the lung epithelial lining to the blood-stream.

[0326] Contemplated for use in the practice of this invention are a wide range of mechanical devices designed for pulmonary delivery of therapeutic products, including but not limited to nebulizers, metered-dose inhalers, and powder inhalers, all of which are familiar to those skilled in the art.

[0327] Some specific examples of commercially available devices suitable for the practice of this invention are the Ultravent nebulizer, manufactured by Mallinckrodt, Inc., St. Louis, Mo.; the Acorn II nebulizer, manufactured by Marquest Medical Products, Englewood, Colo.; the Ventolin metered dose inhaler, manufactured by Glaxo Inc., Research Triangle Park, North Carolina; and the Spinhaler powder inhaler, manufactured by Fisons Corp., Bedford, Mass.

[0328] All such devices require the use of formulations suitable for the dispensing of the complex. Typically, each formulation is specific to the type of device employed and may involve the use of an appropriate propellant material, in addition to the usual diluents, adjuvants and/or carriers useful in therapy. Also, the use of liposomes, microcapsules or microspheres, inclusion complexes, or other types of carriers is contemplated. Chemically modified proteins may also be prepared in different formulations depending on the type of chemical modification or the type of device employed.

[0329] Formulations suitable for use with a nebulizer, either jet or ultrasonic, will typically comprise the complex suspended in water at a concentration of about 0.1 to 25 mg of biologically active protein per ml of solution. The formulation may also include a buffer and a simple sugar (e.g., for protein stabilization and regulation of osmotic pressure). The nebulizer formulation may also contain a surfactant, to reduce or prevent surface induced aggregation of the protein caused by atomization of the solution in forming the aerosol.

[0330] Formulations for use with a metered-dose inhaler device will generally comprise a finely divided powder containing the complex suspended in a propellant with the aid of a surfactant. The propellant may be any conventional material employed for this purpose, such as a chlorofluorocarbon, a hydrochlorofluorocarbon, a hydrofluorocarbon, or a hydrocarbon, including trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol, and 1,1,1,2-tetrafluoroethane, or combinations thereof. Suitable surfactants include sorbitan trioleate and soya lecithin. Oleic acid may also be useful as a surfactant.

[0331] Formulations for dispensing from a powder inhaler device will comprise a finely divided dry powder containing the complex and may also include a bulking agent, such as lactose, sorbitol, sucrose, or mannitol in amounts which facilitate dispersal of the powder from the device, e.g., 50 to 90% by weight of the formulation. The protein (or derivative) should most advantageously be prepared in particulate form

with an average particle size of less than 10 microns, most preferably 0.5 to 5 microns, for most effective delivery to the distal lung.

Nasal Delivery

[0332] Nasal delivery of the vaccine comprising PMC virus polypeptides or polynucleotides is also contemplated. Nasal delivery allows the passage of the protein to the blood stream directly after administering the therapeutic product to the nose, without the necessity for deposition of the product in the lung. Formulations for nasal delivery include those with dextran or cyclodextran.

Therapeutic Compositions

Polypeptide Based Therapies

[0333] The PMC virus polypeptides according to present invention also can be used as a prophylactic or therapeutic, which may be utilised for the purpose of stimulating humoral and cell mediated responses in animals, such as swine, thereby providing protection against infection with PMC virus. Natural infection with PMC virus induces circulating antibody titres against PMC virus. Therefore, PMC virus amino acid sequence or parts thereof, have the potential to form the basis of a systemically or orally administered prophylactic or therapeutic to provide protection against PMC.

[0334] Thus, the invention provides pharmaceutical compositions comprising a PMC virus polypeptide that enhances the immunocompetence of the host individual and elicits specific immunity against pathogens, preferably PMC virus.

[0335] The therapeutic regimens and pharmaceutical compositions of the invention are described elsewhere in the specification. These compositions are believed to have the capacity to prevent the onset and progression of infectious disease such as PMC.

[0336] Preferably the compositions are combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition (which may be for human or animal use). Compositions of the invention comprising PMC virus polypeptides may also be combined with suitable components to obtain vaccine compositions. Accordingly, in one embodiment the present invention provides a PMC virus amino acid sequence or fragments thereof described herein in a therapeutically effective amount admixed with a pharmaceutically acceptable carrier, diluent, or excipient.

[0337] The phrase "therapeutically effective amount" is used herein to mean an amount sufficient to reduce by at least about 15%, preferably by at least 50%, more preferably by at least 90%, and most preferably prevent, a clinically significant deficit in the activity, function and response of the animal host. Alternatively, a therapeutically effective amount is sufficient to cause an improvement in a clinically significant condition in the animal host or to stimulate by at least about 15%, preferably by at least 50%, more preferably by at least 90%, and most preferably completely, a animal's immune system, causing it to generate an immunological memory against the antigenic determinant.

[0338] The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an allergic or similarly untoward reaction, such as gastric upset and the like, when administered to an animal. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered. Such pharmaceutical carriers can be

sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water or saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described in Martin, *Remington's Pharmaceutical Sciences*, 18th Ed., Mack Publishing Co., Easton, Pa., (1990).

[0339] In a more specific form of the invention there are provided pharmaceutical compositions comprising therapeutically effective amounts of PMC virus amino acid sequence or an analogue, fragment or derivative product thereof together with pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers. Such compositions include diluents of various buffer content (e.g., Tris-HCl, acetate, phosphate), pH and ionic strength and additives such as detergents and solubilizing agents (e.g., Tween 80, Polysorbate 80), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimersol, benzyl alcohol) and bulking substances (e.g., lactose, mannitol). The material may be incorporated into particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, etc. or into liposomes. Hylauronic acid may also be used. Such compositions may influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the present proteins and derivatives. See, e.g., Martin, *Remington's Pharmaceutical Sciences*, 18th Ed. 1990, Mack Publishing Co., Easton, Pa., pp 1435-1712 that are herein incorporated by reference. The compositions may be prepared in liquid form, or may be in dried powder, such as lyophilised form.

[0340] The present invention also provides for the use of PMC virus amino acid sequences according to the invention, for manufacture of a medicament for modulation of a disease associated with PMC virus.

Antibody Based Therapeutics

[0341] The present invention also provides therapeutic compositions comprising antibodies prepared against the polypeptides of the invention.

[0342] The antibodies can be used directly as antiviral agents. To prepare antibodies, a host animal is immunized using one or more PMC virus proteins bound to a carrier as described above for vaccines. The host serum or plasma is collected following an appropriate time interval to provide a composition comprising antibodies reactive with the protein (s) of the virus particle. The gamma globulin fraction or the IgG antibodies can be obtained, for example, by use of saturated ammonium sulfate or DEAE Sephadex, or other techniques known to those skilled in the art. The antibodies are substantially free of many of the adverse side effects which may be associated with other anti-viral agents such as drugs.

[0343] Such therapeutic antibody compositions may additionally contain one or more of the additional agents described above in relation to polypeptide therapeutics.

[0344] The present invention provides for the use of antibodies against the PMC virus according to the invention, for manufacture of a medicament for modulation of a disease associated with PMC virus.

Polynucleotide Based Therapy

[0345] The present invention further provides therapeutic compositions comprising PMC virus nucleic acid sequences

as well as antisense and ribozyme polynucleotide sequences hybridisable to a polynucleotide sequence encoding a PMC virus amino acid sequence according to the invention.

[0346] Polynucleotide sequences encoding antisense constructs or ribozymes for use in therapeutic methods are desirably administered directly as a naked nucleic acid construct. Uptake of naked nucleic acid constructs is enhanced by several known transfection techniques, for example those including the use of transfection agents. Example of these agents include cationic agents (for example calcium phosphate and DEAE-dextran) and lipofectants (for example Lipofectam™ and Transfectam™). Typically, nucleic acid constructs are mixed with the transfection agent to produce a composition.

[0347] Alternatively the antisense construct or ribozymes may be combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition. Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline. The composition may be formulated for parenteral, intramuscular, intravenous, subcutaneous, intraocular, oral or transdermal administration.

[0348] Also addressed by the present invention is the use of polynucleotide sequences of the invention, as well as antisense and ribozyme polynucleotide sequences hybridisable to a polynucleotide sequence encoding a PMC virus amino acid sequence according to the invention, for manufacture of a medicament for modulation of a disease associated with PMC virus.

Administration of Therapeutic Compositions

[0349] It will be appreciated that therapeutic compositions provided accordingly to the invention may be administered by any means known in the art. Therapeutic compositions may be for administration by injection, or prepared for oral, pulmonary, nasal or other forms of administration. The mode of administration of the therapeutic compositions prepared in accordance with the invention will necessarily depend upon such factors as the stability of the complex under physiological conditions, the intensity of the immune response required etc.

[0350] Preferably, the pharmaceutical compositions for administration are administered by injection, orally, or by the pulmonary, or nasal route.

[0351] Preferably, the therapeutic compositions are administered using standard procedures, for example, intravenously, subcutaneously, intramuscularly, intraorbitally, ophthalmically, intraventricularly, intracranially, intracapsularly, intraspinally, intracisternally, intraperitoneally, buccal, rectally, vaginally, intranasally, orally or by aerosol administration.

[0352] The PMC virus amino acid sequence or antibodies derived there from, or polynucleotide sequences are more preferably delivered by intravenous, intra-arterial, intraperitoneal, intramuscular, or subcutaneous routes of administration. Alternatively, the PMC virus amino acid sequence or antibodies derived there from, properly formulated, can be administered by nasal or oral administration. The routes of administration described are intended only as a guide since a skilled practitioner will be able to determine readily the optimum route of administration and any dosage for any particular animal and condition.

[0353] The present invention further provides a method of inducing a protective immune response in an animal or human against a PMC virus comprising the steps of:

[0354] a) administering to said animal or human an effective amount of a composition of the invention.

[0355] The present invention also provides methods for enhancing an animal's immunocompetence and the activity of its immune effector cells against a PMC virus comprising the step of:

[0356] a) administering a composition comprising a therapeutically effective amount of a PMC virus peptide or polypeptide.

Live Vector Delivery Agent

[0357] In another aspect of the invention, the PMC virus may be used as a live vector for delivery of recombinant antigens.

[0358] Thus, the present invention provides a live vector comprising the PMC virus and a heterologous polynucleotide.

[0359] Preferably, the heterologous polynucleotide is operably linked to the polynucleotide sequence of the PMC virus, such that expression of the polynucleotide sequence of the PMC virus also leads to expression of the heterologous polynucleotide sequence.

[0360] Furthermore, the PMC virus may have one or more sections of autologous polynucleotide sequence removed. Removal of such sequence may preferably render the live virus attenuated in pathogenicity in a host subject.

[0361] For example, the PMC virus may be used as a delivery vector to deliver gene sequences that encode a protein from a second infective agent into a subject to be vaccinated against the second infective agent. The second infective agent may be a virus (such as classical swine fever virus), a bacteria, a parasite etc.

[0362] Alternatively, the PMC virus may be used as a delivery vector to deliver antigens from some other source. For example, a PMC virus vector may be used to deliver antigenic proteins to a subject to stimulate the subject to make antibodies against the antigenic proteins that may be collected for purposes such as use in diagnostic kits etc.

Drug Screening Assays

[0363] The present invention also provides assays that are suitable for identifying substances such as drugs, agents or ligands that bind to PMC virus amino acid sequences. In addition, assays are provided that are suitable for identifying substances that interfere with PMC virus amino acid sequences. Assays are also provided that test the effects of candidate substances identified in preliminary *in vitro* assays on intact cells in whole cell assays.

[0364] Thus, the present invention provides a method of screening for drugs comprising the steps of:

[0365] a) contacting an agent with a PMC virus amino acid sequence or fragment thereof and

[0366] b) assaying for the presence of a complex between the agent and the PMC virus amino acid sequence or fragment.

[0367] The present invention also provides a method of screening for ligands of the proteins of the PMC virus comprising the steps of:

[0368] a) contacting a ligand with a PMC virus amino acid sequence or fragment thereof and

[0369] b) assaying for the presence of a complex between the PMC virus amino acid sequence or fragment and a ligand.

[0370] One type of assay for identifying substances such as drugs, agents or ligands that bind to PMC virus amino acid sequences involves contacting a PMC virus amino acid sequence, which is immobilised on a solid support, with a non-immobilised candidate substance and determining whether and/or to what extent the PMC virus amino acid sequences and candidate substance bind to each other. Alternatively, the candidate substance may be immobilised and the PMC virus amino acid sequence non-immobilised.

[0371] In a preferred assay method, the PMC virus amino acid sequence is immobilised on beads such as agarose beads. Typically this is achieved by expressing the component as a GST-fusion protein in bacteria, yeast or higher eukaryotic cell lines and purifying the GST-fusion protein from crude cell extracts using glutathione-agarose beads. The binding of the candidate substance to the immobilised PMC virus amino acid sequence is then determined. This type of assay is known in the art as a GST pulldown assay. Again, the candidate substance may be immobilised and the PMC virus amino acid sequence non-immobilised.

[0372] It is also possible to perform this type of assay using different affinity purification systems for immobilising one of the components, for example Ni-NTA agarose and hexahistidine-tagged components.

[0373] Binding of the PMC virus amino acid sequence to the candidate substance may be determined by a variety of methods well known in the art. For example, the non-immobilised component may be labelled (with for example, a radioactive label, an epitope tag or an enzyme-antibody conjugate). Alternatively, binding may be determined by immunological detection techniques. For example, the reaction mixture can be Western blotted and the blot probed with an antibody that detects the non-immobilised component. ELISA techniques may also be used.

[0374] Candidate substances are typically added to a final concentration of from 1 to 1000 nmol/ml, more preferably from 1 to 100 nmol/ml. In the case of antibodies, the final concentration used is typically from 100 to 500 µg/ml, more preferably from 200 to 300 µg/ml.

[0375] In a competitive binding assay the PMC virus amino acid sequence or fragment is typically labelled. Free PMC virus amino acid sequence or fragment is separated from that present in a protein:protein complex, and the amount of free (i.e., uncomplexed) label is a measure of the binding of the agent being tested to the PMC virus amino acid sequence or its interference with PMC virus amino acid sequence: ligand binding, respectively.

[0376] Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the PMC virus amino acid sequence and is described in detail in PCT Application WO 84/03564, published on Sep. 13, 1984. Briefly stated, large numbers of different small peptide test compounds are synthesised on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with PMC virus amino acid sequence and washed. Bound PMC virus amino acid sequence is then detected by methods well known in the art.

[0377] This invention also contemplates the use of competitive drug screening assays in which antibodies capable of specifically binding the PMC virus amino acid sequence compete with a test compound for binding to the PMC virus amino acid sequence or fragments thereof. In this manner, the

antibodies can be used to detect the presence of any peptide that shares one or more antigenic determinants of the PMC virus amino acid sequence.

Kits

[0378] In a further embodiment of this invention, kits may be prepared to determine the presence or absence of PMC virus in suspected infected animals and/or to quantitatively measure PMC infection. In accordance with the testing techniques discussed above, one class of such kits will contain at least the labelled PMC virus amino acid sequence or its binding partner, for instance an antibody specific thereto, and directions depending upon the method selected, e.g., "competitive," "sandwich," "DASP" and the like. The kits may also contain peripheral reagents such as buffers, stabilizers, etc.

[0379] Thus, kits for PMC virus serum immunoassay may be either (a) a sandwich type immunoassay, employing a first anti-PMC virus antibody as capture or detector antibody and a second anti-PMC virus antibody as a detector or capture antibody to complement the first anti-PMC virus antibody, or (b) a competitive type immunoassay, employing a anti-PMC virus antibody with a labelled PMC virus antigen or a PMC virus antigen attached to a solid phase.

[0380] Accordingly, a test kit may be prepared for the demonstration of the presence of PMC virus comprising:

[0381] (a) a predetermined amount of at least one labelled immunochemically reactive component obtained by the direct or indirect attachment of the present PMC virus amino acid sequence or a specific binding partner thereto, to a detectable label;

[0382] (b) other reagents; and

[0383] (c) directions for use of said kit.

[0384] More specifically, the diagnostic test kit may comprise:

[0385] (a) a known amount of the PMC virus amino acid sequence as described above (or a binding partner) generally bound to a solid phase to form an immunosorbent, or in the alternative, bound to a suitable tag, or there are a plural of such end products, etc;

[0386] (b) if necessary, other reagents; and

[0387] (c) directions for use of said test kit.

[0388] In a further variation, the test kit may be prepared and used for the purposes stated above, which operates according to a predetermined protocol (e.g. "competitive," "sandwich," "double antibody," etc.), and comprises:

[0389] (a) a labelled component which has been obtained by coupling the PMC virus amino acid sequence to a detectable label;

[0390] (b) one or more additional immunochemical reagents of which at least one reagent is a ligand or an immobilized ligand, which ligand is selected from the group consisting of:

[0391] (i) a ligand capable of binding with the labelled component (a);

[0392] (ii) a ligand capable of binding with a binding partner of the labelled component (a);

[0393] (iii) a ligand capable of binding with at least one of the component(s) to be determined; or

[0394] (iv) a ligand capable of binding with at least one of the binding partners of at least one of the component(s) to be determined; and

[0395] (c) directions for the performance of a protocol for the detection and/or determination of one or more

components of an immunochemical reaction between the PMC virus amino acid sequence and a specific binding partner thereto.

Kits to Detect Antibodies

[0396] The invention also provides diagnostic kits for the in vitro detection of antibodies against the PMC virus, which kits comprise any of the polypeptides identified herein and all the biological and chemical reagents, as well as equipment, necessary for performing diagnostic assays.

[0397] Accordingly, the invention provides a kit for demonstrating the presence of PMC virus comprising:

[0398] (a) a predetermined amount of at least one labelled antibody to the PMC virus;

[0399] (b) other reagents; and

[0400] (c) directions for use of said kit.

[0401] Preferably, the polypeptide used in the kit is an antigenic or epitope bearing polypeptide. Most preferably, the polypeptide is a polypeptide encoding, but not exclusively limited to, the E0, E2, NS2 or NS3 protein.

[0402] Preferred kits comprise all reagents required for carrying out ELISA assays. Thus preferred kits will include, in addition to any of said polypeptides, suitable buffers and anti-species immunoglobulins, which anti-species immunoglobulins are labelled either by an immunofluorescent molecule or by an enzyme. In the last instance, preferred kits also comprise a substrate hydrolysable by the enzyme and providing a signal, particularly modified absorption of a radiation, at least in a determined wavelength, which signal is then indicative of the presence of antibody in the biological fluid to be assayed with said kit. Kits may also include labelled monoclonal or polyclonal antibodies that are directed against PMC virus epitopes and these labelled antibodies may be used to block or compete with antibodies from the test specimen. If the activity of the labelled antibody is blocked, no or a reduced reaction will occur and it can be deduced that the test specimen contains antibodies to PMC virus.

[0403] The present invention also relates to a diagnostic kit for use in detecting the presence of PMC virus antibodies, said kit comprising at least one peptide as defined above, with said peptide being preferably bound to a solid support.

[0404] The peptide, for example, can be attached to a variety of different solid supports to enable the washing away of unreacted reagents during the course of using the kit. These include: microwells, coated test tubes, coated magnetic particles, wands or sticks, and membranes (nitrocellulose and others).

[0405] Preferably, the peptides are attached to specific locations on the solid support. More preferably, the solid support is a membrane strip and said peptides are coupled to the membrane in the form of parallel lines. Preferably, the peptide used in the kit is an antigenic or epitope bearing peptide.

[0406] The PMC virus antigens of the present invention will typically be packaged in the form of a kit for use in these immunoassays. The kit will normally contain, in separate containers, the PMC virus antigen, control antibody formulations (positive and/or negative), labelled antibody when the assay format requires the same and signal generating reagents (e.g. enzyme substrate) if the label does not generate a signal directly. The PMC virus antigen may be already bound to a solid support or may be provided separately, with reagents for binding it to the solid support. Instructions (e.g. written, tape, CD-ROM, etc.) for carrying out the assay usually will be included in the kit.

[0407] Immunoassays that utilize PMC virus antigens are useful in screening samples (such as blood, serum, plasma, milk, body fluids) to detect if the subject from which the tissue was derived has been exposed to or infected with PMC virus.

[0408] The solid support used in the kits of the present invention can include polymeric or glass beads, nitrocellulose, microparticles, microwells of a reaction tray, test tubes and magnetic beads.

[0409] The signal generating compound can include an enzyme, a luminescent compound, a fluorophore such as fluorescein, a time-resolved fluorescent probe such as a europium chelate, a chromogen, a radioactive element, a chemiluminescent compound such as an acridinium ester or particles such as colloidal gold, plain latex, or dyed latex. Examples of enzymes include alkaline phosphatase, horseradish peroxidase and beta-galactosidase.

Kits to Detect Polypeptides and Antigens

[0410] The present invention further provides a diagnostic kit for use in detecting the presence of PMC virus proteins.

[0411] Accordingly, the invention provides a kit for demonstrating the presence of PMC virus comprising:

[0412] (a) a predetermined amount of at least one labelled polypeptide derived from the PMC virus;

[0413] (b) other reagents; and

[0414] (c) directions for use of said kit.

[0415] Preferably, said antibody is bound to a solid support. The antibody can be attached to a variety of different solid supports to enable the washing away of unreacted reagents during the course of using the kit. These include: microwells, coated test tubes, coated magnetic particles, wands or sticks, and membranes (nitrocellulose and others). Preferably, the antibodies are attached to specific locations on a solid substrate.

[0416] The anti-PMC virus antibody can be attached to the solid support by a variety of means such as passive adsorption, covalent coupling, or by using a solid phase pre-coated with a secondary binder such as protein A, protein G, a secondary antibody specific for the primary antibody, avidin, or an antibody specific for a particular ligand (i.e.: biotin, dinitrophenol, fluorescein, and others). In the case of avidin or any of the ligand specific antibodies, it is necessary to covalently attach the ligand to the anti-PMC virus antibody.

[0417] For example, ELISA kits may be used to detect the presence of antigens to PMC virus in a sample to demonstrate that an animal is suffering from PMC or is, for example, a non-symptomatic carrier of the virus.

[0418] Preferably, the protein to be detected using the present kit is an antigen or an epitope bearing region of a PMC virus protein. Most preferably, the antibody binds to the E0, E2, NS2 or NS3 protein of PMC.

Kits to Detect Nucleic Acid Sequences

[0419] The invention also provides kits for screening animals suspected of being infected with PMC virus, or to confirm that an animal is infected with PMC virus, by detecting PMC virus nucleic acid sequences.

[0420] Accordingly, the invention provides a kit for demonstrating the presence of PMC virus comprising:

[0421] (a) a predetermined amount of at least one labelled nucleic acid sequence derived from the PMC virus;

[0422] (b) other reagents; and

[0423] (c) directions for use of said kit.

[0424] For example, the polynucleotide sequence may be one or more primers, such as those exemplified above, and the instructions for use may be instructions to perform PCR on RNA or DNA extracted from a tissue sample from a subject.

Vectors, Host Cells Etc

Vectors

[0425] The present invention also provides a recombinant expression vector comprising a PMC virus nucleic acid sequence or a part thereof as defined above, operably linked to prokaryotic, eukaryotic or viral transcription and translation control elements.

[0426] The invention further relates to the hosts (prokaryotic or eukaryotic cells) which are transformed by the above mentioned vectors and recombinants and which are capable of expressing said RNA and/or DNA fragments.

[0427] According to another embodiment the present invention provides methods for preparing a PMC virus amino acid sequence, comprising the steps of:

[0428] (a) culturing a host cell containing a vector as described above under conditions that provide for expression of the PMC virus amino acid sequence; and

[0429] (b) recovering the expressed PMC virus sequence.

[0430] This procedure can also be accompanied by the step of:

[0431] (c) subjecting the amino acid sequence to protein purification.

[0432] The present invention also relates to a method for the production of a recombinant PMC virus polypeptide, comprising the steps of:

[0433] a) transforming an appropriate cellular host with a recombinant vector, in which a PMC virus polynucleotide sequence or a part thereof has been inserted under the control of appropriate regulatory elements,

[0434] b) culturing said transformed cellular host under conditions enabling the expression of said insert, and,

[0435] c) harvesting said polypeptide.

[0436] Vectors provided by the present invention will typically comprise a PMC virus polynucleotide sequence encoding the desired amino acid sequence and preferably transcription and translational regulatory sequences operably linked to the amino acid encoding sequence so as to allow for the expression of the antigenic polypeptide in the cell. Preferably, the vector will include appropriate prokaryotic, eukaryotic or viral promoter sequence followed by the PMC virus nucleotide sequences as defined above. The recombinant vector of the present invention may preferably allow the expression of any one of the PMC virus polypeptides as defined above in a prokaryotic, or eukaryotic host or in living mammals when injected as naked RNA or DNA.

[0437] The vector may comprise a plasmid, a cosmid, a phage, or a virus or a transgenic animal. Particularly useful for vaccine development may be BCG or adenoviral vectors, as well as avipox recombinant viruses. Examples of such expression vectors are described in Sambrook et al., (1989) supra or Ausubel et al., (2001) supra. Many useful vectors are known in the art and may be obtained from such vendors as Stratagene, New England Biolabs, Promega Biotech, and others.

[0438] It may be desirable to use regulatory control sequences that allow for inducible expression of the antigenic polypeptide, for example in response to the administration of an exogenous molecule. Alternatively, temporal control of expression of the antigenic polypeptide may occur by only introducing the polynucleotide into the cell when it is desired to express the polypeptide.

[0439] It may also be convenient to include an N-terminal secretion signal so that the antigenic polypeptide is secreted into the cell medium.

[0440] Expression vectors may also include, for example, an origin of replication or autonomously replicating sequence and expression control sequences, a promoter, an enhancer and necessary processing information sites, such as ribosome-binding sites, RNA splice sites, polyadenylation sites, transcriptional terminator sequences, and mRNA stabilising sequences. Secretion signals may also be included where appropriate, from secreted polypeptides of the same or related species, which allow the protein to cross and/or lodge in cell membranes, and thus attain its functional topology, or to be secreted from the cell. Such vectors may be prepared by means of standard recombinant techniques well known in the art and discussed, for example, in Sambrook et al., (1989) or Ausubel et al., (2001).

[0441] An appropriate promoter and other necessary vector sequences will be selected so as to be functional in the host, and may include, when appropriate, those naturally associated with outer membrane lipoprotein genes.

[0442] Promoters such as the trp, lac and phage promoters, tRNA promoters and glycolytic enzyme promoters may be used in prokaryotic hosts. Useful yeast promoters include promoter regions for metallothionein, 3-phosphoglycerate kinase or other glycolytic enzymes such as enolase or glyceraldehyde-3-phosphate dehydrogenase, enzymes responsible for maltose and galactose utilization, and others. Vectors and promoters suitable for use in yeast expression are further described in Hitzeman et al., EP 73,675A. Appropriate non-native mammalian promoters might include the early and late promoters from SV40 or promoters derived from murine Moloney leukaemia virus, avian sarcoma viruses, adenovirus II, bovine papilloma virus or polyoma. In addition, the construct may be joined to an amplifiable gene (e.g., DHFR) so that multiple copies of the gene may be made.

[0443] While such expression vectors may replicate autonomously, they may also replicate by being inserted into the genome of the host cell, by methods well known in the art.

[0444] Expression and cloning vectors will likely contain a selectable marker, a gene encoding a protein necessary for survival or growth of a host cell transformed with the vector. The presence of this gene ensures growth of only those host cells that express the inserts. Typical selection genes encode proteins that a) confer resistance to antibiotics or other toxic substances, e.g. ampicillin, neomycin, methotrexate, etc.; b) complement auxotrophic deficiencies, or c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for Bacilli. The choice of the proper selectable marker will depend on the host cell, and appropriate markers for different hosts are well known in the art.

[0445] Vectors containing PMC virus polynucleotide sequences can be transcribed in vitro and the resulting RNA introduced into the host cell by well-known methods, e.g., by injection, or the vectors can be introduced directly into host cells by methods well known in the art, which vary depending

on the type of cellular host, including electroporation; transfection employing calcium chloride, rubidium chloride, calcium phosphate, DEAE-dextran, or other substances; micro-projectile bombardment; lipofection; infection (where the vector is an infectious agent, such as a retroviral genome); and other methods. The introduction of PMC virus polynucleotide sequences into the host cell may be achieved by any method known in the art, including, inter alia, those described above.

[0446] In a preferred embodiment, the PMC virus polynucleotide is part of a viral vector, such as a baculovirus vector, or infectious virus, such as a baculovirus. This provides a convenient system since not only can recombinant viral stocks can be maintained and stored until ready for use. Desirably, the nucleotide sequence encoding the antigenic peptide or polypeptides is inserted into a recombinant baculovirus that has been genetically engineered to produce antigenic peptide or polypeptides, for instance, by following the methods of Smith et al (1983) *Mol Cell Biol* 12: 2156-2165. A number of viral transfer vectors allow more than one polynucleotide sequence encoding a polypeptide to be inserted into the same vector so that they can be co-expressed by the same recombinant virus.

Host Cells

[0447] To produce a cell capable of expressing PMC virus amino acid sequences, preferably polynucleotide sequences of the invention are incorporated into a recombinant vector, which is then introduced into a host prokaryotic or eukaryotic cell.

[0448] The invention also provides host cells transformed or transfected with a PMC virus polynucleotide sequence. Preferred host cells include yeast, filamentous fungi, plant cells, insect, amphibian, avian species, bacteria, mammalian cells, and human cells in tissue culture. Illustratively, such host cells are selected from the group consisting of *E. coli*, *Pseudomonas*, *Bacillus*, *Streptomyces*, yeast, CHO, R1.1, B-W, L-M, COS1, COS 7, BSC1, BSC40, BMT10, and Sf9 cells.

[0449] Large quantities of PMC virus polynucleotide sequence of the invention may be prepared by expressing PMC virus polynucleotide sequences or portions thereof in vectors or other expression vehicles in compatible prokaryotic or eukaryotic host cells. The most commonly used prokaryotic hosts are strains of *Escherichia coli*, although other prokaryotes, such as *Bacillus subtilis* or *Pseudomonas* may also be used. Examples of commonly used mammalian host cell lines are VERO and HeLa cells, Chinese hamster ovary (CHO) cells, and WI38, BHK, and COS cell lines, although it will be appreciated by the skilled practitioner that other cell lines may be appropriate.

[0450] Also provided are mammalian cells containing a PMC virus polynucleotide sequences modified in vitro to permit higher expression of PMC virus amino acid sequence by means of a homologous recombinational event consisting of inserting an expression regulatory sequence in functional proximity to the PMC virus amino acid sequence encoding sequence.

[0451] The invention is not limited to the production of one antigenic polypeptide at a time in the host cell. Multiple polynucleotides encoding different antigenic polypeptides of interest may be introduced into the same host cell. The poly-

nucleotides may be part of the same nucleic acid molecule or separate nucleic acid molecules.

General

[0452] Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in the specification, individually or collectively and any and all combinations or any two or more of the steps or features.

[0453] The present invention is not to be limited in scope by the specific embodiments described herein, which are intended for the purpose of exemplification only. Functionally equivalent products, compositions and methods are clearly within the scope of the invention as described herein.

[0454] The entire disclosures of all publications (including patents, patent applications, journal articles, laboratory manuals, books, or other documents) cited herein are hereby incorporated by reference. No admission is made that any of the references constitute prior art or are part of the common general knowledge of those working in the field to which this invention relates.

[0455] As used herein the term “derived” and “derived from” shall be taken to indicate that a specific integer may be obtained from a particular source albeit not necessarily directly from that source.

[0456] Throughout this specification, unless the context requires otherwise, the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

[0457] Other definitions for selected terms used herein may be found within the detailed description of the invention and apply throughout. Unless otherwise defined, all other scientific and technical terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which the invention belongs.

EXAMPLES

[0458] The following examples serve to more fully describe the manner of using the above-described invention, as well as to set forth the best modes contemplated for carrying out various aspects of the invention. It is understood that these methods in no way serve to limit the true scope of this invention, but rather are presented for illustrative purposes.

Example 1

Sample Preparation

[0459] Tissue samples were extracted and prepared using a method whose main basis was derived from Allander et al (2001) “A virus discovery method incorporating DNase treatment and its application to the identification of two bovine parvovirus species.” Proc Natl Acad Sci USA. 98(20): 11609-14, with some modifications to improve the efficiency from Baugh et al (2001) “Quantitative analysis of mRNA amplifi-

cation by in vitro transcription.” Nucleic Acids Res. 29(5): E29. However, the methods were modified to improve efficiency.

1. Preparation of Serum Samples:

- [0460]** a) Obtain at least 240 μ L of supernatant from a tissue homogenate or serum and divide into 2 \times 120 ul lots
- [0461]** b) To each 120 ul of sample add 240 ul of PBS or H₂O (or take 50 ul sera+100 ul PBS)
- [0462]** c) Filter diluted sample through two separate 0.2 μ m filters by centrifuging at 2000 \times g (wash top of filter and keep at -20° C.)
- [0463]** d) Add 25 ul DNASE I (250 U) to each tube of filtered sample and incubate at 37° C. for 2 hr
- [0464]** e) Add 1 ul of RNase Cocktail (500 U RNase A, 20000 U RNase T1) to each tube and incubate at RT for 1 hr.
- [0465]** f) Take 1 tube of treated sample (360 ul) for RNA extraction and one tube for DNA extraction (add 500 ul DNaseasy AL+50 ul proteinase K etc and elute in 50 ul water).

2. RNA Extraction:

- [0466]** a) Divide sample into 90 ul lots and add 600 ul RLT, ie 4 \times 690 ul
- [0467]** b) Homogenize by passing through 21G syringe at least 5 \times
- [0468]** c) Add 690 ul of 70% ethanol to each tube of sample and mix by pipetting
- [0469]** d) Apply 700 ul of sample to column at a time and centrifuge for 15 sec at 10,000 rpm. Place flow through waste in a 5 ml container and keep at -80° C.
- [0470]** e) Add 700 ul of buffer RW1 to the column and centrifuge for 15 sec at 10,000 rpm. Discard flow through material and collection tube.
- [0471]** f) Transfer column to a new tube and add 500 ul of RPE centrifuge for 15 sec at 10,000 rpm, discard flow through material
- [0472]** g) Repeat step (f) using same tube but centrifuge for 2 min at 10,000 rpm.
- [0473]** h) Transfer column to a new tube and centrifuge for 1 min at 10,000 rpm.
- [0474]** i) Elute the RNA in 20 ul of RNase free water, let the water sit on the column for 1 minute before centrifuging. Reuse the eluate and centrifuge for 1 min at 10,000 rpm to collect any left over RNA on column.
- [0475]** j) Store RNA at -80° C. until needed.

3. DNA Extraction:

- [0476]** a) To 360 ul of sample add 36 ul of proteinase K and 360 ul of buffer AL, mix by vortex, incubate at 70° C. for 10 minutes.
- [0477]** b) Add 360 ul of 100% ethanol, mix by vortexing
- [0478]** c) Pipette mixture from step (b) into DNaseasy column and centrifuge at 8,000 rpm for 1 minute. Place flow-through into a tube and store at -80° C.
- [0479]** d) Place column in a new tube and add 500 ul of AW1 spin at 8,000 rpm for 1 minute. Discard flow through and tube.
- [0480]** e) Place column in a new tube and add 500 ul of AW2 and spin at 13,000 rpm for 3 minutes. Discard flow through and spin for another 1 minute and discard flow through and tube.

[0481] f) Place column in a new tube, add 50 ul of water and let sit for 1 minute. Spin at 8,000 rpm for 1 min and collect eluate. Reapply the 50 ul eluate and spin again.

[0482] g) Store DNA at -80°C . until needed.

RNA Sequence-Independent Single Primer Amplification (SISPA) for Double stranded RNA viruses

[0483] The SISPA method employed was developed from that of Baugh et al and Allander et al, to maximise yield and product length while minimising template-independent side reactions. However, the present method is applied to low yield viral RNA, not total mRNA and a melting step has been added.

4. First Strand cDNA Synthesis

a) Mix together the following:

[0484] 1 ul random hexamers (10 pmol)

[0485] 8 ul-9 ul RNA (in H_2O)

b) Mix, heat 90°C . 3 minutes, spin and put on ice

c) On ice add:

[0486]

1 st strand buffer	4 ul
0.1M dTT	2 ul
5 mM dNTP	2 ul
SSIII (400U)	1 ul
T4gene32	1 ul

1st strand buffer: 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl_2

d) Mix, spin and heat at 50°C . for 30 minutes

e) Add another 1 ul of SSIII and leave for another 30 min at 50°C .

f) Heat inactivate at 70°C . for 10 minutes and then place on ice

5. Second Strand cDNA Synthesis

a) On Ice Mix:

[0487]

H_2O	87 ul
5X 2 nd strand buffer	30 ul
5 mM dNTPs	6 ul
DNA polymerase (40U)	4 ul
<i>E. coli</i> DNA ligase (10U)	1 ul
RNase H (2U)	2 ul
1 st strand DNA mix (step 1)	20 ul

2nd Strand Buffer: 20 mM Tris-HCl (pH 6.9), 4.6 mM MgCl_2 , 90 mM KCl, 0.15 mM b-NAD⁺, 10 mM $(\text{NH}_4)_2\text{SO}_4$

b) Mix, spin and incubate at 16°C . for 2 hrs. *NOTE: can start DNA SISPA whilst this incubation is underway.*

c) Add 10 ul (10 U) T4 DNA polymerase (1u/ul) and incubate at 16°C . for 15 min.

d) Heat 2nd strand synthesis at 72°C . 10 minutes, let cool to 37°C .

6. Clean Up DNA

[0488] a) Spin phase lock at 13,000 rpm for 30 sec at 4°C .

[0489] b) Add 150 ul of step 2 reaction

[0490] c) Add equal volume phenol/chloroform 160 ul

[0491] d) Shake lightly

[0492] e) Spin at 13000 rpm 5 minutes, 4°C .

[0493] f) Transfer upper phase to new tube ~160 ul

[0494] g) Precipitate DNA add 100% ethanol 2.5V i.e 375 ul and 1 ul glycogen (20 mg/ml) Leave at -20°C . for 2 hrs or 0/N

[0495] h) Spin at 13000 rpm 20 minutes, remove S/N off pellet

[0496] i) Wash pellet 1x70% ethanol 13000 rpm 5 min at 4°C .

[0497] j) Take pellet up in 35 ul of water *NOTE: can stop here and freeze at -80°C . until the DNA SISPA sample is also ready.*

DNA SISPA

7. Second DNA Strand Synthesis

[0498] a) Mix together the following:

DNA	50 ul
10 pmol random hexamers (10 pmol/ul)	1 ul
5U 3'-5' exo Klenow fragment DNA polymerase	1 ul
Buffer (supplied with Klenow fragment DNA polymerase)	1 ul
5 mM dNTP	1 ul
T4gene32	1 ul

[0499] b) Leave at 37°C . for 1 hr

8. Clean Up DNA

[0500] a) Spin phase lock at 13,000 rpm for 30 sec at 4°C .

[0501] b) Add 60 ul of step 1 reaction

[0502] c) Add equal volume phenol/chloroform 60 ul

[0503] d) Shake lightly

[0504] e) Spin at 13,000 rpm 5 minutes, 4°C .

[0505] f) Transfer upper phase to new tube ~60 ul

[0506] g) Precipitate DNA add 100% ethanol 2.5V i.e 150 ul and 1 ul glycogen (20 mg/ml) Leave at -20°C . for 2 hrs or overnight

[0507] h) Spin at 13,000 rpm for 20 minutes, remove supernatant off pellet

[0508] i) Wash pellet 1x70% ethanol 13,000 rpm 5 min at 4°C .

[0509] j) Take pellet up in 44 ul of water *NOTE: can stop here and freeze at -80°C . until the RNA SISPA sample is also ready.*

Generation of Recombinant Nucleic Acid Sequences

9. Restriction Digest

[0510] a) Add 10 U Csp 6.1 (i.e 1 ul of 10 U/ul stock) to 35 ul of sample, add 4 ul of Buffer B and 5 ul of Csp6I

[0511] b) Incubate at 37°C . for 2 hr

[0512] c) Inactivate at 65°C . for 20 minutes

10. Dephosphorylate Digested DNA

[0513] a) To inactivated restriction digest (50 ul) add:

[0514] 6 ul of 10x CIP dephosphorylation buffer

[0515] 0.3 ul of CIP 18 U/ul

[0516] 3.7 ul water

CIP Dephosphorylase buffer1X: 0.05M Tris-HCl, 0.1 mM EDTA, pH8.5

[0517] b) Incubate at 37°C . for 30 minutes

[0518] c) Add another 0.3 ul of CIP 18 U/ul and incubate at 37°C . for 30 minutes

11. Clean Up DNA

- [0519] a) Spin phase lock at 13,000 rpm for 30 sec at 4° C.
 [0520] b) Add 60 ul dephosphorylated DNA
 [0521] c) Add equal volume (60 ul) phenol/chloroform
 [0522] d) Shake lightly
 [0523] e) Spin at 13,000 rpm 5 minutes, 4° C.
 [0524] f) Transfer upper phase to new tube ~50 ul
 [0525] g) Precipitate DNA add 2.5 volumes 100% ethanol (150 ul) and 1 ul glycogen (20 mg/ml) Leave at -20° C. for 2 hrs or overnight
 [0526] h) Spin at 13,000 rpm 20 minutes, remove supernatant off pellet
 [0527] i) Wash pellet 1x70% ethanol, spin 13,000 rpm 5 min at 4° C.
 [0528] j) Dessicate for 2-3 minutes or air dry for 15 minutes
 [0529] k) Reconstitute in 5.8 ul H₂O.

12. Adaptor Ligation

- [0530] a) Mix together:

T4 DNA ligase (5U/ul)	1.2 ul
5X Ligase Buffer	2 ul
50 pmol adaptor (phosphorylated ends)	1 ul
DNA from Step 3.	5.8 ul

Ligase buffer 5x: 330 mM Tris-HCl, 25 mM MgCl₂, 25 mM DTT, 5 mM ATP, pH 7.5

- [0531] b) Incubate 4° C. for 1 hr and 16° C. overnight

13. PCR Reaction (Results FIG. 2)

- [0532] a) Set up the following mix:

Ligated DNA (step 4)	2 ul
50 pmol NBam24	1 ul
5 mM dNTP	2 ul
2 mM MgCl ₂	2 ul
10X PCR Buffer	5 ul
H ₂ O	38 ul

10X PCR buffer: 100 mM Tris-HCl, 500 mM KCl (pH 8.3)

- b) Heat at 72° C. for 3 minutes
 c) Add 0.5 ul Taq DNA polymerase (5 U/ul)
 d) Run cycle:

[0533] 72° C. for 5 minutes

[0534] (94° C. for 1 minute, 72° C. for 3 minutes) x40 hold at 4° C.

- [0535] e) Run 10 ul and 40 ul of product on 1.0% EtBr gel (leave a well between them to make purification easier)

14. Cloning PCR Product

[0536] a) Cut out sections of smeared region from gel as a lot of the dominant bands can be contaminating sequence from the products used in the methods, rather than the actual sample. Bands can also be hard to see if they are in the smeared regions.

[0537] b) Clean up DNA from agarose using the Minielute Gel Extraction Kit (Qiagen)

[0538] 1. Excise the DNA fragment from the agarose gel with a clean, sharp scalpel.

[0539] 2. Weigh the gel slice in a colourless tube. Add 3 volumes of Buffer QG to 1 volume of gel (100 mg ~100 ul).

[0540] 3. Incubate at 50° C. for 10 min (or until the gel slice has completely dissolved). To help dissolve gel, mix by vortexing the tube every 2-3 min during the incubation.

[0541] 4. After the gel slice has dissolved completely, check that the colour of the mixture is yellow (similar to Buffer QG without dissolved agarose). Note: If the colour of the mixture is orange or violet, add 10 ul of 3 M sodium acetate, pH 5.0, and mix. The colour of the mixture will turn to yellow.

[0542] 5. Add 1 gel volume of isopropanol to the sample and mix by inverting the tube several times.

[0543] 6. Place a MinElute column in a provided 2 ml collection tube in a suitable rack.

[0544] 7. To bind DNA, apply the sample to the MinElute column, and centrifuge for 1 min.

[0545] 8. Discard the flow-through and place the MinElute column back in the same collection tube.

[0546] 9. Add 500 ul of Buffer QG to the spin column and centrifuge for 1 min.

[0547] 10. Discard the flow-through and place the MinElute column back in the same collection tube.

[0548] 11. To wash, add 750 ul of Buffer PE to the MinElute column and centrifuge for 1 min.

[0549] 12. Discard the flow-through and centrifuge the MinElute column for an additional 1 min at $\geq 10,000 \times g$ (13,000 rpm).

[0550] 13. Place the MinElute column into a clean 1.5 ml microcentrifuge tube.

[0551] 14. To elute DNA, add 10 ul of Buffer EB (10 mM Tris.Cl, pH 8.5) or H₂O to the centre of the membrane, let the column stand for 1 min, and then centrifuge for 1 min.

[0552] c) For ligations and cloning use Invitrogen TA Cloning® Kit Version V 7. Set up the 10 ul ligation reaction as follows:

Fresh PCR product	6 ul
10X Ligation Buffer	1 ul
pCR® 2.1 vector (25 ng/ul)	2 ul
T4 DNA Ligase (4.0 Weiss units)	1 ul

[0553] Incubate the ligation reaction at 14° C. overnight, or at -20° C. until you are ready for transformation.

[0554] d) Transform One Shot® Competent Cells.

[0555] 1. Centrifuge vials containing the ligation reactions briefly and place them on ice.

[0556] 2. Thaw on ice one 50 ul vial of frozen One Shot® Competent Cells (enough for 2 ligations).

[0557] 3. Pipette 2 ul of each ligation reaction into 25 ul of competent cells and mix by stirring gently with the pipette tip.

[0558] 4. Incubate the vials on ice for 30 minutes. Store the remaining ligation mixtures at -20° C.

[0559] 5. Heat shock the cells for 30 seconds at 42° C. without shaking. Immediately transfer the vials to ice.

[0560] 6. Add 125 ul of room temperature SOC medium to each vial.

- [0561] 7. Shake the vials horizontally at 37° C. for 1 hour at 225 rpm in a shaking incubator.
- [0562] 8. Spread 50 µl to 100 µl from each transformation vial on LB agar plates containing ~80 mg/ml X-Gal and 100 µg/ml ampicillin.
- [0563] 9. Incubate plates overnight at 37° C. Place plates at 4° C. for 2-3 hours to allow for proper colour development.

15. Screening Colonies for Inserts and Sequencing (Results FIG. 3)

- [0564] a) Use HotStarTaqMaster Mix (50 µl/well of plate):

1X	110X (sufficient for one plate)
25 µl HotStarTaqMaster Mix (vortex)	2750 µl
12.5 µl M13-20f (50 pmol)	1375 µl
12.5 µl M13-20f (50 pmol)	1375 µl
add 50µl per well of the plate	

- [0565] To make the M13-20f (50 µmol) and M13r (50 µmol) stocks: mix 0.5 µl of 100 uM primer with 12 µl of water i.e 500 µl of 100 uM stock primer+1200 µl water (from HotStarTaq Kit).
- [0566] b) Place sterile aluminium foil over the plate containing the HotStar TaqMaster Mix. Stab through the foil to make a hole, and then stab a bacterial colony into each well of the plate.
- [0567] c) Take off aluminium foil and add strip caps to seal plate.
- [0568] d) Run PCR protocol:
- [0569] 95° C. for 15 min
- [0570] (94° C. for 30 s, 50° C. for 30 s, 72° C. for 1 min) X30
- [0571] 72° C. for 1 min
- [0572] 4° C. hold.
- [0573] e) Run 5-10 µl of PCR on gel
- [0574] f) Use Qiagen Mini elute to clean up the remaining PCR product to sequence.

Example 2

Enzyme Linked Immunosorbent Assay to Detect Antibodies to PMC Virus

- [0575] 1. Clone and express the PMC virus protein of interest (eg E2, NS3) in baculovirus and purify the expressed protein. This purified protein can be used as an antigen to detect specific antibodies to the PMC virus proteins of interest.
2. Coat 'medium binding' 96 well microplates (50 µL per well) with antigen diluted in carbonate buffer (0.05M Carbonate buffer 1x (pH 9.6); Na₂CO₃ (1.59 gm); NaHCO₃ (2.93 gm) water to 114 Hold overnight at room temperature (18-25° C.).
3. Dilute samples and controls (Negative, High and Low Positive) 1/100 in sample diluent (phosphate buffered saline (pH 7.3) solution containing 1% skim milk powder and 0.05% Tween 20).
4. Wash plates 5 times with PBS-Tween and tap to dry.
5. Transfer diluted samples and controls to the ELISA plate in duplicate: 50 µL to each well.
6. Incubate at 37° C. for 1 hr in a humidified container.
7. Wash plates 5 times with PBS-Tween, rotate and wash 5 more times, then tap to dry.

8. Dilute conjugate (antiporcine IgG, horseradish peroxidase conjugated) in sample diluent and add 50 µL to each well.
9. Incubate at 37° C. for 1 hr in a humidified container.
10. Wash plates 10 times with PBS-Tween, then 5 times with purified water.
11. Develop by adding 100 µL of TMB substrate to each well. Incubate at 37° C. in the dark for about 10 min until target OD is achieved for controls. A commercially available TMB substrate can be used (eg. Boehringer Mannheim Corp., Pierce Chemical Co., and Kirkegaard & Perry Laboratories).
12. Stop by adding 100 µL of 1M sulphuric acid.
13. Read OD values at 450 nm.
14. Calculate results.

Example 3

Enzyme Linked Immunosorbent Assay to Detect Antigens of PMC Virus

- [0576] It should be noted that working solutions of the detector reagent and enzyme conjugate reagents should be made within approximately 1 hour of anticipated use and then stored at 4° C.
- [0577] Materials
- [0578] ELISA Wash Buffer—10X concentrate: 1 M Tris; HCl (6.25 Normal) for pH adjustment; 0.01% Thimerosal; and 5% Tween 20.
- [0579] Detector Reagent—10X concentrate: 25% Ethylene Glycol, 0.01% Thimerosal, approximately 5% biotinylated goat anti-PMC virus antibody, and 0.06% yellow food colouring in PBS (pH 7.4). The working Detector Reagent is prepared by mixing 1 part of the Detector Reagent—10X concentrate, 1 part of NSB Reagent 10X concentrate, and 8 parts of Reagent Diluent Buffer. This working agent should be prepared within approximately 1 hour of anticipated use.
- [0580] NSB Reagent—10X concentrate: 25% Ethylene Glycol, 0.01% Thimerosal, 0.2% Mouse IgG, 0.06% red food colouring in PBS (pH 7.4).
- [0581] Reagent Diluent Buffer: 2.5% Bovine Serum Albumin, 0.01% Thimerosal, and 1.0% bovine gamma globulin in PBS (pH 7.4).
- [0582] Enzyme Conjugate Reagent—10X concentrate: 25% Ethylene Glycol, 0.01% Thimerosal, streptavidin-biotinylated horseradish peroxidase complex (dilution approximately 1 to 700), 0.1% rabbit albumin, and 0.02% rabbit gamma globulin in PBS (pH7.4). Working Enzyme Conjugate Reagent should be prepared by mixing 1 part of Enzyme Conjugate Reagent—10X concentrate, 1 part of NSB Reagent—10X concentrate, and 8 parts of Reagent Diluent buffer. This working reagent should be prepared within approximately 1 hour of anticipated use.
- [0583] Negative Control: 1% Igepal, and 0.01% Thimerosal in PBS (pH 7.4).
- [0584] Positive Control: 1% Igepal, 0.01% Thimerosal, 1% Bovine Serum Albumin, PMC virus culture (dilution approximately 1:20) and 50 µM phenyl methyl sulfonyl fluoride in PBS (pH7.4).
- [0585] Method
1. Prepare specimens by standard methods. For samples containing cells (tissues, white blood cells) homogenise the tissue and add sample lysis buffer (1% NP40). Allow at least 1 hour for antigen extraction and mix continually.
2. Clarify specimens by centrifuging for 15 minutes at approximately 2000 g;

3. Coat 96 well microplates with purified polyclonal antiserum raised against PMC virus antigens (100 uL/well). Alternatively, a mixture of anti-PMC virus monoclonal antibodies may be used. Each 96-well tray is coated overnight at room temperature with 0.1 ml per well of a solution containing purified antibody at 5 µg/ml and bovine serum albumin at 10 µg/ml in carbonate buffer (pH9.6). Following the coating, each tray is washed three times with ELISA wash buffer and allowed to dry overnight at 4° C. A foil pouch is used to encase each tray after drying, and a desiccant is included inside each pouch to remove moisture.
4. Wash ELISA plates 3 times by pipetting 0.2 ml of ELISA Wash Buffer into each well and tap or pipette dry prior to the addition of sample.
5. Block ELISA plates with Blocking solution 1 (200 uL/well) for 30 min at 37° C. in a humidified container.
6. Transfer 100 uL of each specimen (including controls) to the ELISA plate;
7. Incubate plates for 60 min at 37° C. in a humidified container;
8. Wash ELISA plates 5 times with ELISA Wash Solution;
9. Block ELISA plates with Blocking Solution 2 (150 uL) for 30 min at 37° C. in a humidified container; Wash ELISA plates 5 times;
11. Add Detector Reagent containing biotinylated anti-PMC virus monoclonal antibody (100 uL) to all wells;
12. Incubate plates for 60 min at 37° C. in a humidified container;
13. Wash plates 5 times;
14. Add Enzyme Conjugate Reagent containing streptavidin-biotinylated horseradish peroxidase complex and add 100 uL to all wells;
15. Incubate plates for 30 min at 37° C. in a humidified container;
16. Wash plates 10 times;
17. Prepare and add 100 uL of TMB substrate solution to all wells. A commercially available TMB substrate may be used (eg. Boehringer Mannheim Corp, Pierce Chemical Co, and Kirkegaard & Perry Laboratories).
18. Incubate plates for approx 10 min at room temperature in the dark;
19. Stop reaction with 1M sulphuric acid (100 uL per well);
20. Read ODs on ELISA plate reader at 450 nm;
21. Calculate results.

Example 4

Detection of PMC Virus RNA by Reverse Transcriptase (RT) Polymerase Chain Reaction (PCR)

[0586] a) Extract RNA from the test specimen as described in Example 1. Include in all steps of the reactions known positive and negative controls and a 'blank'.

b) Reverse transcribe (RT) the RNA as follows:

[0587] 1. Mix together the following:

random hexamers (50 pmol)	1 ul
RNA (in H ₂ O)	9 ul

[0588] 2. Heat at 90° C. for 3 minutes, spin and put on ice

[0589] 3. On ice add:

1st strand buffer	4 ul
0.1M dTT	2 ul
5 mM dNTP	2 ul
SSIII (200U)	1 ul

[0590] 4. Mix, spin heat at 45° C. for 60 minutes.

[0591] 5. Heat inactivate at 70° C. for 10 minutes

[0592] 6. Place on ice.

c) Set up 1st round PCR

[0593] 1. Mix together the following PCR reagents

RT	5 ul
Forward primer 4 uM	1 ul
Reverse primer 4 uM	1 ul
Hotstart PCR mix (Qiagen)	12.5 ul
Water	5.5 ul

[0594] (see Table 3 for 1st reaction PCR primers)

[0595] 2. Cycle the PCR machine at:

[0596] 95° C. for 15 minutes

[0597] (94° C. for 30 sec, 50° C. for 30 sec, 72° C. for 1 min)×40

[0598] 72° C. for 1 min

[0599] 4° C. hold

d) Set up Nested PCR

[0600] 1. Mix together the following PCR reagents:

1st PCR product	1 ul
Forward nested primer 2 0uM	1 ul
Reverse nested primer 2 0uM	1 ul
Hotstart PCR mix (Qiagen)	12.5 ul
Water	9.5 ul

[0601] (see Table 3 for nested PCR primers. If no nested primer is listed, use 1st PCR primer)

[0602] 2. Cycle the PCR machine at

[0603] 95° C. for 15 minutes

[0604] (94° C. for 30 sec, 50° C. for 30 sec, 72° C. for 1 min)×25

[0605] 72° C. for 1 min

[0606] 4° C. hold

e) Run 5 ul of nested PCR product on a 1.5% ethidium bromide gel for 1 hour. Depending on the primers used, the expected size of the product is as listed in Table 1.

TABLE 3

Primers for PCR detection of PMC virus					
Clone	Virus	*Primer name	Primer Sequence (5' to 3')	SEQ	
				ID NO	Nested Product
CR3	9 Pestivirus	CR39F (63)	CACATCTAGCAGCAGACTATGA	28	103 bp
		CR39R (190)	GTACCAGTTGCCACCACC	29	
		CR39FN (87)	TGAAAAGGATTCACGG	30	
ER5	10 Pestivirus	ER510F (7)	AAACCGACGAAGTAGACC	31	114 bp
		ER510R (213)	AGACGAGAACATAGTGGC	32	
		ER510FN (68)	GAAACAGTAAAGCCAACG	33	
		ER510RN (182)	CTGGTAATCGGAAACATC	34	
ER6	2 Pestivirus	ER62F (203)	GGGACCGAGGGATACGA	35	98 bp
		ER62FN (373)	AGAGGTAATTGGGTAT	36	
		ER62R (637)	CAGCAGTTGATTTCTTCAT	37	
		ER62RN (516)	TTGCCAAGTTTCAC	38	
ER5	5 Pestivirus	ER55F (31)	AAACCGCCGAAGTAAACC	39	143 bp
		ER55R (214)	CTGGAGCCCTGGTAATGG	40	
		ER55FN (64)	GACGGGAATGGGTCA	41	
		ER55RN (162)	TAGGTGCTTCTTATTGGTAT	42	

*F = forward primer, R = reverse primer, FN = forward nested primer, RN = reverse nested primer

Example 5

[0607] Determination of Full Length Viral Sequence

[0608] Once the authenticity of the presence of PMC virus sequence has been confirmed in a sample by PCR, the entire viral sequence can be acquired by designing PCR primers to span the gaps between the clones (refer to Table 4). RT-PCR was carried out as either a two step (RT then PCR) or one step RT-PCR reaction.

1. RT Reaction:

[0609] a) Mix together the following:

[0610] 1 ul random hexamers (50 μmol)

[0611] 4 ul RNA

[0612] 4 ul Rnase free water

b) Heat 70° C. 10 minutes, spin and put on ice

c) On ice add

[0613] 4 ul 1st strand buffer

[0614] 2 ul 0.1M dTT

[0615] 2 ul 5 mM dNTP

[0616] 2 ul SSIII (400 U)

d) Mix, spin heat at 42° C. for 60 minutes.

e) Heat inactivate at 70° C. for 10 minutes

f) Place on ice

2. PCR Reaction:

[0617] a) Mix together the following PCR reagents

RT	1 ul
Forward primer 20 uM	1 ul
Reverse primer 20 uM	1 ul
Hotstart PCR mix (Qiagen)	12.5 ul
Water	13.5 ul

[0618] (see Table 4 for PCR primers)

b) Cycle the PCR machine at:

[0619] 95° C. for 15 minutes

[0620] (94° C. for 30 sec, 47° C. for 30 sec, 72° C. for 2 min)×40

[0621] 72° C. for 1 min

[0622] 4° C.—hold

3. One Step RT-PCR Method

[0623] a) Mix Together the Following Reagents from the SSIII RT-PCR Kit

2x reaction mix	25 ul
Forward primer 30 uM	1 ul
Reverse primer 30 uM	1 ul
SSIII RT/Platinum mix	2 ul for products 2.5 kb or less 4 ul for products 2.5 kb or more
Water	15.8 ul for products 2.5 kb or less 13.8 ul for products 2.5 kb or more

[0624] (see Table 4 for PCR primers)

b) Cycle the PCR machine at:

[0625] 50° C. for 50 minutes

[0626] 94° C. for 2 min

[0627] (94° C. for 15 sec, 50° C. for 30 sec, 68° C. for 1 min/kb)×40

[0628] 68° C. for 5 min

[0629] 4° C.—hold

[0630] RT-PCR product of interest was PCR spin cleaned and cloned into the Invitrogen TA cloning vector PCR2.1 (see Example 1). Positive clones were then identified and sent for sequencing, as described in Example 1.

[0631] The primers used for sequencing were M13r, m13-20, primers in Table 4 and primers designed specifically for sequencing (see Table 5).

[0632] Plasmid sequence, PCR primers and poor sequence reads were removed from the sequence before being used in the program Bioedit (Hall, T. A. (1999) BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl. Acids. Symp. Ser. 41:95-98.). Bioedit allowed the construction of contigs and the production of the full length consensus sequence for the virus.

TABLE 4

Primers designed to PCR the gaps between the SISPA clones sequences				
Region to PCR	*Primer names	Primer Sequence (5' to 3')	SEQ ID NO	Product size
5'UTR-Erns	JFP1F	CATGCCCATAGTAGGAC	43	1338 bp
	JFR3R	ACCAGTTRCACCAMCCAT	44	
Erns-P7	CR39-Er55PCRF	AGGGCTCTCACATGGTTGTC	45	1810 bp
	ER55-510-512 R	CCATTACCAGGGCTCCAG	46	
Erns-NS5A	CR39F(63)	CACATCTAGCAGCAGACTATGA	47	2349 bp
	ER55RN(162)	TAGGTGCTTCTTATTGGTAT	48	
P7-NS5A	ER55-510-512 F	CGTTGGCTTTACTGTTTCATTG	49	5560 bp
	CR316-CR24R	TCCCCGAAGCTTGGTTTAAT	50	
NS3-NS5A	NS3F	GTCAGGCCTGCCTATCTTTG	51	4431 bp
	CR316-CR24R	TCCCCGAAGCTTGGTTTAAT	52	
NS5A-NS5B	CR316-CR24F	CGGGACCATTAAACCAAGC	53	2440 bp
	ER62-ER63R	CAGGGGTTCCAAGAATACA	54	

*F = forward primer, R = reverse primer

TABLE 5

Primers designed for sequencing			
Protein location of primer	*Primer names	Primer Sequence (5' to 3')	SEQ ID NO
5 UTR	5utr(140)R	GGTGTACTCACCCTTAGCC	55
NPRO	NPRO(630)RS	TTGTACAATCGCCCTTCTT	56
NPRO	NPRO(779)FS	AGGGAGAATGACAGGGTCTG	57
Capsid	capsid(927)FS	ACAAAGGAGCAAAACCCAAG	58
ERNS	EO(1365)RS	GTCACGTGGTGGACCCTAC	59
E1	E1(2402)RS	AGCCAGAAATGCCACAGC	60
E1	E1(2606)FS	ACCTGTGTGGGTGCTAACAT	61
E2	E2(3086)RS	TTACTTTGTCTTCCCGTTGC	62
NS2	NS2(4409)FS	CCAAGAACTTCCCATACG	63
NS2	ns2(4460)RS	TTCCACATCCTCTTCTTCTTTT	64
NS3	NS3(5170)RS	GCTGGCCCTCGAATGATCCA	65
NS3	NS3(5468)FS	GTTCCCTGTGTCCTTGCTGA	66
NS3	NS3(5670)RS	TGTTTTTGTCTTGGCACTGG	67
NS3	NS3(6296)FS	GAGCACACAGGGCAGAAAT	68
NS3	NS3(6479)RS	CCATCTTCCCTGTAGGCACA	69
NS3	NS3F(6525)F	GTCAGGCCTGCCTATCTTTG	70
NS3	NS3(7153)FS	GGAGAAGTCACTGACGCACA	71
NS3	NS3(7241)RS	GCCATTTCAATCCAGTATG	72
NS4B	NS4B(7715)FS	GGGGTCCACACAGCATTGTA	73

TABLE 5-continued

Primers designed for sequencing			
Protein location of primer	*Primer names	Primer Sequence (5' to 3')	SEQ ID NO
NS4B	NS4B(7893)RS	CCCTTGATACTACGCCTGT	74
NS4B	NS4B(8532)FS	GCCGACTCAAATGGAGAAA	75
NS5A	NS5A(8810)RS	GCCACCCCTATTCTTGGATCTC	76
NS5B	NS5B(10889)FS	AAATGAGAAGAGGGCAGTGG	77
NS5B	NS5BF-10936	AAGGCCACCACTCAAATCAC	78
NS5B	NS5BR-12039	AGGCTTCTGCTTGACCCAGT	79

*FS = forward primer, RS = reverse primer

NOTE:

Numbers in brackets are estimated locations on Reference pestivirus strain NADL.

Example 6

UTR Sequences

[0633] 5'RACE and 3'RACE were used to acquire the 5'UTR and 3'UTR sequences.

[0634] 5' RACE Method

[0635] Sequence data from the complete 5' untranslated region (UTR) was generated using rapid amplification of cDNA ends (RACE, BD), as described by BD Biosciences Clontech with the following modifications. PMC virus-specific primer CR24R (5'TCCCCGAAGCTTGGTTTAAT3', SEQ ID NO: 80) was used to generate the cDNA. Hotstart PCR (Qiagen) was carried out with primers CR39R (Table 3) and BD Universal primer A mix (5'CTAATACGACTCAC-TATAGGGCAAGCAGTGGTATCAACGCAGAGT3', SEQ ID NO: 81; and 5'CTAATACGACTCACTATAGGGC3', SEQ ID NO: 82) with an annealing temperature of 67° C. and extension time of 2 minutes. The PMC virus specific primer

N^{Pro}(630)RS (Table 5) and BD nested Universal Primer A (5'AAGCAGTGGTATCAACGCAGAT3', SEQ ID NO: 83) were used for the Hotstart Nested PCR, with an annealing temperature of 55° C. and an extension time 2 minutes. Nested PCR products were cleaned, cloned and sequenced.

[0636] 2. 3' RACE Method

[0637] Sequence data from the complete 3' untranslated region was generated by first adding a poly (A) tail to the viral RNA, using Epicentre's A-Plus Ploy(A) polymerase tailing Kit for 8 minutes. This was followed by rapid amplification of cDNA ends (RACE, BD), as described by BD Biosciences Clontech with the following modifications. Hotstart PCR (Qiagen) was carried out with primers ER62F (Table 3) and BD Universal primer A mix (5' CTAATACGACTCACTATAGGGCAAGCAGTGGTATCAACGCAGAGT3', SEQ ID NO: 84; and 5'CTAATACGACTCACTATAGGGC3', SEQ ID NO: 85) with an annealing temperature of 65° C. and extension time of 2 minutes. The PMC virus specific primer NS5B (12100)F (Table 5) and BD nested Universal Primer A (5'AAGCAGTGGTATCAACGCAGAT3', SEQ ID NO: 86) were used for the Hotstart Nested PCR, with an annealing temperature of 65° C. and an extension time 2 minutes. Nested PCR products were cleaned, cloned and sequenced.

Example 7

Real Time PCR

[0638] The following primers and a matching probe based on Taqman® technology were developed:

Forward primer: (SEQ ID NO: 87)
CAGTTGGTGTGATCCATGATCCT

Reverse primer: (SEQ ID NO: 88)
GGCCTCACCCCTGCAACTTT

Probe: (SEQ ID NO: 89)
6FAM-AAGTCTTCAGCAGTAACT-MGBNFQ

[0639] 6FAM=6 carboxyfluorescein; MGBNFQ="minor groove binder non-fluorescence quencher." Similar primer/probe combinations may be developed for other segments of the PMC genome.

[0640] A Real Time PCR assay was carried out using the following steps:

[0641] a) Extract RNA from the test specimen. Include in all steps of the reactions known positive and negative controls and a 'blank'.

[0642] b) Prepare reaction mixture (volumes per sample) as follows:

2x Mastermix (Roche)	12.5 uL
40x Multiscribe	0.625 uL
Forward primer	1 uL
Reverse Primer	1 uL
Taqman Probe	1 uL
Template (sample)	2 uL
Water	6.875 uL

[0643] c) Set up cycling conditions for the PCR cyclor available (the cycles below are appropriate for a Cepheid Smartcycler)

[0644] Cycle the PCR machine at:

[0645] Stage 1: Repeat 1x

[0646] 48° C. for 30 min

[0647] 95° C. for 10 min

[0648] Stage 2: Repeat 45x

[0649] 95° C. for 15 secs

[0650] 58° C. for 30 secs each

[0651] d) Determine results using the Smartcycler software using cycle-threshold (CT) values. A CT value of <35 is considered to be positive. Values between 35-40 are suspicious and values >40 are negative.

Example 8

Production of Recombinant Baculoviruses and Expression of Recombinant PMC Virus Proteins

1. Cloning of PCR Fragments

[0652] PCR products are purified with PCR SPIN-CLEAN™ columns (Progen Industries, Limited), according to the manufacturer's instructions. If the PCR reaction produces non-specific bands in addition to the required product, or subcloning from another plasmid was necessary, the DNA can be further purified by elution from a 0.8% agarose gel, using a modification of the method described by Heery (1990).

[0653] Purified PCR fragments are digested and ligated into pBlueBacHis A, B or C baculovirus transfer vectors (MaxBac Baculovirus Expression System, Invitrogen Corporation) containing compatible cohesive overhangs, using standard cloning protocols (Sambrook et al., 1989; Current Protocols in Molecular Biology, 1991). A, B or C vectors provide three different reading frames to achieve protein expression in the baculovirus expression system.

2. Transformation of Baculovirus Plasmids with the PCR Fragments

[0654] The ligations are transformed into competent *E. coli* strain Top 10 (Invitrogen Corporation), Genotype: FmcrA D(mrr-hsdRMS-mcrBC) f80lacZDM15 DlacX74 deoR recA1 araD139 D(ara-leu)7697 galU galK rpsL endA1 nupJ, and/or Sure® *E. coli* (Stratagene), Genotype: e14⁻(McrA⁻)D (mcrCB-hsdSMR-mrr) 171 endA1 supE44 thi-1 gyrA96 rel A1 lac recB recJ sbcc umuc::Tn5 (kan^r) uurC[F' proAB lacI^Z D m15 Tn10(Tet^r)^o. Protocols for the preparation of competent cells and transformation of the bacteria are taken from the Invitrogen MaxBac Baculovirus Expression System Manual Version 1.8.

[0655] Screening bacterial clones for plasmid containing PCR fragment and plasmid purification for transfection

[0656] Bacterial clones containing pBlueBacHis+PCR fragment are identified by growing colonies, extracting the plasmids using the boiling miniprep method described in Sambrook, et al. (1989), and then undertaking restriction digests of the plasmids to verify those containing the correct-sized insert. Recombinant plasmids are purified to a level suitable for transfection reactions using plasmid purification kits (QIAGEN Pty Ltd., tip-20 or tip-100 columns), according to the manufacturer's instructions.

3. Production of Purified Recombinant Baculoviruses by Cationic Liposome Transfection of Sf9 Cells to Produce Recombinant Baculoviruses

[0657] Recombinant baculoviruses are produced by co-transfecting linearised wild-type *Autographa californica*

nuclear polyhedrosis virus (AcMNPV) DNA and baculovirus transfer vector containing PCR fragment into Sf9 cells, by the technique of cationic liposome mediated transfection. This is carried out according to the Invitrogen MaxBac Baculovirus Expression System Manual Version 1.8.

4. Plaque Purifying Recombinant Baculoviruses

[0658] Recombinant virus is plaque purified three times before virus master stocks are prepared, ensuring the virus is cloned from a single particle and no wild-type virus is present. Plaque assays are set up according the Invitrogen MaxBac Baculovirus Expression System Manual Version 1.8.

[0659] After each round of plaque purification, the recombinant viruses are screened using a modified Pestivirus antigen-capture ELISA (PACE) (Shannon et al., 1991). The modified method involves supernatant+cells (50 µl/well) being added directly to a blocked, washed ELISA plate, and the plate incubated for 1 hr at 37° C. Antibody solution (50 µl/well) is then added. The antibody used is either biotinylated goat anti-pestivirus antiserum or individual anti-PMC virus monoclonal antibodies (mAbs). The plate is incubated overnight at 22° C., then developed as described by Shannon et al. (1991), omitting the incubation with biotinylated anti-mouse IgG for samples that are reacted with the biotinylated goat antiserum.

5. Recombinant Baculovirus Master, Seed and Working Stocks

[0660] The master virus stock for each of the recombinant baculoviruses constructed are made according the Invitrogen MaxBac Baculovirus Expression System Manual Version 1.8. The titre of the stock is determined by a plaque assay, as described above, except that the cells are overlaid with 1.5% carboxymethylcellulose (CMC, BDH; 6% CMC in deionised water, diluted 1 in 4 with complete TC100+X-gal [125 µg/ml, Boehringer Mannheim]). After 7 days, the blue plaques are counted to give the virus titre.

[0661] The seed and working stock are made from the master and seed stock, respectively using a low MOI of 0.1 to 0.5 pfu/ml. All virus stocks are stored at 4° C. for use in vaccine production. For long term storage of Master, Seed and Working stocks, each recombinant virus is ampouled and frozen at -80° C.

6. Optimisation of Recombinant Protein Production

[0662] Sf9 insect-cell suspensions, adapted to Sf-900 II Serum Free Media according to the protocol described by Gibco BRL (1995), are used to optimise recombinant protein expression. Two conical flasks, containing 50 ml cells (1.5× 10⁶ cells per ml), are infected with recombinant baculovirus at a high and low MOI, between 0.1 and 5.0. A third flask acts as an uninfected control culture. The 3 flasks are incubated with shaking at 28° C., and 5 ml aliquots removed at 24 hr intervals for up to 7 days.

[0663] The samples are centrifuged at room temperature (RT) for 10 min at 900×g, and the supernatants carefully removed. The pellets and supernatants are stored at -20° C. until daily sampling is completed. The amount of specific, recombinant pestivirus protein in the samples is then determined using the modified PACE described above. The cell pellets are reconstituted in 200 µl or 250 µl NP-40 (1% [v/v] in PBS), vortexed and centrifuged at RT for 10 min at 900×g. Serial dilutions of the pellet extract (in 1% [v/v] NP40) are assayed. The culture supernatants are assayed undiluted, as well as serially diluted (in 1% [v/v] NP40). If cell viability is reduced at a higher rate of infection, then an MOI or 0.1 to 2 is more appropriate.

[0664] Modifications of the above-described modes of carrying out the various embodiments of this invention will be apparent to those skilled in the art based on the above teachings related to the disclosed invention. The above embodiments of the invention are merely exemplary and should not be construed to be in any way limiting.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 89

<210> SEQ ID NO 1

<211> LENGTH: 12077

<212> TYPE: DNA

<213> ORGANISM: PMC Virus

<400> SEQUENCE: 1

```

gtataacgac agtagttcaa gtgtcgttat gcatcattgg ccataacaaa ttatctaatt      60
tggaataggg acctgcgacc tgtacgaagg ccgagcgtcg gtagccattc cgactagtag      120
gactagtaca aatagggtcaa ctgggtgagc aggtgagtggt gctgcagcgg ctaagcggtg      180
agtacaccgt attcgtcaac aggtgctact ggaaaggatc acccactagc gatgcctgtg      240
tggacgagga catgtccaag ccaatgttat cagtagcggg ggtcgttact gagaaagctg      300
cccagaatgg gtagttgcaac atacagtctg ataggatgcc ggcggatgcc ctgtattttg      360
accagtataa atattatccg ttgtaaagca tatgaatact tttactttta atacatatgg      420

```

-continued

agggagtgag gaaggaaca tgttcttag aactgcacc acgcgcacc cagggtgcca	480
agaaccggtt tacacaagca caatgagacc aatTTTTTgGc gaaccccatc cacctctaca	540
caaacacagc acgttaaaat tgccacattg gaggggggac aaaacaatta gagttaagaa	600
gagagaattg ccaagaaggg gcgattgtag caactcaaca acagctccca cttcgggggg	660
gtacgttgaa ttaggggctg tgttctataa agattacacg ggcacggat accatcgtgt	720
accgctagaa ctttgtacaa accaagagag gtgcgagggg tccaagtgtg tagggagaat	780
gacagggctc gatggcaggt tgtacaacgt tttagtatgt ccggacgatt gtatcctctt	840
tgagagacac tgtagaggtc aaacagtcgt cctgaaatgg atttccaacc ccttgacatc	900
accacttgg gtccagagtt gttctgacga caaaggagca aaaccaagg tgaacccaaa	960
agacgacagg atgaagcaag gaaaaatagt gacaaagcct aaagagactg aagcagatca	1020
aaaaactaga ccaccagatg ccacgatagt ggttgacggg cagaagtatc aggtgaggaa	1080
gaaggggaaa gcgaaaccca agactcaaga cggtctatac cacaacaaga acaaacaga	1140
agcgtccagg aagaagcttg agaaggcctt gctagcatgg gcaatattag cctgcctatt	1200
gggtgtaccg gtagggtcca ccaacgtgac acaatggaac ttatgggaca ataaaagtac	1260
tacagacata catagcgtca tgtttcttag agggattaaa aggagtctgc atggaatttg	1320
gcccacacaa atctgcaaag ggatccctac acatctagca gcagactatg aactgaaaag	1380
gattcacggg atgggtggat caagccccat gaccaacttc acatgttgta ggctacagag	1440
acatgagtgg aacaagcatg ggtggtgcaa ctggtacaat atagagccgt ggatcaatct	1500
catgaataat acccaaggac tattaacac tgagacaat ttcactgagt gcgcagtcac	1560
atgcaggat gatgcagact taggggtgaa tatagtact caagccagga ctactccaac	1620
tatcctgact ggctgtaaga aagggcacaa cttctcttcc tcaggggagg tcagggcctc	1680
accctgcaac tttgagttaa ctgctgaaga cttgctcagg atcatggatc acaccaactg	1740
cgagggattt acctacttcg gggaaaggaat cgttgacggg tacaccgagg tagtagagaa	1800
ggccaggtea agtggtttca gggctctcac atggttgtcg agtaagattg aaaacaccaa	1860
gaaaaaata ttcggagctg aagccagtc ttactgcca gtggctaaga ggtcttcaa	1920
cattatztat accaacaatt gcaacccgct tggactgcca gataagtcaa aaattatagg	1980
accaggaacc tttgacatca gtggcagggg tgaattcata tttccaaaac tcccctacca	2040
cgtagatgac tcattctac tgagcttaat tgcaatgtct gatTTTgctc cagagacatc	2100
aagtataatc tacctggctt tgcactacct aatgccaagt aatgacaaca gggacttcgt	2160
gatggacctg gacccaaata aactaaacct tactgcaact aaatccgtgg caagtgtggt	2220
ccctacatcg gtgaatgtgt taggtgaatg ggtgtgcgtc aaaccaagtt ggtggcctta	2280
ttccgccgaa atcactaatc tgataggagg tgcatacacc gtggcagact tagttatcaa	2340
gaccattgaa gaattgctaa atttgtggac cgaagcaaca gctgtggcat tctggctgc	2400
tctaataaaa attttttagg gccagccgat ccaagcggta gcatggttaa tcatcatagg	2460
gggagcacia gcccaaacct gcaaccctga attcatgtac gcattagcga aaaataccag	2520
cataggttca ttaggaccag aatcactgac gacaaggtgg taccactaa ccagcggttt	2580
caaaactact gacagcacga ttgaagtcaac ctgtgtgggt gctaacatga ggattcatgt	2640
agtgtgcca cttgtaagtg acagatattt ggccataaac caccttagag cactgccaac	2700

-continued

aacggcgtgg ttcaggaaaa tacacactca gcatgaggta ccaagagaaa gaatcatgag	2760
tgagtcaaaa aggaggtaca cttgtccttg tggttctaaa ccagtggtga ggtcaacaac	2820
acaattcaac ccaatatcta tatctacccc aagctttgaa cttgaatgcc ctagggggtg	2880
gactggggct gtagagtgtg cactagtctc cccatcaact ctgacaacag agactatatt	2940
cacatacagg aagcccaaac cattcggact tgaaaactgg tgcaagtata cagtggtgga	3000
gaaagggatc ctgtattctt gtaaatttgg gggcaattca acatgcatca aagggcttat	3060
agttaaaggg caacgggaag acaaagtaag gtactgtgaa tgggtggtt ataagttcag	3120
ttcaccaaat ggactgcctc agtatccact gggattgtgt gagaaagaac aatcagaagg	3180
actcagggat tatggtgact tcccatgctg caacaacggc acttgattg acaagaagg	3240
tagtgtgcaa tgtacatag gggataagaa agttaccgtg aagctgtata atgcctcact	3300
attggcccc atgccctgca aaccatagtg gtataactcc caggggcccc cagcgcctaa	3360
gacctgcact tatagggtgg cctcaacatt agaaaataaa tattatgaac ccagggacag	3420
ctactaccag caatacatta taaagtcagg gtatcaatat tggtttgatc tcacagcaaa	3480
ggatcatgtg gcagactgga tcacaaaata cttccaata ataatagtg ccttgtagg	3540
gggcagaggc accttggtgg tggtagtagc ttatgagttg ctaactcagt atgaggtagt	3600
aggagacgag aacatagtggt ctcaagctga agccctggtg atcggaaaca tcttgatgag	3660
tttagactta gagataatta gctgcttctc tctgtgttg atcgtggtg aaaaacaagc	3720
tgtcaggaga acgttggtt tactgtttca ttggataact atgaacccat tccagtcagt	3780
aatgatcaca gtggctact tcgtcggttt ggtgagggcc gaagagggaa ctaaagaggg	3840
tagtacaagc gggccacca tccatgtagt tgcaactctg ttattcctct tgtaccacac	3900
agtgaagtat aaggacttta acatagcaat gatcttactt ataacattgt cctgaaaag	3960
ctcatcctac atacatacca gcttgatga aattccattg cttgtggctg taataagtct	4020
cacatgctcc atatacattt ttgacttgca ggtaaagagc aagctagtgg cccaactat	4080
aggataaatt ggagttacc tagcaatgag agttttgtgg ctggaaggc aaatgactat	4140
accaaccccc tctgtgtcca ttagtctgat agatccaaag atggtcataa tactctactt	4200
gatatcccta actattacag tcaatcacia cctagaccta gcaagttatt gcttgaact	4260
gggacctttt atcctatcat tccaaacaat gtgggtggat gttgtcatcc tctgtctcat	4320
gctgccttg tacgaactag taaaagtota ctacctaaaa aagaagaaag aggatgtgga	4380
aacatggttc caaaattcag gaatatccac ccaagaaact tcccatacg gatttgattt	4440
ttctagcccc ggggagggag tgcacacact accaatgcaa aataaaacca aattttgtag	4500
gactgcttac atgactgtac taagggtctt ggtgataaca gccatcagca gtgtctgga	4560
accaataatt ttagcagaac tccaataga ggcagtgtat tggacacaca ttaaaatagc	4620
caaagaattg gcgggttcaa gcaggttcgt tgctagggtc attgcatcta ttagagatt	4680
gaattgggcc atggacgaaa aagaagcacc tcggtacaaa agattttacc tattatcacc	4740
caaaataaca gatctaattg ttaagcacia aatccaaaat gagacagtaa aatcctggtt	4800
tgaagaaact gaaatatttg gaatacaaaa agtggcaatg gtgataaggg ctattctct	4860
gagtttgtag ccaaatgcca tcccttgctc cgtttgtgaa gaaaaacaaa atcaaaaagc	4920
caaaaagccc tgcctaaagt gtggtagtag aggcactcaa ataaagtgtg gctgacact	4980

-continued

ggccgagttt gaggaagaac attacaaaa aatatacatc ctccaaggcc aagatgaaac	5040
tcccatgagg aaagaagaaa gacagcaagt aacttatgtc tctaggggtg ctctgttcct	5100
taggaatcctt cctatccttag cttcaaaaa caaatccta cttgtaggca atctgggtat	5160
ggaattgcaa gatttgaaa gtatgggatg gatcattcga gggccagccg tctgcaagaa	5220
gataatacac catgagaaa gcaggccttc aataccagac aaactcatgg cattcttcgg	5280
gattatgect aggggagtta caccaagagc cctacacagg ttccctgtgt ccttctgaa	5340
gataagacgg ggttttgaga ccggctgggc ctacacacac cctggagggg taagtagtgt	5400
gatgcatgtc accgctgggt cggatatata tgtcaatgac tcaataggga ggacaaaaat	5460
ccagtgccaa gacaaaaaca ctacaacaga tgagtgtgaa tatgggtgta aaacagactc	5520
agggtgctct gatggagctc ggtgctatgt catcaaccct gaagcaacca acatagcagg	5580
gaccaagggg gccatggtac acctgaggaa agctggagga gagttcaact gcgtgactgc	5640
ccagggtacc cccgccttct ataactaaa gaacttaaaa ggatggtcag gcctgcctat	5700
ctttgaagct gccacaggaa gagtggtagg aagggtaaaa gcaggaaaaa aactgacaa	5760
tgctccaaca accattatgt cagggacgca agtggcaaaa ccatcagagt gtgacctaga	5820
atcagtgggt aggaaactag agacaatgaa cagaggggaa ttcaacaag tgactctggc	5880
tacaggcga gaaagacaa ccatgctacc aaagtgtta atagaatcca taggcaggca	5940
taagagagtg ttagtactga tcccgttgag agctgcagcg gaggggtgt accagtacat	6000
gagaacaaa caccaagca tatctttcaa cttgaggata ggggatctga aagaagggtga	6060
catggcaact gggatcacct atgcctctta tgggtacttc tgccaaatgg acatgcctag	6120
actggagaat gcaatgaagg aataaccata tattttcttg gatgaatc actgtgccac	6180
accagaacag ttggcagtga tgtcaaaaat acataggctc ggtgaatcag ttagggtaat	6240
agccatgacc gccacgcat ccgggactgt gagcacaaca gggcagaaat tcacaattga	6300
ggagggtgta gtacctgaag tgatgaaggg ggaggacctt gctgatgatt acatcgaat	6360
agcagggttg aagggtccaa agaaagagtt agaggtaac gtactgactt ttgtgcctac	6420
aaggaagatg gcatcgaaa cagcaaaaa attaaccaca caggatata atgctggata	6480
ctacttcagt ggagaagatc catcatcctt gcggacaact acttetaagt caccatata	6540
agtagttgca accaatgcca ttgaatccgg ggtaacctta ccggaccttg atacagtaat	6600
agatacaggc atgaagtgtg aaaagagact aagaatcga aacaaagctc cctacatcgt	6660
aacaggactg aaaagaatgg ctataacaac gggggagcaa gctcaaagaa aaggtagggt	6720
aggcagggtt aaacctggga ggtacttgag aggacctgaa aacctgcag gtgaaaagga	6780
ctatcactat gaccttttac aggcacagag gtacggcatc caagactcaa taaacatcac	6840
caagtcttc agggagatga actatgattg ggcattatat gaggaagacc cgttaaagat	6900
tgcccaatta gagttgctaa acacactcct gatctcaagg gatctgccag tagtaacaaa	6960
aaatctgatg gcccgacaa cacatccga acctatacaa ttggcttaca atagtttaga	7020
aacctctgta ccggtggcat tcccaaaagt gaaaaatgga gaagtcactg acgcacatga	7080
aacttacgag ttgatgact gttaggaagct tgagaagac cccctatat acctgtatgc	7140
aacagaagaa gaagatctcg tagtggacat actgggattg aaatggccag acgccacaga	7200
gagggtctgc ttggaagtgc aagacgcctt gggccagatc acaggtttat ctgcagggga	7260

-continued

gacagcttta	ctcatagccc	tattaggggtg	ggtgggctac	gaagccttgg	tgaagaggca	7320
cgtgcctatg	gtgacagaca	tatacaccct	agaagatgaa	aaattggaag	acactacaca	7380
cctacaatth	gccccagatg	atctgaacaa	ttcagatacc	attgagctcc	aagacttate	7440
gaatcaccaa	atccaacaaa	ttctagaagg	tgggaaggaa	tatgtcggcc	aagcctacca	7500
attcctcagg	ttgcaagctg	agagggctgc	caactcagac	aaaggcaaga	aagcaatggc	7560
agcggcccca	ttactagccc	acaagttcct	ggaatacttg	caagagcatg	caggtgacat	7620
aaagaagtat	ggtctatggg	gggtccacac	agcattgtat	aacagcataa	aagaaagact	7680
gggtcacgaa	actgcattcg	catctctggt	tataaaatgg	attgcctttt	cctcagatgg	7740
agtcccgggg	atgattaagc	aagcagcagt	agacttgggt	gtatactata	taatcaacag	7800
gcctgagtat	caaggggata	aggagacaca	gaatgcaggt	agacaatttg	ttggctccct	7860
ttttgtttca	tgtctagcag	agtacacatt	caaaaacttc	aataaatcag	cattagaagg	7920
attgatcgag	cctgccttaa	gctatctacc	ctacgcttca	agcgcactaa	agttattcct	7980
accgactaga	cttgaagtg	tagtgatact	gtccactact	atatacagaa	catacttate	8040
aatcaggaaa	ggatctagtc	agggtttagc	cgggctggca	gtagctcag	cgatggagat	8100
catgaaccag	aacccaatca	gcgtggctat	tgcactggca	ctaggagtgc	gagcaatagc	8160
ggcacataat	gccattgaga	gcagtgaggg	aaaaggact	ctcctgatga	aggtctttgt	8220
taagaacttt	ttggaccaag	cagccactga	tgagcttggt	aaagagaacc	ctgagaagat	8280
cataatggca	gtgtttgagg	gcattcaaac	agctggaaat	ccattgagac	ttgtatacca	8340
tctatatgca	atgtttctaca	aagggtggac	tgccgcgaa	atagctgaaa	aaaccgctgg	8400
taggaacatt	tttgtgttaa	caatatttga	aggattggaa	atgtaggccc	tggatgccga	8460
ctcaaatgg	agaaatctga	gctctaatta	tcttattgat	gcagtgaaga	aaatcattga	8520
aaaaatgact	aaaacagcaa	caagcttcac	ctacagcttt	ttgaaatcct	tgcttctctgc	8580
ccccttctcg	tgtactaaat	cagaagaga	tccaagaata	gggtggcccc	aaaagacta	8640
cgactacctc	gaggtccgat	gcgcttggtg	gtataacagg	agagctataa	aaagagactc	8700
aggacctgtg	ttatgggaga	ccttagagga	gacgggtcca	gagtactgcc	acaacagagg	8760
tgaagggggg	ctcagcaatg	tgaagactac	tagatgcttt	gtccaaggag	aggaaatccc	8820
tccaattgca	ctgaggaaaag	gagtaggtga	gatgttggtc	aagggtgttt	cattcagaat	8880
agattttgat	aaagacaaga	tactttcaac	agacaagtgg	aaggtaccac	atagggcagt	8940
tacatcaatc	tttgaggatt	ggcagggtat	tggttacaga	gaggcttacc	tagggaccaa	9000
accagactat	gggggtctgg	tgcccagatc	ttgtgtaact	gtaacaaaac	aagggttaac	9060
attcttgaaa	actgccagag	gcattggcttt	cacgactgac	ctgaccatcc	agaacatcaa	9120
aatgctgata	gctacatgct	tcaagaacaa	ggtgaaggaa	ggggagatac	cagctacgat	9180
tgaaggggaa	acatggatca	acataccact	agtgaatgag	gacaccggga	ccattaaac	9240
aagcttcggg	gaaagagtga	ttcccgaacc	atatgaggag	gacccacttg	aaggcccaag	9300
tgtaatcggt	gaaacaggag	gcatagccat	caaccaaata	ggggtcaatc	cacaatccag	9360
tacatgtgga	acagttttta	cagcagtgaa	ggatctgtgc	caaacagtta	gtaataaagc	9420
caagaatate	aaaattgggt	tttcggaagg	ccaataccca	ggccaggggg	ttgcaagaa	9480
gacactgaac	cagctcatac	aagatgaaga	ccccaaaaca	ttcatatttg	tttgtggctc	9540

-continued

tgacaagtca atgtctaato gggcaaaaac tgcgaggaac atcaagagaa tcaccaccac	9600
aacacctgag aaattcagag acttggcaaa aaacaagaaa ttgataattg tgctgttagg	9660
tgatagatac catgaagata tagaaaagta tgcagacttc aagggcacct tcttgaccag	9720
acaaaccttg gaagcactag caagtgccaa agctgtagag aaggacatga ccaagaaaga	9780
agcagcaaga gtattggcaa tggaaagaaa ggatgaacta gaactcccag ggtggctgca	9840
tacagatgca cccaaattcc tagacattac taaggacaac atcacacatc acctaatagg	9900
ggacatgcag agtctgagag aaagagcagg ggagatagga gcaaaggcca cactcaaat	9960
cactaagaaa gggagtgtat acacaatcaa tctgagtacg tgggtggagt cagagaggtt	10020
ggcatctttg gaacctttgt tccgggaact actatctaaa tgcaggccag tggacagggg	10080
gacataaag aattgtcatt ttgcaacagc agcccaactt gccggaggaa actgggtacc	10140
ggtagacca gttgtacatc ttggggaaat tccggtaaag aagaaaaaga ctctccccta	10200
cgaggcatac aagctcctaa aagagatggg tgactcggag aaggaattcc ataaccagt	10260
gagcagggaa aaacaccaat ggatactgaa caaagtgaaa actggtgggtg acctcggctt	10320
aaaaaatcta gtatgtccag gttaggttgg agaaccaatc ctaagagaga agaagaaatt	10380
caacatttac aacaagagga ttaccagtac tatgttatca gtagggataa gccagaaaa	10440
attgccagtg gtaagagccc agaccagtac caaagaattt catgaagcaa taagggacaa	10500
aatagacaaa aaagcaaaa cacagacccc aggcctacac aaagaattgt tggagatatt	10560
caactcaata tgtgccatcc ccgaacttag aaatacctac aaagaggttg attgggacgt	10620
tctaacctca ggcataaata ggaaggtgc agccgggtac ttcgaaaaaa tgaacatagg	10680
ggagatcata gatagtgaca aaaaatcagt ggaacaactc ataagagaa tgaatcagg	10740
gctagaattc aactactatg agactgcaat accaaaaat gagaagaggg cagtggtaga	10800
tgattggatg gaaggtgact atgtagaaga aaaaagacca agagtcatac agtatcctga	10860
ggcaaagatg agattagcta taaccaaagt aatgtataac tgggtcaagc agaagcctat	10920
agtaatccct ggatacgaag gtaagactcc tttgtttcat gtttctgaca aggtccacaa	10980
agaatggaaa aatttcaaca gtccagttgc agtcagtttt gacactaaag cctgggacac	11040
acaagtaaca cccaaagacc ttctcctcat atcagaaatc caaaagtatt attacaagaa	11100
agaataccat agattcatag ataatttgac cgagaaaatg gtggaggtag cagtggtttg	11160
tgaagacgga aacgtctaca taagagaagg tcagagggga agtggcaac cagacactag	11220
cgcaggtaat agtatgttga atgtactgac tatgatataat gccttctgca aagctaactc	11280
catcccttac tcagccttcc acagggtagc aaagatacat gtgtgtggag atgatggttt	11340
cttgataact gagaaaagtt ttggtgaggc ctttgcgac aaggggctc aaattttgat	11400
ggaagcagga aaaccacaaa aacttatagg tgaatttggg ctgaaattgg catataaatt	11460
tgatgacatt gaattttgct cgcatacacc aataaaggtc aggtgggctg acaacaacac	11520
atcatacatg cccggaagag acacagctac cattctagct aaaatggcaa cccgccttga	11580
ctctagtggg gagaggggga ccgagggata cgagctggcc gtggccttca gtttcttact	11640
aatgtattct tggaaacccc tggtaagaag aatatgcctg cttgtcatgt ctacaattga	11700
cacaaaagaa gctagccaaa ataacactat atatacattt aggggggac ccataggtgc	11760
ctacacagag gtaattgggt ataggctgga ccaactaaaa cagacagagt tctctaaatt	11820

-continued

```

ggctcagctg aatttgctca tggcaatact tcaaatatac aataaaaaaca caaccaagag 11880
actcatcgaa gattgtgtga aactggcaa ccaaaataag caaatattgg tgaatgcaga 11940
ccgtttgatc agcaagaaaa cgggctacac atatgagcca acagctggcc acactaagat 12000
aggcaagcac tatgaagaaa tcaacctgct gaaagataca ccacaaaaaa ctgtctacca 12060
aggaactgaa aggtata 12077

```

```

<210> SEQ ID NO 2
<211> LENGTH: 3886
<212> TYPE: PRT
<213> ORGANISM: PMC Virus

```

```

<400> SEQUENCE: 2

```

```

Gly Gly Ser Glu Glu Gly Asn Met Phe Phe Arg Thr Ala Pro Thr Pro
1          5          10          15
Pro Pro Gly Cys Gln Glu Pro Val Tyr Thr Ser Thr Met Arg Pro Ile
20          25          30
Phe Gly Glu Pro His Pro Pro Leu His Lys His Ser Thr Leu Lys Leu
35          40          45
Pro His Trp Arg Gly Ile Lys Thr Ile Arg Val Lys Lys Arg Glu Leu
50          55          60
Pro Lys Lys Gly Asp Cys Ser Asn Ser Thr Thr Ala Pro Thr Ser Gly
65          70          75          80
Val Tyr Val Glu Leu Gly Ala Val Phe Tyr Lys Asp Tyr Thr Gly Thr
85          90          95
Val Tyr His Arg Val Pro Leu Glu Leu Cys Thr Asn Gln Glu Arg Cys
100         105         110
Glu Gly Ser Lys Cys Val Gly Arg Met Thr Gly Ser Asp Gly Arg Leu
115         120         125
Tyr Asn Val Leu Val Cys Pro Asp Asp Cys Ile Leu Phe Glu Arg His
130         135         140
Cys Arg Gly Gln Thr Val Val Leu Lys Trp Ile Ser Asn Pro Leu Thr
145         150         155         160
Ser Pro Leu Trp Val Gln Ser Cys Ser Asp Asp Lys Gly Ala Lys Pro
165         170         175
Lys Val Lys Pro Lys Asp Asp Arg Met Lys Gln Gly Lys Ile Val Thr
180         185         190
Lys Pro Lys Glu Thr Glu Ala Asp Gln Lys Thr Arg Pro Pro Asp Ala
195         200         205
Thr Ile Val Val Asp Gly Gln Lys Tyr Gln Val Arg Lys Lys Gly Lys
210         215         220
Ala Lys Pro Lys Thr Gln Asp Gly Leu Tyr His Asn Lys Asn Lys Pro
225         230         235         240
Glu Ala Ser Arg Lys Lys Leu Glu Lys Ala Leu Leu Ala Trp Ala Ile
245         250         255
Leu Ala Cys Leu Leu Val Val Pro Val Gly Ser Thr Asn Val Thr Gln
260         265         270
Trp Asn Leu Trp Asp Asn Lys Ser Thr Thr Asp Ile His Ser Val Met
275         280         285
Phe Ser Arg Gly Ile Lys Arg Ser Leu His Gly Ile Trp Pro Thr Gln
290         295         300
Ile Cys Lys Gly Ile Pro Thr His Leu Ala Ala Asp Tyr Glu Leu Lys

```


-continued

Thr Met 1115	Asn Pro Phe Gln 1120	Ser Val Met Ile Thr 1125	Val Tyr Phe 1125
Val Gly 1130	Leu Val Arg Ala 1135	Glu Gly Thr Lys 1140	Gly Ser Thr 1140
Ser Gly 1145	Pro Pro Ile His 1150	Val Val Ala Ile Leu 1155	Phe Leu Leu 1155
Tyr His 1160	Thr Val Lys Tyr 1165	Lys Asp Phe Asn Ile 1170	Ala Met Ile Leu 1170
Leu Ile 1175	Thr Leu Ser Leu 1180	Lys Ser Ser Ser Tyr 1185	Ile His Thr Ser 1185
Leu Tyr 1190	Glu Ile Pro Leu 1195	Leu Val Ala Val Ile 1200	Ser Leu Thr Cys 1200
Ser Ile 1205	Tyr Ile Phe Asp 1210	Leu Gln Val Lys Ser 1215	Lys Leu Val Ala 1215
Pro Thr 1220	Ile Gly Ile Ile 1225	Gly Val Thr Leu Ala 1230	Met Arg Val Leu 1230
Trp Leu 1235	Val Arg Gln Met 1240	Thr Ile Pro Thr Pro 1245	Ser Val Ser Ile 1245
Ser Leu 1250	Ile Asp Pro Lys 1255	Met Val Ile Ile Leu 1260	Tyr Leu Ile Ser 1260
Leu Thr 1265	Ile Thr Val Asn 1270	His Asn Leu Asp Leu 1275	Ala Ser Tyr Cys 1275
Leu Lys 1280	Leu Gly Pro Phe 1285	Ile Leu Ser Phe Leu 1290	Thr Met Trp Val 1290
Asp Val 1295	Val Ile Leu Leu 1300	Leu Met Leu Pro Trp 1305	Tyr Glu Leu Val 1305
Lys Val 1310	Tyr Tyr Leu Lys 1315	Lys Lys Lys Glu Asp 1320	Val Glu Thr Trp 1320
Phe Gln 1325	Asn Ser Gly Ile 1330	Ser Thr Gln Glu Thr 1335	Ser Pro Tyr Gly 1335
Phe Asp 1340	Phe Ser Ser Pro 1345	Gly Glu Gly Val His 1350	Thr Leu Pro Met 1350
Gln Asn 1355	Lys Thr Lys Phe 1360	Cys Arg Thr Ala Tyr 1365	Met Thr Val Leu 1365
Arg Ala 1370	Leu Val Ile Thr 1375	Ala Ile Ser Ser Val 1380	Trp Lys Pro Ile 1380
Ile Leu 1385	Ala Glu Leu Leu 1390	Ile Glu Ala Val Tyr 1395	Trp Thr His Ile 1395
Lys Ile 1400	Ala Lys Glu Leu 1405	Ala Gly Ser Ser Arg 1410	Phe Val Ala Arg 1410
Phe Ile 1415	Ala Ser Ile Ile 1420	Glu Leu Asn Trp Ala 1425	Met Asp Glu Lys 1425
Glu Ala 1430	Ser Arg Tyr Lys 1435	Arg Phe Tyr Leu Leu 1440	Ser Ser Lys Ile 1440
Thr Asp 1445	Leu Met Val Lys 1450	His Lys Ile Gln Asn 1455	Glu Thr Val Lys 1455
Ser Trp 1460	Phe Glu Glu Thr 1465	Glu Ile Phe Gly Ile 1470	Gln Lys Val Ala 1470
Met Val 1475	Ile Arg Ala His 1480	Ser Leu Ser Leu Glu 1485	Pro Asn Ala Ile 1485
Leu Cys	Ser Val Cys Glu 1490	Glu Lys Gln Asn Gln 1495	Lys Ala Lys Arg 1495

-continued

1490						1495							1500
Pro Cys	Pro Lys	Cys Gly	Ser	Arg Gly	Thr Gln	Ile	Lys Cys	Gly					
1505			1510			1515							
Leu Thr	Leu Ala	Glu Phe	Glu	Glu Gly	His Tyr	Lys	Lys Ile	Tyr					
1520			1525			1530							
Ile Leu	Glu Gly	Gln Asp	Glu	Thr Pro	Met Arg	Lys	Glu Glu	Arg					
1535			1540			1545							
Gln Gln	Val Thr	Tyr Val	Ser	Arg Gly	Ala Leu	Phe	Leu Arg	Asn					
1550			1555			1560							
Leu Pro	Ile Leu	Ala Ser	Lys	Asn Lys	Tyr Leu	Leu	Val Gly	Asn					
1565			1570			1575							
Leu Gly	Met Glu	Leu Gln	Asp	Leu Glu	Ser Met	Gly	Trp Ile	Ile					
1580			1585			1590							
Arg Gly	Pro Ala	Val Cys	Lys	Lys Ile	Ile His	His	Glu Lys	Cys					
1595			1600			1605							
Arg Pro	Ser Ile	Pro Asp	Lys	Leu Met	Ala Phe	Phe	Gly Ile	Met					
1610			1615			1620							
Pro Arg	Gly Val	Thr Pro	Arg	Ala Pro	Thr Arg	Phe	Pro Val	Ser					
1625			1630			1635							
Leu Leu	Lys Ile	Arg Arg	Gly	Phe Glu	Thr Gly	Trp	Ala Tyr	Thr					
1640			1645			1650							
His Pro	Gly Gly	Val Ser	Ser	Val Met	His Val	Thr	Ala Gly	Ser					
1655			1660			1665							
Asp Ile	Tyr Val	Asn Asp	Ser	Ile Gly	Arg Thr	Lys	Ile Gln	Cys					
1670			1675			1680							
Gln Asp	Lys Asn	Thr Thr	Thr	Asp Glu	Cys Glu	Tyr	Gly Val	Lys					
1685			1690			1695							
Thr Asp	Ser Gly	Cys Ser	Asp	Gly Ala	Arg Cys	Tyr	Val Ile	Asn					
1700			1705			1710							
Pro Glu	Ala Thr	Asn Ile	Ala	Gly Thr	Lys Gly	Ala	Met Val	His					
1715			1720			1725							
Leu Arg	Lys Ala	Gly Gly	Glu	Phe Asn	Cys Val	Thr	Ala Gln	Gly					
1730			1735			1740							
Thr Pro	Ala Phe	Tyr Asn	Leu	Lys Asn	Leu Lys	Gly	Trp Ser	Gly					
1745			1750			1755							
Leu Pro	Ile Phe	Glu Ala	Ala	Thr Gly	Arg Val	Val	Gly Arg	Val					
1760			1765			1770							
Lys Ala	Gly Lys	Asn Thr	Asp	Asn Ala	Pro Thr	Thr	Ile Met	Ser					
1775			1780			1785							
Gly Thr	Gln Val	Ala Lys	Pro	Ser Glu	Cys Asp	Leu	Glu Ser	Val					
1790			1795			1800							
Val Arg	Lys Leu	Glu Thr	Met	Asn Arg	Gly Glu	Phe	Lys Gln	Val					
1805			1810			1815							
Thr Leu	Ala Thr	Gly Ala	Gly	Lys Thr	Thr Met	Leu	Pro Lys	Leu					
1820			1825			1830							
Leu Ile	Glu Ser	Ile Gly	Arg	His Lys	Arg Val	Leu	Val Leu	Ile					
1835			1840			1845							
Pro Leu	Arg Ala	Ala Ala	Glu	Gly Val	Tyr Gln	Tyr	Met Arg	Thr					
1850			1855			1860							
Lys His	Pro Ser	Ile Ser	Phe	Asn Leu	Arg Ile	Gly	Asp Leu	Lys					
1865			1870			1875							

-continued

Glu Gly Asp Met Ala Thr	Gly Ile Thr Tyr Ala Ser Tyr Gly Tyr
1880	1885 1890
Phe Cys Gln Met Asp Met	Pro Arg Leu Glu Asn Ala Met Lys Glu
1895	1900 1905
Tyr His Tyr Ile Phe Leu	Asp Glu Tyr His Cys Ala Thr Pro Glu
1910	1915 1920
Gln Leu Ala Val Met Ser	Lys Ile His Arg Phe Gly Glu Ser Val
1925	1930 1935
Arg Val Ile Ala Met Thr	Ala Thr Pro Ser Gly Thr Val Ser Thr
1940	1945 1950
Thr Gly Gln Lys Phe Thr	Ile Glu Glu Val Val Val Pro Glu Val
1955	1960 1965
Met Lys Gly Glu Asp Leu	Ala Asp Asp Tyr Ile Glu Ile Ala Gly
1970	1975 1980
Leu Lys Val Pro Lys Lys	Glu Leu Glu Gly Asn Val Leu Thr Phe
1985	1990 1995
Val Pro Thr Arg Lys Met	Ala Ser Glu Thr Ala Lys Lys Leu Thr
2000	2005 2010
Thr Gln Gly Tyr Asn Ala	Gly Tyr Tyr Phe Ser Gly Glu Asp Pro
2015	2020 2025
Ser Ser Leu Arg Thr Thr	Thr Ser Lys Ser Pro Tyr Ile Val Val
2030	2035 2040
Ala Thr Asn Ala Ile Glu	Ser Gly Val Thr Leu Pro Asp Leu Asp
2045	2050 2055
Thr Val Ile Asp Thr Gly	Met Lys Cys Glu Lys Arg Leu Arg Ile
2060	2065 2070
Glu Asn Lys Ala Pro Tyr	Ile Val Thr Gly Leu Lys Arg Met Ala
2075	2080 2085
Ile Thr Thr Gly Glu Gln	Ala Gln Arg Lys Gly Arg Val Gly Arg
2090	2095 2100
Val Lys Pro Gly Arg Tyr	Leu Arg Gly Pro Glu Asn Thr Ala Gly
2105	2110 2115
Glu Lys Asp Tyr His Tyr	Asp Leu Leu Gln Ala Gln Arg Tyr Gly
2120	2125 2130
Ile Gln Asp Ser Ile Asn	Ile Thr Lys Ser Phe Arg Glu Met Asn
2135	2140 2145
Tyr Asp Trp Ala Leu Tyr	Glu Glu Asp Pro Leu Lys Ile Ala Gln
2150	2155 2160
Leu Glu Leu Leu Asn Thr	Leu Leu Ile Ser Arg Asp Leu Pro Val
2165	2170 2175
Val Thr Lys Asn Leu Met	Ala Arg Thr Thr His Pro Glu Pro Ile
2180	2185 2190
Gln Leu Ala Tyr Asn Ser	Leu Glu Thr Pro Val Pro Val Ala Phe
2195	2200 2205
Pro Lys Val Lys Asn Gly	Glu Val Thr Asp Ala His Glu Thr Tyr
2210	2215 2220
Glu Leu Met Thr Cys Arg	Lys Leu Glu Lys Asp Pro Pro Ile Tyr
2225	2230 2235
Leu Tyr Ala Thr Glu Glu	Glu Asp Leu Val Val Asp Ile Leu Gly
2240	2245 2250

-continued

Leu 2255	Lys	Trp	Pro	Asp	Ala	Thr 2260	Glu	Arg	Ala	Val	Leu 2265	Glu	Val	Gln
Asp 2270	Ala	Leu	Gly	Gln	Ile	Thr 2275	Gly	Leu	Ser	Ala	Gly 2280	Glu	Thr	Ala
Leu 2285	Leu	Ile	Ala	Leu	Leu	Gly 2290	Trp	Val	Gly	Tyr	Glu 2295	Ala	Leu	Val
Lys 2300	Arg	His	Val	Pro	Met	Val 2305	Thr	Asp	Ile	Tyr	Thr 2310	Leu	Glu	Asp
Glu 2315	Lys	Leu	Glu	Asp	Thr	Thr 2320	His	Leu	Gln	Phe	Ala 2325	Pro	Asp	Asp
Leu 2330	Asn	Asn	Ser	Asp	Thr	Ile 2335	Glu	Leu	Gln	Asp	Leu 2340	Ser	Asn	His
Gln 2345	Ile	Gln	Gln	Ile	Leu	Glu 2350	Gly	Gly	Lys	Glu	Tyr 2355	Val	Gly	Gln
Ala 2360	Tyr	Gln	Phe	Leu	Arg	Leu 2365	Gln	Ala	Glu	Arg	Ala 2370	Ala	Asn	Ser
Asp 2375	Lys	Gly	Lys	Lys	Ala	Met 2380	Ala	Ala	Ala	Pro	Leu 2385	Leu	Ala	His
Lys 2390	Phe	Leu	Glu	Tyr	Leu	Gln 2395	Glu	His	Ala	Gly	Asp 2400	Ile	Lys	Lys
Tyr 2405	Gly	Leu	Trp	Gly	Val	His 2410	Thr	Ala	Leu	Tyr	Asn 2415	Ser	Ile	Lys
Glu 2420	Arg	Leu	Gly	His	Glu	Thr 2425	Ala	Phe	Ala	Ser	Leu 2430	Val	Ile	Lys
Trp 2435	Ile	Ala	Phe	Ser	Ser	Asp 2440	Gly	Val	Pro	Gly	Met 2445	Ile	Lys	Gln
Ala 2450	Ala	Val	Asp	Leu	Val	Val 2455	Tyr	Tyr	Ile	Ile	Asn 2460	Arg	Pro	Glu
Tyr 2465	Gln	Gly	Asp	Lys	Glu	Thr 2470	Gln	Asn	Ala	Gly	Arg 2475	Gln	Phe	Val
Gly 2480	Ser	Leu	Phe	Val	Ser	Cys 2485	Leu	Ala	Glu	Tyr	Thr 2490	Phe	Lys	Asn
Phe 2495	Asn	Lys	Ser	Ala	Leu	Glu 2500	Gly	Leu	Ile	Glu	Pro 2505	Ala	Leu	Ser
Tyr 2510	Leu	Pro	Tyr	Ala	Ser	Ser 2515	Ala	Leu	Lys	Leu	Phe 2520	Leu	Pro	Thr
Arg 2525	Leu	Glu	Ser	Val	Val	Ile 2530	Leu	Ser	Thr	Thr	Ile 2535	Tyr	Arg	Thr
Tyr 2540	Leu	Ser	Ile	Arg	Lys	Gly 2545	Ser	Ser	Gln	Gly	Leu 2550	Ala	Gly	Leu
Ala 2555	Val	Ser	Ser	Ala	Met	Glu 2560	Ile	Met	Asn	Gln	Asn 2565	Pro	Ile	Ser
Val 2570	Ala	Ile	Ala	Leu	Ala	Leu 2575	Gly	Val	Gly	Ala	Ile 2580	Ala	Ala	His
Asn 2585	Ala	Ile	Glu	Ser	Ser	Glu 2590	Ala	Lys	Arg	Thr	Leu 2595	Leu	Met	Lys
Val 2600	Phe	Val	Lys	Asn	Phe	Leu 2605	Asp	Gln	Ala	Ala	Thr 2610	Asp	Glu	Leu
Val 2615	Lys	Glu	Asn	Pro	Glu	Lys 2620	Ile	Ile	Met	Ala	Val 2625	Phe	Glu	Gly
Ile	Gln	Thr	Ala	Gly	Asn	Pro	Leu	Arg	Leu	Val	Tyr	His	Leu	Tyr

-continued

2630	2635	2640
Ala Met Phe Tyr Lys Gly Trp Thr Ala Ala Glu Ile Ala Glu Lys 2645 2650 2655		
Thr Ala Gly Arg Asn Ile Phe Val Leu Thr Ile Phe Glu Gly Leu 2660 2665 2670		
Glu Met Leu Gly Leu Asp Ala Asp Ser Lys Trp Arg Asn Leu Ser 2675 2680 2685		
Ser Asn Tyr Leu Ile Asp Ala Val Lys Lys Ile Ile Glu Lys Met 2690 2695 2700		
Thr Lys Thr Ala Thr Ser Phe Thr Tyr Ser Phe Leu Lys Ser Leu 2705 2710 2715		
Leu Pro Ala Pro Phe Ser Cys Thr Lys Ser Glu Arg Asp Pro Arg 2720 2725 2730		
Ile Gly Trp Pro Gln Lys Asp Tyr Asp Tyr Leu Glu Val Arg Cys 2735 2740 2745		
Ala Cys Gly Tyr Asn Arg Arg Ala Ile Lys Arg Asp Ser Gly Pro 2750 2755 2760		
Val Leu Trp Glu Thr Leu Glu Glu Thr Gly Pro Glu Tyr Cys His 2765 2770 2775		
Asn Arg Gly Glu Arg Gly Leu Ser Asn Val Lys Thr Thr Arg Cys 2780 2785 2790		
Phe Val Gln Gly Glu Glu Ile Pro Pro Ile Ala Leu Arg Lys Gly 2795 2800 2805		
Val Gly Glu Met Leu Val Lys Gly Val Ser Phe Arg Ile Asp Phe 2810 2815 2820		
Asp Lys Asp Lys Ile Leu Ser Thr Asp Lys Trp Lys Val Pro His 2825 2830 2835		
Arg Ala Val Thr Ser Ile Phe Glu Asp Trp Gln Gly Ile Gly Tyr 2840 2845 2850		
Arg Glu Ala Tyr Leu Gly Thr Lys Pro Asp Tyr Gly Gly Leu Val 2855 2860 2865		
Pro Arg Ser Cys Val Thr Val Thr Lys Gln Gly Leu Thr Phe Leu 2870 2875 2880		
Lys Thr Ala Arg Gly Met Ala Phe Thr Thr Asp Leu Thr Ile Gln 2885 2890 2895		
Asn Ile Lys Met Leu Ile Ala Thr Cys Phe Lys Asn Lys Val Lys 2900 2905 2910		
Glu Gly Glu Ile Pro Ala Thr Ile Glu Gly Glu Thr Trp Ile Asn 2915 2920 2925		
Ile Pro Leu Val Asn Glu Asp Thr Gly Thr Ile Lys Pro Ser Phe 2930 2935 2940		
Gly Glu Arg Val Ile Pro Glu Pro Tyr Glu Glu Asp Pro Leu Glu 2945 2950 2955		
Gly Pro Ser Val Ile Val Glu Thr Gly Gly Ile Ala Ile Asn Gln 2960 2965 2970		
Ile Gly Val Asn Pro Gln Ser Ser Thr Cys Gly Thr Val Phe Thr 2975 2980 2985		
Ala Val Lys Asp Leu Cys Gln Thr Val Ser Asn Lys Ala Lys Asn 2990 2995 3000		
Ile Lys Ile Gly Phe Ser Glu Gly Gln Tyr Pro Gly Pro Gly Val 3005 3010 3015		

-continued

Ala Lys	Lys Thr Leu Asn	Gln	Leu Ile Gln Asp	Glu	Asp Pro Lys
3020		3025		3030	
Pro Phe	Ile Phe Val Cys	Gly	Ser Asp Lys Ser	Met	Ser Asn Arg
3035		3040		3045	
Ala Lys	Thr Ala Arg Asn	Ile	Lys Arg Ile Thr	Thr	Thr Thr Pro
3050		3055		3060	
Glu Lys	Phe Arg Asp Leu	Ala	Lys Asn Lys Lys	Leu	Ile Ile Val
3065		3070		3075	
Leu Leu	Gly Asp Arg Tyr	His	Glu Asp Ile Glu	Lys	Tyr Ala Asp
3080		3085		3090	
Phe Lys	Gly Thr Phe Leu	Thr	Arg Gln Thr Leu	Glu	Ala Leu Ala
3095		3100		3105	
Ser Ala	Lys Ala Val Glu	Lys	Asp Met Thr Lys	Lys	Glu Ala Ala
3110		3115		3120	
Arg Val	Leu Ala Met Glu	Glu	Lys Asp Glu Leu	Glu	Leu Pro Gly
3125		3130		3135	
Trp Leu	His Thr Asp Ala	Pro	Lys Phe Leu Asp	Ile	Thr Lys Asp
3140		3145		3150	
Asn Ile	Thr His His Leu	Ile	Gly Asp Met Gln	Ser	Leu Arg Glu
3155		3160		3165	
Arg Ala	Gly Glu Ile Gly	Ala	Lys Ala Thr Thr	Gln	Ile Thr Lys
3170		3175		3180	
Lys Gly	Ser Val Tyr Thr	Ile	Asn Leu Ser Thr	Trp	Trp Glu Ser
3185		3190		3195	
Glu Arg	Leu Ala Ser Leu	Glu	Pro Leu Phe Arg	Glu	Leu Leu Ser
3200		3205		3210	
Lys Cys	Arg Pro Val Asp	Arg	Glu Thr Tyr Lys	Asn	Cys His Phe
3215		3220		3225	
Ala Thr	Ala Ala Gln Leu	Ala	Gly Gly Asn Trp	Val	Pro Val Ala
3230		3235		3240	
Pro Val	Val His Leu Gly	Glu	Ile Pro Val Lys	Lys	Lys Lys Thr
3245		3250		3255	
Leu Pro	Tyr Glu Ala Tyr	Lys	Leu Leu Lys Glu	Met	Val Asp Ser
3260		3265		3270	
Glu Lys	Glu Phe His Lys	Pro	Val Ser Arg Glu	Lys	His Gln Trp
3275		3280		3285	
Ile Leu	Asn Lys Val Lys	Thr	Gly Gly Asp Leu	Gly	Leu Lys Asn
3290		3295		3300	
Leu Val	Cys Pro Gly Arg	Val	Gly Glu Pro Ile	Leu	Arg Glu Lys
3305		3310		3315	
Lys Lys	Phe Asn Ile Tyr	Asn	Lys Arg Ile Thr	Ser	Thr Met Leu
3320		3325		3330	
Ser Val	Gly Ile Arg Pro	Glu	Lys Leu Pro Val	Val	Arg Ala Gln
3335		3340		3345	
Thr Ser	Thr Lys Glu Phe	His	Glu Ala Ile Arg	Asp	Lys Ile Asp
3350		3355		3360	
Lys Lys	Ala Asn Thr Gln	Thr	Pro Gly Leu His	Lys	Glu Leu Leu
3365		3370		3375	
Glu Ile	Phe Asn Ser Ile	Cys	Ala Ile Pro Glu	Leu	Arg Asn Thr
3380		3385		3390	

-continued

Tyr	Lys	Glu	Val	Asp	Trp	Asp	Val	Leu	Thr	Ser	Gly	Ile	Asn	Arg
3395						3400					3405			
Lys	Gly	Ala	Ala	Gly	Tyr	Phe	Glu	Lys	Met	Asn	Ile	Gly	Glu	Ile
3410						3415					3420			
Ile	Asp	Ser	Asp	Lys	Lys	Ser	Val	Glu	Gln	Leu	Ile	Lys	Arg	Met
3425						3430					3435			
Lys	Ser	Gly	Leu	Glu	Phe	Asn	Tyr	Tyr	Glu	Thr	Ala	Ile	Pro	Lys
3440						3445					3450			
Asn	Glu	Lys	Arg	Ala	Val	Val	Asp	Asp	Trp	Met	Glu	Gly	Asp	Tyr
3455						3460					3465			
Val	Glu	Glu	Lys	Arg	Pro	Arg	Val	Ile	Gln	Tyr	Pro	Glu	Ala	Lys
3470						3475					3480			
Met	Arg	Leu	Ala	Ile	Thr	Lys	Val	Met	Tyr	Asn	Trp	Val	Lys	Gln
3485						3490					3495			
Lys	Pro	Ile	Val	Ile	Pro	Gly	Tyr	Glu	Gly	Lys	Thr	Pro	Leu	Phe
3500						3505					3510			
His	Val	Phe	Asp	Lys	Val	His	Lys	Glu	Trp	Lys	Asn	Phe	Asn	Ser
3515						3520					3525			
Pro	Val	Ala	Val	Ser	Phe	Asp	Thr	Lys	Ala	Trp	Asp	Thr	Gln	Val
3530						3535					3540			
Thr	Pro	Lys	Asp	Leu	Leu	Leu	Ile	Ser	Glu	Ile	Gln	Lys	Tyr	Tyr
3545						3550					3555			
Tyr	Lys	Lys	Glu	Tyr	His	Arg	Phe	Ile	Asp	Asn	Leu	Thr	Glu	Lys
3560						3565					3570			
Met	Val	Glu	Val	Pro	Val	Val	Cys	Glu	Asp	Gly	Asn	Val	Tyr	Ile
3575						3580					3585			
Arg	Glu	Gly	Gln	Arg	Gly	Ser	Gly	Gln	Pro	Asp	Thr	Ser	Ala	Gly
3590						3595					3600			
Asn	Ser	Met	Leu	Asn	Val	Leu	Thr	Met	Ile	Tyr	Ala	Phe	Cys	Lys
3605						3610					3615			
Ala	Asn	Ser	Ile	Pro	Tyr	Ser	Ala	Phe	His	Arg	Val	Ala	Lys	Ile
3620						3625					3630			
His	Val	Cys	Gly	Asp	Asp	Gly	Phe	Leu	Ile	Thr	Glu	Lys	Ser	Phe
3635						3640					3645			
Gly	Glu	Ala	Phe	Ala	Ile	Lys	Gly	Pro	Gln	Ile	Leu	Met	Glu	Ala
3650						3655					3660			
Gly	Lys	Pro	Gln	Lys	Leu	Ile	Gly	Glu	Phe	Gly	Leu	Lys	Leu	Ala
3665						3670					3675			
Tyr	Lys	Phe	Asp	Asp	Ile	Glu	Phe	Cys	Ser	His	Thr	Pro	Ile	Lys
3680						3685					3690			
Val	Arg	Trp	Ala	Asp	Asn	Asn	Thr	Ser	Tyr	Met	Pro	Gly	Arg	Asp
3695						3700					3705			
Thr	Ala	Thr	Ile	Leu	Ala	Lys	Met	Ala	Thr	Arg	Leu	Asp	Ser	Ser
3710						3715					3720			
Gly	Glu	Arg	Gly	Thr	Glu	Gly	Tyr	Glu	Leu	Ala	Val	Ala	Phe	Ser
3725						3730					3735			
Phe	Leu	Leu	Met	Tyr	Ser	Trp	Asn	Pro	Leu	Val	Arg	Arg	Ile	Cys
3740						3745					3750			
Leu	Leu	Val	Met	Ser	Thr	Ile	Asp	Thr	Lys	Glu	Ala	Ser	Gln	Asn
3755						3760					3765			
Asn	Thr	Ile	Tyr	Thr	Phe	Arg	Gly	Asp	Pro	Ile	Gly	Ala	Tyr	Thr

-continued

3770	3775	3780
Glu Val Ile Gly Tyr Arg	Leu Asp Gln Leu Lys Gln Thr Glu Phe	
3785	3790	3795
Ser Lys Leu Ala Gln Leu Asn Leu Ser Met Ala Ile Leu Gln Ile		
3800	3805	3810
Tyr Asn Lys Asn Thr Thr Lys Arg Leu Ile Glu Asp Cys Val Lys		
3815	3820	3825
Leu Gly Asn Gln Asn Lys Gln Ile Leu Val Asn Ala Asp Arg Leu		
3830	3835	3840
Ile Ser Lys Lys Thr Gly Tyr Thr Tyr Glu Pro Thr Ala Gly His		
3845	3850	3855
Thr Lys Ile Gly Lys His Tyr Glu Glu Ile Asn Leu Leu Lys Asp		
3860	3865	3870
Thr Pro Gln Lys Thr Val Tyr Gln Gly Thr Glu Arg Tyr		
3875	3880	3885

<210> SEQ ID NO 3
 <211> LENGTH: 418
 <212> TYPE: DNA
 <213> ORGANISM: PMC Virus

<400> SEQUENCE: 3

```

gtataacgac agtagttcaa gtgtcgttat gcatcattgg ccataacaaa ttatctaatt    60
tggaaataggg acctgcgacc tgtaacgaagg ccgagcgtcg gtagccattc cgactagtag    120
gactagtaca aataggtcaa ctggttgagc aggtgagtgt gctgcagcgg ctaagcggtg    180
agtacaccgt attcgtcaac aggtgtctact ggaaaggatc acccactagc gatgcctgtg    240
tggacgagga catgtccaag ccaatgttat cagtagcggg ggtagttact gagaaagctg    300
cccagaatgg gtagtgtcac atacagtctg ataggatgcc ggcggatgcc ctgtattttg    360
accagtataa atattatccg ttgtaaagca tatgaatact tttactttta atacatat    418
    
```

<210> SEQ ID NO 4
 <211> LENGTH: 504
 <212> TYPE: DNA
 <213> ORGANISM: PMC Virus

<400> SEQUENCE: 4

```

ggagggagtg aggaaggaaa catgttcttt agaactgcac ccacgccgcc accaggggtc    60
caagaaccgg tttacacaag cacaatgaga ccaatttttg gcgaacccca tccacctcta    120
cacaacaca gcacgttaaa attgccacat tggaggggga tcaaaacaat tagagttaag    180
aagagagaat tgccaagaa gggcgattgt agcaactcaa caacagctcc cacttcgggg    240
gtgtacgttg aattaggggc tgtgttctat aaagattaca cgggcacggt ataccatcgt    300
gtaccgctag aactttgtac aaaccaagag aggtgagagg gatccaagtg tgtagggaga    360
atgacagggc ctgatggcag gttgtacaac gttttagat gtccggacga ttgtatcctc    420
tttgagagac actgtagagg tcaaacagtc gtctgaaat ggatttccaa ccccttgaca    480
tcaccacttt ggtccagag ttgt                    504
    
```

<210> SEQ ID NO 5
 <211> LENGTH: 297
 <212> TYPE: DNA
 <213> ORGANISM: PMC Virus

-continued

<400> SEQUENCE: 5

```
tctgacgaca aaggagcaaa acccaagggtg aaacccaaaag acgacaggat gaagcaagga    60
aaaatagtga caaagcctaa agagactgaa gcagatcaaa aaactagacc accagatgcc    120
acgatatgtg ttgacgggca gaagtatcag gtgaggaaga aggggaaagc gaaacccaag    180
actcaagacg gcttatacca caacaagaac aaaccagaag cgtccaggaa gaagcttgag    240
aaggccttgc tagcatgggc aatattagcc tgctatttgg tggtagccgt aggggtcc    297
```

<210> SEQ ID NO 6

<211> LENGTH: 666

<212> TYPE: DNA

<213> ORGANISM: PMC Virus

<400> SEQUENCE: 6

```
accaacgtga cacaatggaa cttatgggac aataaaagta ctacagacat acatagcgtc    60
atgttttcta gagggattaa aaggagtctg catggaattt ggcccacaca aatctgcaaa    120
gggatcccta cacatctagc agcagactat gaactgaaaa ggattcacgg gatggtggat    180
gcaagcccca tgaccaactt cacatgttgt aggetacaga gacatgagtg gaacaagcat    240
gggtggtgca actggtacaa tatagagccg tggatcaatc tcatgaataa tacccaagga    300
ctattaaaca ctggagacaa tttcactgag tgcgcagtca catgcaggta tgatgcagac    360
ttaggggtga atatagtgac tcaagccagg actactccaa ctatcctgac tggctgtaag    420
aaagggcaca acttctcttt ctccagggag gtcagggcct caccctgcaa ctttgagtta    480
actgctgaag acttgctcag gatcatggat cacaccaact gcgagggatt tactacttc    540
ggggaaggaa tcgttgacgg ttacaccgag gtatgagaga aggccaggtc aagtggtttc    600
agggctctca catggttctg gagtaagatt gaaaacacca agaaaaaat attcggagct    660
gaagcc
```

<210> SEQ ID NO 7

<211> LENGTH: 588

<212> TYPE: DNA

<213> ORGANISM: PMC Virus

<400> SEQUENCE: 7

```
agtccttact gccagtggtc taagaggggc ttcaacatta tttataccaa caattgcacc    60
ccgcttggtc tgccagataa gtcaaaaatt ataggaccag gaaccttga catcagtggc    120
agggatgaat tcatatttcc aaaactcccc taccacgtag atgacttcat tctactgagc    180
ttaattgcaa tgtctgattt tgctocagag acatcaagta taatctacct ggctttgcac    240
tacctaatgc caagtaatga caacagggac ttcgtgatgg acctggaccc aaataaacta    300
aaccttactg caactaaatc cgtggcaagt gtggteccca catcgggtgaa tgtgttaggt    360
gaatgggtgt gcgtcaaacc aagttggtgg ccttattccg ccgaaatcac taatctgata    420
ggagggtgca tcaccgtggc agacttagtt atcaagacca ttgaagaatt gctaaatttg    480
tggaccgaag caacagctgt ggcatttctg gctgctctaa taaaaatatt tagaggccag    540
ccgatccaag cggtagcatg gttaatcatc atagggggag cacaagcc
```

<210> SEQ ID NO 8

<211> LENGTH: 1131

-continued

```

<212> TYPE: DNA
<213> ORGANISM: PMC Virus

<400> SEQUENCE: 8
caaacctgca accctgaatt catgtacgca ttagcgaaaa ataccagcat aggttcatta    60
ggaccagaat cactgacgac aaggtggtac caactaacca gcggtttcaa actcactgac    120
agcacgattg aagtcacctg tgtgggtgct aacatgagga ttcattgtagt gtgccactt    180
gtaagtgaca gatatttggc cataaacacc cctagagcac tgccaacaac ggcgtgggtc    240
aggaaaatac acactcagca tgaggtacca agagaaagaa tcatgagtga gtcaaaaagg    300
aggtacactt gtccttgtgg ttctaaacca gtggtgaggt caacaacaca attcaacca    360
atatctatat ctacccaag ctttgaactt gaatgoccta ggggttggac tggggtgta    420
gagtgtacac tagtctcccc atcaactctg acaacagaga ctatattcac atacaggaag    480
cccaaaccat tcggacttga aaactggtgc aagtatacag tgggtggagaa agggatcctg    540
tattcttgta aatttggggg caattcaaca tgcatacaag ggcttatagt taaagggcaa    600
cgggaagaca aagtaaggta ctgtgaatgg tgtggttata agttcagttc accaaatgga    660
ctgcctcagt atccactggg attgtgtgag aaagaacaat cagaaggact cagggattat    720
ggtgacttcc catgctgcaa caacggcact tgtattgaca aagaaggtag tgtgcaatgc    780
tacatagggg ataagaaagt taccgtgaag ctgtataatg cctcactatt ggccccatg    840
ccctgcaaac ccatagtgtg taactcccag gggccccag cgcctaagac ctgcaettat    900
aggtgggct caacattaga aaataaatat tatgaacca gggacagcta ctaccagcaa    960
tacattataa agtcagggta tcaatattgg tttgatctca cagcaaagga tcatgtggca 1020
gactggatca caaaatactt tccaataata atagtggcct tgttaggggg cagaggcacc 1080
ttgtgggtgt tgatagctta tgagttgcta actcagtatg aggtagtagg a          1131

```

```

<210> SEQ ID NO 9
<211> LENGTH: 216
<212> TYPE: DNA
<213> ORGANISM: PMC Virus

<400> SEQUENCE: 9
gacgagaaca tagtggctca agctgaagcc ctggtaatcg gaaacatctt gatgagtta    60
gacttagaga taattagctg cttccttctg ttgttgatcg tggtgaaaaa acaagctgtc    120
aggagaacgt tggtttact gtttcattgg ataactatga acccattcca gtcagtaatg    180
atcacagtgg tctacttcgt cggtttggtg agggcc          216

```

```

<210> SEQ ID NO 10
<211> LENGTH: 1404
<212> TYPE: DNA
<213> ORGANISM: PMC Virus

<400> SEQUENCE: 10
gaagagggaa ctaaagaggg tagtacaagc gggccaccaa tccatgtagt tgcaatactg    60
ttattcctct tgtaccacac agtgaagtat aaggacttta acatagcaat gatcttactt    120
ataacattgt cctgaaaag ctcacctac atacatacca gcttgatga aattccattg    180
cttgtggctg taataagtct cacatgctcc atatacattt ttgacttga ggtaaagagc    240
aagctagtag cccaactat aggtataatt ggagttacc tagcaatgag agttttgtgg    300

```

-continued

```

ctggttaaggc aaatgactat accaaccccc tctgtgtcca ttagtctgat agatccaaag 360
atggtcataa tactctactt gatatacccta actattacag tcaatcacia cctagacctt 420
gcaagttatt gcttgaactt gggacctttt atcctatcat tctaacaat gtgggtggat 480
gttgtcatcc tctgtctcat gctgaccttg tacgaactag taaaagtcta ctacctaaaa 540
aagaagaaag aggatgtgga aacatggttc caaaattcag gaatatccac ccaagaaact 600
tccccatacg gatttgattt ttctagcccc ggggaggagg tgcacacact accaatgcaa 660
aataaaacca aattttgtag gactgcttac atgactgtac taagggtttt ggtgataaca 720
gccatcagca gtgtctggaa accaataatt ttagcagaac tctaataaga ggcagtgtat 780
tggacacaca ttaaaatagc caaagaattg gcgggggtcaa gcagggtcgt tgcagggttc 840
attgcatcta ttatagagtt gaattgggcc atggacgaaa aagaagcatc tcggtacaaa 900
agattttacc tattatcctc caaataaca gatctaattg ttaagcacia aatccaaaat 960
gagacagtaa aatcctgggt tgaagaaact gaaatatttg gaatacaaaa agtggcaatg 1020
gtgataaggg ctcatctctt gagtttggag ccaaatgcca tcttttgctc cgtttgtgaa 1080
gaaaaacaaa atcaaaaagc caaaaggccc tgcctaagt gtggtagtag aggcactcaa 1140
ataaagtgtg ggctgacact ggccgagttt gaggaagaac attacaaaaa aatatacatc 1200
ctcgaaggcc aagatgaaac tcccatgagg aaagaagaaa gacagcaagt aacttatgtc 1260
tctaggggtg ctctgttctt taggaacttt cctatcttag cttcaaaaaa caaataccta 1320
ctttaggca atctgggat ggaattgcaa gatttggaaa gtatgggatg gatcattcga 1380
gggccagccg tctgcaagaa gata 1404

```

<210> SEQ ID NO 11

<211> LENGTH: 2028

<212> TYPE: DNA

<213> ORGANISM: PMC virus

<400> SEQUENCE: 11

```

ataccatg agaaatgcag gccttcaata ccagacaaac tcatggcatt cttcgggatt 60
atgcctaggg gagttacacc aagagccctt acacggttcc ctgtgtcctt gctgaagata 120
agacggggtt ttgagaccgg ctgggcctac acacaccctg gaggggtaag tagtgtgatg 180
catgtcaccg ctgggtcggg tatatatgtc aatgactcaa tagggaggac aaaaatccag 240
tgccaagaca aaaacactac aacagatgag tgtgaatatg gtgtgaaaac agactcaggg 300
tgctctgatg gagctcgggt ctatgtcatc aaccctgaag caaccaacat agcagggacc 360
aagggggcca tggtagacct gaggaaagct ggaggagagt tcaactgcgt gactgcccag 420
ggtacccccg ccttctataa tctaaagaac taaaaggat ggtcaggcct gcctatcttt 480
gaagctgcca caggaagagt ggtaggaagg gtaaaagcag gaaaaaacac tgacaatgct 540
ccaacaacca ttatgtcagg gacgcaagtg gcaaaacct cagagtgtga cctagaatca 600
gtggtgagga aactagagac aatgaacaga ggggaattca aacaagtac tctggctaca 660
ggcgcaggaa agacaacct gctaccaaag ctgttaatag aatccatagg caggcataag 720
agagtgttag tactgatccc gttgagagct gcagcggagg ggggtgacca gtacatgaga 780
acaaaacacc caagcatatc tttcaacttg aggatagggg atctgaaaga aggtgacatg 840
gcaactggga tcacctatgc ctcttatggg tacttctgcc aaatggacat gcctagactg 900

```

-continued

```

gagaatgcaa tgaaggaata ccactatatt ttcttgatg aatatcactg tgccacacca 960
gaacagttgg cagtgatgtc aaaaatacat aggttcggtg aatcagttag ggtaatagcc 1020
atgaccgcca cgccatccgg gactgtgagc acaacagggc agaaattcac aattgaggag 1080
gtggtagtac ctgaagtgat gaagggggag gaccttgctg atgattacat cgaaatagca 1140
gggttgaagg tgccaagaa agagttagag ggtaacgtac tgacttttgt gcctacaagg 1200
aagatggcat cggaaacagc aaaaaatta accacacagg gatacaatgc tggatactac 1260
ttcagtggag aagatccatc atccctgccc acaactactt ctaagtcacc atatatagta 1320
gttgcaacca atgccattga atccgggta accttaccgg accttgatac agtaatagat 1380
acaggcatga agtgtgaaaa gagactaaga atcgaaaaca aagctcccta catcgtaaca 1440
ggactgaaaa gaatggctat aacaacgggg gagcaagctc aaagaaaagg tagggtaggc 1500
agggttaaac ctgggaggta cttgagagga cctgaaaaca ctgcaggta aaaggactat 1560
cactatgacc ttttacaggc acagaggtac ggcatccaag actcaataaa catcaccaag 1620
tctttcaggg agatgaacta tgattgggca ttatatgagg aagaccggtt aaagattgcc 1680
caattagagt tgctaaacac actcctgac tcaagggatc tgccagtagt aacaaaaaat 1740
ctgatggccc gcacaacaca tcccgaacct atacaattgg cttacaatag tttagaacc 1800
cctgtaccgg tggcattccc aaaagtgaaa aatggagaag tcaactgacgc acatgaaact 1860
tacgagtga tgacctgtag gaagcttgag aaagaccccc ctatatacct gtatgcaaca 1920
gaagaagaag atctcgtagt ggacatactg ggattgaaat ggccagacgc cacagagagg 1980
gctgtcttgg aagtgcaga cgccctgggc cagatcacag gtttatct 2028

```

```

<210> SEQ ID NO 12
<211> LENGTH: 189
<212> TYPE: DNA
<213> ORGANISM: PMC Virus

```

```

<400> SEQUENCE: 12

```

```

gcaggggaga cagctttact catagcccta ttaggggtggg tgggctacga agccttggtg 60
aagaggcacg tgcctatggt gacagacata tacaccctag aagatgaaaa attggaagac 120
actacacacc tacaatttgc cccagatgat ctgaacaatt cagataccat tgagctccaa 180
gacttatcg 189

```

```

<210> SEQ ID NO 13
<211> LENGTH: 1041
<212> TYPE: DNA
<213> ORGANISM: PMC Virus

```

```

<400> SEQUENCE: 13

```

```

aatcaccaaa tccaacaaat tctagaaggt gggaaggaat atgtoggcca agcctaccaa 60
ttcctcaggt tgcaagctga gagggtgccc aactcagaca aaggcaagaa agcaatggca 120
gcgcccccat tactagccca caagttcctg gaatacttgc aagagcatgc aggtgacata 180
aagaagtatg gtctatgggg ggtccacaca gcattgtata acagcataaa agaaagactg 240
ggtcacgaaa ctgcattcgc atctctgggt ataaaatgga ttgccttttc ctcagatgga 300
gtccccggga tgattaagca agcagcagta gacttgggtg tatactatat aatcaacagg 360
cctgagtatc aaggggataa ggagacacag aatgcaggtg gacaatttgt tggctccctt 420

```

-continued

```

tttgtttcat gtctagcaga gtacacattc aaaaacttca ataaatcagc attagaagga 480
ttgatcgagc ctgccttaag ctatctaccc tacgcttcaa gcgcactaaa gttattccta 540
ccgactagac ttgaaagtgt agtgatactg tccactacta tatacagaac atacttatca 600
atcaggaaag gatctagtca gggtttagcc gggctggcag ttagctcagc gatggagatc 660
atgaaccaga acccaatcag cgtggctatt gcaactggcac taggagtcgg agcaatagcg 720
gcacataatg ccattgagag cagtgaggca aaaaggactc tcctgatgaa ggtctttggt 780
aagaactttt tggaccaagc agccactgat gagcttctga aagagaaccc tgagaagatc 840
ataatggcag tgtttgaggg cattcaaaca gctggaatc cattgagact tgtataccat 900
ctatatgcaa tgttctacaa aggggtggact gccgcggaaa tagctgaaaa aaccgctggt 960
aggaacatth tttgtttaa aatattttaa ggattggaat ttttaggcct ggatgccgac 1020
tcaaatgga gaaatctgag c 1041

```

```

<210> SEQ ID NO 14
<211> LENGTH: 1515
<212> TYPE: DNA
<213> ORGANISM: PMC Virus

```

```

<400> SEQUENCE: 14

```

```

tctaattatc ttattgatgc agtgaagaaa atcattgaaa aaatgactaa aacagcaaca 60
agcttcacct acagcttttt gaaatctttg cttcctgccc ccttctctgt tactaaatca 120
gaaagagatc caagaatagg gtggocccaa aaagactacg actacctcga ggtccgatgc 180
gcttgtgggt ataacaggag agctataaaa agagactcag gacctgtggt atgggagacc 240
ttagaggaga cgggtccaga gtactgccac aacagagggt aaagggggct cagcaatgtg 300
aagactacta gatgctttgt ccaaggagag gaaatccctc caattgcaact gaggaagga 360
gtaggtgaga tgttggtaaa ggggtgttca ttcagaatag attttgataa agacaagata 420
ctttcaacag acaagtggaa ggtaccacat agggcagtta catcaatctt tgaggattgg 480
cagggatttg gttacagaga ggcttaccta gggaccaaac cagactatgg gggctctggtg 540
cccagatctt gtgtaactgt aacaaaaaaa gggttaacat tcttgaaaac tgccagaggc 600
atggctttca cgactgacct gaccatccag aacatcaaaa tgetgatagc tacatgcttc 660
aagaacaagg tgaaggaagg ggagatacca gctacgattg aaggggaaac atggatcaac 720
ataccactag tgaatgagga caccgggacc attaaaccaa gcttcgggga aagagtgatt 780
cccgaacct atgaggagga ccacttgaa ggcccaagt taatcgtga aacaggaggc 840
atagccatca accaaatagg ggtcaatcca caatccagta catgtggaac agtttttaca 900
gcagtgaagg atctgtgcca aacagttagt aataaagcca agaatacaa aattgggttt 960
tcggaaggcc aataccaggg tccaggggtt gcaaagaaga cactgaacca gctcatacaa 1020
gatgaagacc caaaaccatt catatttgtt tgtggctctg acaagtcaat gtctaactcg 1080
gcaaaaactg cgaggaacat caagagaatc accaccacaa cacctgagaa attcagagac 1140
ttggcaaaaa acaagaatg gataattgtg ctgttaggtg atagatacca tgaagatata 1200
gaaaagtatg cagacttcaa gggcaccttc ttgaccagac aaaccttga agcactagca 1260
agtgccaaag ctgtagagaa ggacatgacc aagaaagaag cagcaagagt attggcaatg 1320
gaagaaaagg atgaactaga actcccaggg tggctgcata cagatgcacc caaattccta 1380

```

-continued

```

gacattacta aggacaacat cacacatcac ctaatagggg acatgcagag tctgagagaa 1440
agagcagggg agataggagc aaaggccacc actcaaatca ctaagaaagg gagtgataac 1500
acaatcaatc tgagt 1515

<210> SEQ ID NO 15
<211> LENGTH: 2080
<212> TYPE: DNA
<213> ORGANISM: PMC Virus

<400> SEQUENCE: 15
acgtgggtggg agtcagagag gttggcatct ttggaacctt tgttccggga actactatct 60
aaatgcaggc cagtggacag ggagacatat aagaattgtc attttgcaac agcagcccaa 120
cttgccggag gaaactgggt accggtagca ccagttgtac atcttgggga aattccggta 180
aagaagaaaa agactctccc ctacgaggca tacaagctcc taaaagagat ggttgactcg 240
gagaaggaat tccataaacc agtgagcagg gaaaaacacc aatggatact gaacaaagtg 300
aaaactggtg gtgacctcgg cttaaaaaat ctagtatgtc caggtagggt tggagaacca 360
atcctaagag agaagaagaa attcaacatt tacaacaaga ggattaccag tactatgtta 420
tcagtaggga taaggccaga aaaattgcca gtggtaagag cccagaccag taccaaagaa 480
tttcatgaag caataagggg caaaatagac aaaaaagcaa acacacagac cccaggccta 540
cacaaagaat tgttgagat attcaactca atatgtgcca tccccgaact tagaaaatac 600
tacaagagg ttgattggga cgttctaacc tcaggcataa ataggaaagg tgcagccggg 660
tacttcgaaa aaatgaacat aggggagatc atagatagtg acaaaaaatc agtggacaa 720
ctcataaaga gaatgaatc agggctagaa ttcaactact atgagactgc aatacaaaaa 780
aatgagaaga gggcagtggt agatgattgg atggaagggt actatgtaga agaaaaaaga 840
ccaagagtca tacagtatcc tgaggcaaaag atgagattag ctataacca agtaatgtat 900
aactgggtca agcagaagcc tatagtaatc cctggatacg aaggtaagac tcctttgttt 960
catgttttcg acaaggtcca caaagaatgg aaaaatttca acagtccagt tgcagtcagt 1020
tttgacacta aagcctggga cacacaagta acacccaag accttctcct catatcagaa 1080
atccaaaagt attattacaa gaaagaatac catagattca tagataatth gaccgagaaa 1140
atggtggagg taccagtggg ttgtgaagac ggaacgtct acataagaga aggtcagagg 1200
ggaagtggtc aaccagacac tagcgcaggt aatagtatgt tgaatgtact gactatgata 1260
tatgccttct gcaaagctaa ctccatccct tactcagcct tccacagggt agcaaagata 1320
catgtgtgtg gagatgatgg tttcttgata actgagaaaa gttttggtga ggcccttgcg 1380
atcaaggggc ctcaaattht gatggaagca gaaaaccac aaaaacttat aggtgaatth 1440
ggactgaaat tggcatataa atttgatgac attgaattht gctcgcatac accaataaag 1500
gtcaggtggg ctgacaacaa cacatcatic atgcccggaa gagacacagc taccattcta 1560
gctaaaatgg caaccgcct tgactctagt ggggagaggg ggaccgaggg atacgagctg 1620
gccgtggcct tcagtttctt actaatgtat tcttgaacc ccctggtgta agaatatgc 1680
ctgcttgta tgtctacaat tgacacaaaa gaagctagcc aaaataacac tatatataca 1740
tttagggggg atcccatagg tgcctacaca gaggtaattg ggtataggct ggaccaacta 1800
aaacagacag agttctctaa attggctcag ctgaattht caatggcaat acttcaata 1860

```

-continued

```
tacaataaaa acacaaccaa gagactcatc gaagattgtg tgaacttgg caacaaaaat 1920
aagcaaatat tggatgatgc agaccgtttg atcagcaaga aaacgggcta cacatatgag 1980
ccaacagctg gccacactaa gataggcaag cactatgaag aaatcaacct gctgaaagat 2040
acaccacaaa aaactgtcta ccaaggaact gaaaggtata 2080
```

```
<210> SEQ ID NO 16
<211> LENGTH: 167
<212> TYPE: PRT
<213> ORGANISM: PMC Virus
```

```
<400> SEQUENCE: 16
```

```
Gly Gly Ser Glu Glu Gly Asn Met Phe Phe Arg Thr Ala Pro Thr Pro
1 5 10 15
Pro Pro Gly Cys Gln Glu Pro Val Tyr Thr Ser Thr Met Arg Pro Ile
20 25 30
Phe Gly Glu Pro His Pro Pro Leu His Lys His Ser Thr Leu Lys Leu
35 40 45
Pro His Trp Arg Gly Ile Lys Thr Ile Arg Val Lys Lys Arg Glu Leu
50 55 60
Pro Lys Lys Gly Asp Cys Ser Asn Ser Thr Thr Ala Pro Thr Ser Gly
65 70 75 80
Val Tyr Val Glu Leu Gly Ala Val Phe Tyr Lys Asp Tyr Thr Gly Thr
85 90 95
Val Tyr His Arg Val Pro Leu Glu Leu Cys Thr Asn Gln Glu Arg Cys
100 105 110
Glu Gly Ser Lys Cys Val Gly Arg Met Thr Gly Ser Asp Gly Arg Leu
115 120 125
Tyr Asn Val Leu Val Cys Pro Asp Asp Cys Ile Leu Phe Glu Arg His
130 135 140
Cys Arg Gly Gln Thr Val Val Leu Lys Trp Ile Ser Asn Pro Leu Thr
145 150 155 160
Ser Pro Leu Trp Val Gln Ser
165
```

```
<210> SEQ ID NO 17
<211> LENGTH: 99
<212> TYPE: PRT
<213> ORGANISM: PMC Virus
```

```
<400> SEQUENCE: 17
```

```
Ser Asp Asp Lys Gly Ala Lys Pro Lys Val Lys Pro Lys Asp Asp Arg
1 5 10 15
Met Lys Gln Gly Lys Ile Val Thr Lys Pro Lys Glu Thr Glu Ala Asp
20 25 30
Gln Lys Thr Arg Pro Pro Asp Ala Thr Ile Val Val Asp Gly Gln Lys
35 40 45
Tyr Gln Val Arg Lys Lys Gly Lys Ala Lys Pro Lys Thr Gln Asp Gly
50 55 60
Leu Tyr His Asn Lys Asn Lys Pro Glu Ala Ser Arg Lys Lys Leu Glu
65 70 75 80
Lys Ala Leu Leu Ala Trp Ala Ile Leu Ala Cys Leu Leu Val Val Pro
85 90 95
```

-continued

Val Gly Ser

<210> SEQ ID NO 18

<211> LENGTH: 222

<212> TYPE: PRT

<213> ORGANISM: PMC Virus

<400> SEQUENCE: 18

Thr Asn Val Thr Gln Trp Asn Leu Trp Asp Asn Lys Ser Thr Thr Asp
 1 5 10 15
 Ile His Ser Val Met Phe Ser Arg Gly Ile Lys Arg Ser Leu His Gly
 20 25 30
 Ile Trp Pro Thr Gln Ile Cys Lys Gly Ile Pro Thr His Leu Ala Ala
 35 40 45
 Asp Tyr Glu Leu Lys Arg Ile His Gly Met Val Asp Ala Ser Pro Met
 50 55 60
 Thr Asn Phe Thr Cys Cys Arg Leu Gln Arg His Glu Trp Asn Lys His
 65 70 75 80
 Gly Trp Cys Asn Trp Tyr Asn Ile Glu Pro Trp Ile Asn Leu Met Asn
 85 90 95
 Asn Thr Gln Gly Leu Leu Asn Thr Gly Asp Asn Phe Thr Glu Cys Ala
 100 105 110
 Val Thr Cys Arg Tyr Asp Ala Asp Leu Gly Val Asn Ile Val Thr Gln
 115 120 125
 Ala Arg Thr Thr Pro Thr Ile Leu Thr Gly Cys Lys Lys Gly His Asn
 130 135 140
 Phe Ser Phe Ser Gly Glu Val Arg Ala Ser Pro Cys Asn Phe Glu Leu
 145 150 155 160
 Thr Ala Glu Asp Leu Leu Arg Ile Met Asp His Thr Asn Cys Glu Gly
 165 170 175
 Phe Thr Tyr Phe Gly Glu Gly Ile Val Asp Gly Tyr Thr Glu Val Val
 180 185 190
 Glu Lys Ala Arg Ser Ser Gly Phe Arg Ala Leu Thr Trp Leu Ser Ser
 195 200 205
 Lys Ile Glu Asn Thr Lys Lys Lys Ile Phe Gly Ala Glu Ala
 210 215 220

<210> SEQ ID NO 19

<211> LENGTH: 196

<212> TYPE: PRT

<213> ORGANISM: PMC Virus

<400> SEQUENCE: 19

Ser Pro Tyr Cys Pro Val Ala Lys Arg Val Phe Asn Ile Ile Tyr Thr
 1 5 10 15
 Asn Asn Cys Thr Pro Leu Gly Leu Pro Asp Lys Ser Lys Ile Ile Gly
 20 25 30
 Pro Gly Thr Phe Asp Ile Ser Gly Arg Asp Glu Phe Ile Phe Pro Lys
 35 40 45
 Leu Pro Tyr His Val Asp Asp Phe Ile Leu Leu Ser Leu Ile Ala Met
 50 55 60
 Ser Asp Phe Ala Pro Glu Thr Ser Ser Ile Ile Tyr Leu Ala Leu His
 65 70 75 80
 Tyr Leu Met Pro Ser Asn Asp Asn Arg Asp Phe Val Met Asp Leu Asp

-continued

	85							90						95					
Pro	Asn	Lys	Leu	Asn	Leu	Thr	Ala	Thr	Lys	Ser	Val	Ala	Ser	Val	Val				
	100							105					110						
Pro	Thr	Ser	Val	Asn	Val	Leu	Gly	Glu	Trp	Val	Cys	Val	Lys	Pro	Ser				
	115						120				125								
Trp	Trp	Pro	Tyr	Ser	Ala	Glu	Ile	Thr	Asn	Leu	Ile	Gly	Gly	Val	Ile				
	130					135					140								
Thr	Val	Ala	Asp	Leu	Val	Ile	Lys	Thr	Ile	Glu	Glu	Leu	Leu	Asn	Leu				
	145			150						155					160				
Trp	Thr	Glu	Ala	Thr	Ala	Val	Ala	Phe	Leu	Ala	Ala	Leu	Ile	Lys	Ile				
				165				170						175					
Phe	Arg	Gly	Gln	Pro	Ile	Gln	Ala	Val	Ala	Trp	Leu	Ile	Ile	Ile	Gly				
			180					185					190						
Gly	Ala	Gln	Ala																
	195																		

<210> SEQ ID NO 20
 <211> LENGTH: 377
 <212> TYPE: PRT
 <213> ORGANISM: PMC Virus

<400> SEQUENCE: 20

Gln	Thr	Cys	Asn	Pro	Glu	Phe	Met	Tyr	Ala	Leu	Ala	Lys	Asn	Thr	Ser				
1				5					10					15					
Ile	Gly	Ser	Leu	Gly	Pro	Glu	Ser	Leu	Thr	Thr	Arg	Trp	Tyr	Gln	Leu				
			20					25					30						
Thr	Ser	Gly	Phe	Lys	Leu	Thr	Asp	Ser	Thr	Ile	Glu	Val	Thr	Cys	Val				
		35					40					45							
Gly	Ala	Asn	Met	Arg	Ile	His	Val	Val	Cys	Pro	Leu	Val	Ser	Asp	Arg				
	50				55						60								
Tyr	Leu	Ala	Ile	Asn	His	Pro	Arg	Ala	Leu	Pro	Thr	Thr	Ala	Trp	Phe				
	65			70						75					80				
Arg	Lys	Ile	His	Thr	Gln	His	Glu	Val	Pro	Arg	Glu	Arg	Ile	Met	Ser				
			85						90					95					
Glu	Ser	Lys	Arg	Arg	Tyr	Thr	Cys	Pro	Cys	Gly	Ser	Lys	Pro	Val	Val				
			100					105					110						
Arg	Ser	Thr	Thr	Gln	Phe	Asn	Pro	Ile	Ser	Ile	Ser	Thr	Pro	Ser	Phe				
		115				120						125							
Glu	Leu	Glu	Cys	Pro	Arg	Gly	Trp	Thr	Gly	Ala	Val	Glu	Cys	Thr	Leu				
	130					135					140								
Val	Ser	Pro	Ser	Thr	Leu	Thr	Thr	Glu	Thr	Ile	Phe	Thr	Tyr	Arg	Lys				
	145				150					155					160				
Pro	Lys	Pro	Phe	Gly	Leu	Glu	Asn	Trp	Cys	Lys	Tyr	Thr	Val	Val	Glu				
			165					170						175					
Lys	Gly	Ile	Leu	Tyr	Ser	Cys	Lys	Phe	Gly	Gly	Asn	Ser	Thr	Cys	Ile				
			180					185					190						
Lys	Gly	Leu	Ile	Val	Lys	Gly	Gln	Arg	Glu	Asp	Lys	Val	Arg	Tyr	Cys				
	195						200				205								
Glu	Trp	Cys	Gly	Tyr	Lys	Phe	Ser	Ser	Pro	Asn	Gly	Leu	Pro	Gln	Tyr				
	210					215					220								
Pro	Leu	Gly	Leu	Cys	Glu	Lys	Glu	Gln	Ser	Glu	Gly	Leu	Arg	Asp	Tyr				
	225				230					235					240				

-continued

Gly Asp Phe Pro Cys Cys Asn Asn Gly Thr Cys Ile Asp Lys Glu Gly
 245 250 255

Ser Val Gln Cys Tyr Ile Gly Asp Lys Lys Val Thr Val Lys Leu Tyr
 260 265 270

Asn Ala Ser Leu Leu Ala Pro Met Pro Cys Lys Pro Ile Val Tyr Asn
 275 280 285

Ser Gln Gly Pro Pro Ala Pro Lys Thr Cys Thr Tyr Arg Trp Ala Ser
 290 295 300

Thr Leu Glu Asn Lys Tyr Tyr Glu Pro Arg Asp Ser Tyr Tyr Gln Gln
 305 310 315 320

Tyr Ile Ile Lys Ser Gly Tyr Gln Tyr Trp Phe Asp Leu Thr Ala Lys
 325 330 335

Asp His Val Ala Asp Trp Ile Thr Lys Tyr Phe Pro Ile Ile Ile Val
 340 345 350

Ala Leu Leu Gly Gly Arg Gly Thr Leu Trp Val Leu Ile Ala Tyr Glu
 355 360 365

Leu Leu Thr Gln Tyr Glu Val Val Gly
 370 375

<210> SEQ ID NO 21
 <211> LENGTH: 72
 <212> TYPE: PRT
 <213> ORGANISM: PMC Virus

<400> SEQUENCE: 21

Asp Glu Asn Ile Val Ala Gln Ala Glu Ala Leu Val Ile Gly Asn Ile
 1 5 10 15

Leu Met Ser Leu Asp Leu Glu Ile Ile Ser Cys Phe Leu Leu Leu Leu
 20 25 30

Ile Val Val Lys Lys Gln Ala Val Arg Arg Thr Leu Ala Leu Leu Phe
 35 40 45

His Trp Ile Thr Met Asn Pro Phe Gln Ser Val Met Ile Thr Val Val
 50 55 60

Tyr Phe Val Gly Leu Val Arg Ala
 65 70

<210> SEQ ID NO 22
 <211> LENGTH: 468
 <212> TYPE: PRT
 <213> ORGANISM: PMC Virus

<400> SEQUENCE: 22

Glu Glu Gly Thr Lys Glu Gly Ser Thr Ser Gly Pro Pro Ile His Val
 1 5 10 15

Val Ala Ile Leu Leu Phe Leu Leu Tyr His Thr Val Lys Tyr Lys Asp
 20 25 30

Phe Asn Ile Ala Met Ile Leu Leu Ile Thr Leu Ser Leu Lys Ser Ser
 35 40 45

Ser Tyr Ile His Thr Ser Leu Tyr Glu Ile Pro Leu Leu Val Ala Val
 50 55 60

Ile Ser Leu Thr Cys Ser Ile Tyr Ile Phe Asp Leu Gln Val Lys Ser
 65 70 75 80

Lys Leu Val Ala Pro Thr Ile Gly Ile Ile Gly Val Thr Leu Ala Met
 85 90 95

-continued

```

Arg Val Leu Trp Leu Val Arg Gln Met Thr Ile Pro Thr Pro Ser Val
      100                               105                110

Ser Ile Ser Leu Ile Asp Pro Lys Met Val Ile Ile Leu Tyr Leu Ile
      115                               120                125

Ser Leu Thr Ile Thr Val Asn His Asn Leu Asp Leu Ala Ser Tyr Cys
      130                               135                140

Leu Lys Leu Gly Pro Phe Ile Leu Ser Phe Leu Thr Met Trp Val Asp
      145                               150                155                160

Val Val Ile Leu Leu Leu Met Leu Pro Trp Tyr Glu Leu Val Lys Val
      165                               170                175

Tyr Tyr Leu Lys Lys Lys Lys Glu Asp Val Glu Thr Trp Phe Gln Asn
      180                               185                190

Ser Gly Ile Ser Thr Gln Glu Thr Ser Pro Tyr Gly Phe Asp Phe Ser
      195                               200                205

Ser Pro Gly Glu Gly Val His Thr Leu Pro Met Gln Asn Lys Thr Lys
      210                               215                220

Phe Cys Arg Thr Ala Tyr Met Thr Val Leu Arg Ala Leu Val Ile Thr
      225                               230                235                240

Ala Ile Ser Ser Val Trp Lys Pro Ile Ile Leu Ala Glu Leu Leu Ile
      245                               250                255

Glu Ala Val Tyr Trp Thr His Ile Lys Ile Ala Lys Glu Leu Ala Gly
      260                               265                270

Ser Ser Arg Phe Val Ala Arg Phe Ile Ala Ser Ile Ile Glu Leu Asn
      275                               280                285

Trp Ala Met Asp Glu Lys Glu Ala Ser Arg Tyr Lys Arg Phe Tyr Leu
      290                               295                300

Leu Ser Ser Lys Ile Thr Asp Leu Met Val Lys His Lys Ile Gln Asn
      305                               310                315                320

Glu Thr Val Lys Ser Trp Phe Glu Glu Thr Glu Ile Phe Gly Ile Gln
      325                               330                335

Lys Val Ala Met Val Ile Arg Ala His Ser Leu Ser Leu Glu Pro Asn
      340                               345                350

Ala Ile Leu Cys Ser Val Cys Glu Glu Lys Gln Asn Gln Lys Ala Lys
      355                               360                365

Arg Pro Cys Pro Lys Cys Gly Ser Arg Gly Thr Gln Ile Lys Cys Gly
      370                               375                380

Leu Thr Leu Ala Glu Phe Glu Glu Glu His Tyr Lys Lys Ile Tyr Ile
      385                               390                395                400

Leu Glu Gly Gln Asp Glu Thr Pro Met Arg Lys Glu Glu Arg Gln Gln
      405                               410                415

Val Thr Tyr Val Ser Arg Gly Ala Leu Phe Leu Arg Asn Leu Pro Ile
      420                               425                430

Leu Ala Ser Lys Asn Lys Tyr Leu Leu Val Gly Asn Leu Gly Met Glu
      435                               440                445

Leu Gln Asp Leu Glu Ser Met Gly Trp Ile Ile Arg Gly Pro Ala Val
      450                               455                460

Cys Lys Lys Ile
      465

```

<210> SEQ ID NO 23

<211> LENGTH: 676

<212> TYPE: PRT

-continued

```

<213> ORGANISM: PMC Virus
<400> SEQUENCE: 23
Ile His His Glu Lys Cys Arg Pro Ser Ile Pro Asp Lys Leu Met Ala
1          5          10          15
Phe Phe Gly Ile Met Pro Arg Gly Val Thr Pro Arg Ala Pro Thr Arg
20          25          30
Phe Pro Val Ser Leu Leu Lys Ile Arg Arg Gly Phe Glu Thr Gly Trp
35          40          45
Ala Tyr Thr His Pro Gly Gly Val Ser Ser Val Met His Val Thr Ala
50          55          60
Gly Ser Asp Ile Tyr Val Asn Asp Ser Ile Gly Arg Thr Lys Ile Gln
65          70          75          80
Cys Gln Asp Lys Asn Thr Thr Thr Asp Glu Cys Glu Tyr Gly Val Lys
85          90          95
Thr Asp Ser Gly Cys Ser Asp Gly Ala Arg Cys Tyr Val Ile Asn Pro
100         105         110
Glu Ala Thr Asn Ile Ala Gly Thr Lys Gly Ala Met Val His Leu Arg
115         120         125
Lys Ala Gly Gly Glu Phe Asn Cys Val Thr Ala Gln Gly Thr Pro Ala
130         135         140
Phe Tyr Asn Leu Lys Asn Leu Lys Gly Trp Ser Gly Leu Pro Ile Phe
145         150         155         160
Glu Ala Ala Thr Gly Arg Val Val Gly Arg Val Lys Ala Gly Lys Asn
165         170         175
Thr Asp Asn Ala Pro Thr Thr Ile Met Ser Gly Thr Gln Val Ala Lys
180         185         190
Pro Ser Glu Cys Asp Leu Glu Ser Val Val Arg Lys Leu Glu Thr Met
195         200         205
Asn Arg Gly Glu Phe Lys Gln Val Thr Leu Ala Thr Gly Ala Gly Lys
210         215         220
Thr Thr Met Leu Pro Lys Leu Leu Ile Glu Ser Ile Gly Arg His Lys
225         230         235         240
Arg Val Leu Val Leu Ile Pro Leu Arg Ala Ala Ala Glu Gly Val Tyr
245         250         255
Gln Tyr Met Arg Thr Lys His Pro Ser Ile Ser Phe Asn Leu Arg Ile
260         265         270
Gly Asp Leu Lys Glu Gly Asp Met Ala Thr Gly Ile Thr Tyr Ala Ser
275         280         285
Tyr Gly Tyr Phe Cys Gln Met Asp Met Pro Arg Leu Glu Asn Ala Met
290         295         300
Lys Glu Tyr His Tyr Ile Phe Leu Asp Glu Tyr His Cys Ala Thr Pro
305         310         315         320
Glu Gln Leu Ala Val Met Ser Lys Ile His Arg Phe Gly Glu Ser Val
325         330         335
Arg Val Ile Ala Met Thr Ala Thr Pro Ser Gly Thr Val Ser Thr Thr
340         345         350
Gly Gln Lys Phe Thr Ile Glu Glu Val Val Val Pro Glu Val Met Lys
355         360         365
Gly Glu Asp Leu Ala Asp Asp Tyr Ile Glu Ile Ala Gly Leu Lys Val
370         375         380

```

-continued

Pro Lys Lys Glu Leu Glu Gly Asn Val Leu Thr Phe Val Pro Thr Arg
 385 390 395 400

Lys Met Ala Ser Glu Thr Ala Lys Lys Leu Thr Thr Gln Gly Tyr Asn
 405 410 415

Ala Gly Tyr Tyr Phe Ser Gly Glu Asp Pro Ser Ser Leu Arg Thr Thr
 420 425 430

Thr Ser Lys Ser Pro Tyr Ile Val Val Ala Thr Asn Ala Ile Glu Ser
 435 440 445

Gly Val Thr Leu Pro Asp Leu Asp Thr Val Ile Asp Thr Gly Met Lys
 450 455 460

Cys Glu Lys Arg Leu Arg Ile Glu Asn Lys Ala Pro Tyr Ile Val Thr
 465 470 475 480

Gly Leu Lys Arg Met Ala Ile Thr Thr Gly Glu Gln Ala Gln Arg Lys
 485 490 495

Gly Arg Val Gly Arg Val Lys Pro Gly Arg Tyr Leu Arg Gly Pro Glu
 500 505 510

Asn Thr Ala Gly Glu Lys Asp Tyr His Tyr Asp Leu Leu Gln Ala Gln
 515 520 525

Arg Tyr Gly Ile Gln Asp Ser Ile Asn Ile Thr Lys Ser Phe Arg Glu
 530 535 540

Met Asn Tyr Asp Trp Ala Leu Tyr Glu Glu Asp Pro Leu Lys Ile Ala
 545 550 555 560

Gln Leu Glu Leu Leu Asn Thr Leu Leu Ile Ser Arg Asp Leu Pro Val
 565 570 575

Val Thr Lys Asn Leu Met Ala Arg Thr Thr His Pro Glu Pro Ile Gln
 580 585 590

Leu Ala Tyr Asn Ser Leu Glu Thr Pro Val Pro Val Ala Phe Pro Lys
 595 600 605

Val Lys Asn Gly Glu Val Thr Asp Ala His Glu Thr Tyr Glu Leu Met
 610 615 620

Thr Cys Arg Lys Leu Glu Lys Asp Pro Pro Ile Tyr Leu Tyr Ala Thr
 625 630 635 640

Glu Glu Glu Asp Leu Val Val Asp Ile Leu Gly Leu Lys Trp Pro Asp
 645 650 655

Ala Thr Glu Arg Ala Val Leu Glu Val Gln Asp Ala Leu Gly Gln Ile
 660 665 670

Thr Gly Leu Ser
 675

<210> SEQ ID NO 24
 <211> LENGTH: 63
 <212> TYPE: PRT
 <213> ORGANISM: PMC Virus

<400> SEQUENCE: 24

Ala Gly Glu Thr Ala Leu Leu Ile Ala Leu Leu Gly Trp Val Gly Tyr
 1 5 10 15

Glu Ala Leu Val Lys Arg His Val Pro Met Val Thr Asp Ile Tyr Thr
 20 25 30

Leu Glu Asp Glu Lys Leu Glu Asp Thr Thr His Leu Gln Phe Ala Pro
 35 40 45

Asp Asp Leu Asn Asn Ser Asp Thr Ile Glu Leu Gln Asp Leu Ser
 50 55 60

-continued

```

<210> SEQ ID NO 25
<211> LENGTH: 347
<212> TYPE: PRT
<213> ORGANISM: PMC Virus

<400> SEQUENCE: 25

Asn His Gln Ile Gln Gln Ile Leu Glu Gly Gly Lys Glu Tyr Val Gly
1          5          10
Gln Ala Tyr Gln Phe Leu Arg Leu Gln Ala Glu Arg Ala Ala Asn Ser
20         25         30
Asp Lys Gly Lys Lys Ala Met Ala Ala Ala Pro Leu Leu Ala His Lys
35         40         45
Phe Leu Glu Tyr Leu Gln Glu His Ala Gly Asp Ile Lys Lys Tyr Gly
50         55         60
Leu Trp Gly Val His Thr Ala Leu Tyr Asn Ser Ile Lys Glu Arg Leu
65         70         75         80
Gly His Glu Thr Ala Phe Ala Ser Leu Val Ile Lys Trp Ile Ala Phe
85         90         95
Ser Ser Asp Gly Val Pro Gly Met Ile Lys Gln Ala Ala Val Asp Leu
100        105        110
Val Val Tyr Tyr Ile Ile Asn Arg Pro Glu Tyr Gln Gly Asp Lys Glu
115        120        125
Thr Gln Asn Ala Gly Arg Gln Phe Val Gly Ser Leu Phe Val Ser Cys
130        135        140
Leu Ala Glu Tyr Thr Phe Lys Asn Phe Asn Lys Ser Ala Leu Glu Gly
145        150        155        160
Leu Ile Glu Pro Ala Leu Ser Tyr Leu Pro Tyr Ala Ser Ser Ala Leu
165        170        175
Lys Leu Phe Leu Pro Thr Arg Leu Glu Ser Val Val Ile Leu Ser Thr
180        185        190
Thr Ile Tyr Arg Thr Tyr Leu Ser Ile Arg Lys Gly Ser Ser Gln Gly
195        200        205
Leu Ala Gly Leu Ala Val Ser Ser Ala Met Glu Ile Met Asn Gln Asn
210        215        220
Pro Ile Ser Val Ala Ile Ala Leu Ala Leu Gly Val Gly Ala Ile Ala
225        230        235        240
Ala His Asn Ala Ile Glu Ser Ser Glu Ala Lys Arg Thr Leu Leu Met
245        250        255
Lys Val Phe Val Lys Asn Phe Leu Asp Gln Ala Ala Thr Asp Glu Leu
260        265        270
Val Lys Glu Asn Pro Glu Lys Ile Ile Met Ala Val Phe Glu Gly Ile
275        280        285
Gln Thr Ala Gly Asn Pro Leu Arg Leu Val Tyr His Leu Tyr Ala Met
290        295        300
Phe Tyr Lys Gly Trp Thr Ala Ala Glu Ile Ala Glu Lys Thr Ala Gly
305        310        315        320
Arg Asn Ile Phe Val Leu Thr Ile Phe Glu Gly Leu Glu Met Leu Gly
325        330        335
Leu Asp Ala Asp Ser Lys Trp Arg Asn Leu Ser
340        345

```

-continued

```

<210> SEQ ID NO 26
<211> LENGTH: 505
<212> TYPE: PRT
<213> ORGANISM: PMC Virus

<400> SEQUENCE: 26

Ser Asn Tyr Leu Ile Asp Ala Val Lys Lys Ile Ile Glu Lys Met Thr
1          5          10          15

Lys Thr Ala Thr Ser Phe Thr Tyr Ser Phe Leu Lys Ser Leu Leu Pro
          20          25          30

Ala Pro Phe Ser Cys Thr Lys Ser Glu Arg Asp Pro Arg Ile Gly Trp
          35          40          45

Pro Gln Lys Asp Tyr Asp Tyr Leu Glu Val Arg Cys Ala Cys Gly Tyr
          50          55          60

Asn Arg Arg Ala Ile Lys Arg Asp Ser Gly Pro Val Leu Trp Glu Thr
65          70          75          80

Leu Glu Glu Thr Gly Pro Glu Tyr Cys His Asn Arg Gly Glu Arg Gly
          85          90          95

Leu Ser Asn Val Lys Thr Thr Arg Cys Phe Val Gln Gly Glu Glu Ile
          100         105         110

Pro Pro Ile Ala Leu Arg Lys Gly Val Gly Glu Met Leu Val Lys Gly
          115         120         125

Val Ser Phe Arg Ile Asp Phe Asp Lys Asp Lys Ile Leu Ser Thr Asp
          130         135         140

Lys Trp Lys Val Pro His Arg Ala Val Thr Ser Ile Phe Glu Asp Trp
          145         150         155         160

Gln Gly Ile Gly Tyr Arg Glu Ala Tyr Leu Gly Thr Lys Pro Asp Tyr
          165         170         175

Gly Gly Leu Val Pro Arg Ser Cys Val Thr Val Thr Lys Gln Gly Leu
          180         185         190

Thr Phe Leu Lys Thr Ala Arg Gly Met Ala Phe Thr Thr Asp Leu Thr
          195         200         205

Ile Gln Asn Ile Lys Met Leu Ile Ala Thr Cys Phe Lys Asn Lys Val
          210         215         220

Lys Glu Gly Glu Ile Pro Ala Thr Ile Glu Gly Glu Thr Trp Ile Asn
          225         230         235         240

Ile Pro Leu Val Asn Glu Asp Thr Gly Thr Ile Lys Pro Ser Phe Gly
          245         250         255

Glu Arg Val Ile Pro Glu Pro Tyr Glu Glu Asp Pro Leu Glu Gly Pro
          260         265         270

Ser Val Ile Val Glu Thr Gly Gly Ile Ala Ile Asn Gln Ile Gly Val
          275         280         285

Asn Pro Gln Ser Ser Thr Cys Gly Thr Val Phe Thr Ala Val Lys Asp
          290         295         300

Leu Cys Gln Thr Val Ser Asn Lys Ala Lys Asn Ile Lys Ile Gly Phe
          305         310         315         320

Ser Glu Gly Gln Tyr Pro Gly Pro Gly Val Ala Lys Lys Thr Leu Asn
          325         330         335

Gln Leu Ile Gln Asp Glu Asp Pro Lys Pro Phe Ile Phe Val Cys Gly
          340         345         350

Ser Asp Lys Ser Met Ser Asn Arg Ala Lys Thr Ala Arg Asn Ile Lys
          355         360         365

```

-continued

Arg Ile Thr Thr Thr Thr Pro Glu Lys Phe Arg Asp Leu Ala Lys Asn
 370 375 380

Lys Lys Leu Ile Ile Val Leu Leu Gly Asp Arg Tyr His Glu Asp Ile
 385 390 395 400

Glu Lys Tyr Ala Asp Phe Lys Gly Thr Phe Leu Thr Arg Gln Thr Leu
 405 410 415

Glu Ala Leu Ala Ser Ala Lys Ala Val Glu Lys Asp Met Thr Lys Lys
 420 425 430

Glu Ala Ala Arg Val Leu Ala Met Glu Glu Lys Asp Glu Leu Glu Leu
 435 440 445

Pro Gly Trp Leu His Thr Asp Ala Pro Lys Phe Leu Asp Ile Thr Lys
 450 455 460

Asp Asn Ile Thr His His Leu Ile Gly Asp Met Gln Ser Leu Arg Glu
 465 470 475 480

Arg Ala Gly Glu Ile Gly Ala Lys Ala Thr Thr Gln Ile Thr Lys Lys
 485 490 495

Gly Ser Val Tyr Thr Ile Asn Leu Ser
 500 505

<210> SEQ ID NO 27
 <211> LENGTH: 693
 <212> TYPE: PRT
 <213> ORGANISM: PMC Virus

<400> SEQUENCE: 27

Thr Trp Trp Glu Ser Glu Arg Leu Ala Ser Leu Glu Pro Leu Phe Arg
 1 5 10 15

Glu Leu Leu Ser Lys Cys Arg Pro Val Asp Arg Glu Thr Tyr Lys Asn
 20 25 30

Cys His Phe Ala Thr Ala Ala Gln Leu Ala Gly Gly Asn Trp Val Pro
 35 40 45

Val Ala Pro Val Val His Leu Gly Glu Ile Pro Val Lys Lys Lys Lys
 50 55 60

Thr Leu Pro Tyr Glu Ala Tyr Lys Leu Leu Lys Glu Met Val Asp Ser
 65 70 75 80

Glu Lys Glu Phe His Lys Pro Val Ser Arg Glu Lys His Gln Trp Ile
 85 90 95

Leu Asn Lys Val Lys Thr Gly Gly Asp Leu Gly Leu Lys Asn Leu Val
 100 105 110

Cys Pro Gly Arg Val Gly Glu Pro Ile Leu Arg Glu Lys Lys Lys Phe
 115 120 125

Asn Ile Tyr Asn Lys Arg Ile Thr Ser Thr Met Leu Ser Val Gly Ile
 130 135 140

Arg Pro Glu Lys Leu Pro Val Val Arg Ala Gln Thr Ser Thr Lys Glu
 145 150 155 160

Phe His Glu Ala Ile Arg Asp Lys Ile Asp Lys Lys Ala Asn Thr Gln
 165 170 175

Thr Pro Gly Leu His Lys Glu Leu Leu Glu Ile Phe Asn Ser Ile Cys
 180 185 190

Ala Ile Pro Glu Leu Arg Asn Thr Tyr Lys Glu Val Asp Trp Asp Val
 195 200 205

Leu Thr Ser Gly Ile Asn Arg Lys Gly Ala Ala Gly Tyr Phe Glu Lys
 210 215 220

-continued

Met Asn Ile Gly Glu Ile Ile Asp Ser Asp Lys Lys Ser Val Glu Gln
 225 230 235 240
 Leu Ile Lys Arg Met Lys Ser Gly Leu Glu Phe Asn Tyr Tyr Glu Thr
 245 250 255
 Ala Ile Pro Lys Asn Glu Lys Arg Ala Val Val Asp Asp Trp Met Glu
 260 265 270
 Gly Asp Tyr Val Glu Glu Lys Arg Pro Arg Val Ile Gln Tyr Pro Glu
 275 280 285
 Ala Lys Met Arg Leu Ala Ile Thr Lys Val Met Tyr Asn Trp Val Lys
 290 295 300
 Gln Lys Pro Ile Val Ile Pro Gly Tyr Glu Gly Lys Thr Pro Leu Phe
 305 310 315 320
 His Val Phe Asp Lys Val His Lys Glu Trp Lys Asn Phe Asn Ser Pro
 325 330 335
 Val Ala Val Ser Phe Asp Thr Lys Ala Trp Asp Thr Gln Val Thr Pro
 340 345 350
 Lys Asp Leu Leu Leu Ile Ser Glu Ile Gln Lys Tyr Tyr Tyr Lys Lys
 355 360 365
 Glu Tyr His Arg Phe Ile Asp Asn Leu Thr Glu Lys Met Val Glu Val
 370 375 380
 Pro Val Val Cys Glu Asp Gly Asn Val Tyr Ile Arg Glu Gly Gln Arg
 385 390 395 400
 Gly Ser Gly Gln Pro Asp Thr Ser Ala Gly Asn Ser Met Leu Asn Val
 405 410 415
 Leu Thr Met Ile Tyr Ala Phe Cys Lys Ala Asn Ser Ile Pro Tyr Ser
 420 425 430
 Ala Phe His Arg Val Ala Lys Ile His Val Cys Gly Asp Asp Gly Phe
 435 440 445
 Leu Ile Thr Glu Lys Ser Phe Gly Glu Ala Phe Ala Ile Lys Gly Pro
 450 455 460
 Gln Ile Leu Met Glu Ala Gly Lys Pro Gln Lys Leu Ile Gly Glu Phe
 465 470 475 480
 Gly Leu Lys Leu Ala Tyr Lys Phe Asp Asp Ile Glu Phe Cys Ser His
 485 490 495
 Thr Pro Ile Lys Val Arg Trp Ala Asp Asn Asn Thr Ser Tyr Met Pro
 500 505 510
 Gly Arg Asp Thr Ala Thr Ile Leu Ala Lys Met Ala Thr Arg Leu Asp
 515 520 525
 Ser Ser Gly Glu Arg Gly Thr Glu Gly Tyr Glu Leu Ala Val Ala Phe
 530 535 540
 Ser Phe Leu Leu Met Tyr Ser Trp Asn Pro Leu Val Arg Arg Ile Cys
 545 550 555 560
 Leu Leu Val Met Ser Thr Ile Asp Thr Lys Glu Ala Ser Gln Asn Asn
 565 570 575
 Thr Ile Tyr Thr Phe Arg Gly Asp Pro Ile Gly Ala Tyr Thr Glu Val
 580 585 590
 Ile Gly Tyr Arg Leu Asp Gln Leu Lys Gln Thr Glu Phe Ser Lys Leu
 595 600 605
 Ala Gln Leu Asn Leu Ser Met Ala Ile Leu Gln Ile Tyr Asn Lys Asn
 610 615 620

-continued

Thr Thr Lys Arg Leu Ile Glu Asp Cys Val Lys Leu Gly Asn Gln Asn
625 630 635 640

Lys Gln Ile Leu Val Asn Ala Asp Arg Leu Ile Ser Lys Lys Thr Gly
645 650 655

Tyr Thr Tyr Glu Pro Thr Ala Gly His Thr Lys Ile Gly Lys His Tyr
660 665 670

Glu Glu Ile Asn Leu Leu Lys Asp Thr Pro Gln Lys Thr Val Tyr Gln
675 680 685

Gly Thr Glu Arg Tyr
690

<210> SEQ ID NO 28
 <211> LENGTH: 22
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: oligonucleotide primer

<400> SEQUENCE: 28

cacatctagc agcagactat ga 22

<210> SEQ ID NO 29
 <211> LENGTH: 18
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: oligonucleotide primer

<400> SEQUENCE: 29

gtaccagttg caccaccc 18

<210> SEQ ID NO 30
 <211> LENGTH: 16
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: oligonucleotide primer

<400> SEQUENCE: 30

tgaaaaggat tcacgg 16

<210> SEQ ID NO 31
 <211> LENGTH: 18
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: oligonucleotide primer

<400> SEQUENCE: 31

aaaccgacga agtagacc 18

<210> SEQ ID NO 32
 <211> LENGTH: 18
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: oligonucleotide primer

<400> SEQUENCE: 32

agacgagaac atagtggc 18

-continued

<210> SEQ ID NO 33
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: oligonucleotide primer

<400> SEQUENCE: 33

gaaacagtaa agccaacg 18

<210> SEQ ID NO 34
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: oligonucleotide primer

<400> SEQUENCE: 34

ctggtaatcg gaaacatc 18

<210> SEQ ID NO 35
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: oligonucleotide primer

<400> SEQUENCE: 35

gggaccgagg gatcacga 17

<210> SEQ ID NO 36
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: oligonucleotide primer

<400> SEQUENCE: 36

agaggtaatt gggtat 16

<210> SEQ ID NO 37
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: oligonucleotide primer

<400> SEQUENCE: 37

cagcaggttg atttcttcat 20

<210> SEQ ID NO 38
<211> LENGTH: 14
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: oligonucleotide primer

<400> SEQUENCE: 38

ttgccaagtt tcac 14

<210> SEQ ID NO 39
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

```

<220> FEATURE:
<223> OTHER INFORMATION: oligonucleotide primer

<400> SEQUENCE: 39
aaaccgccga agtaaacc 18

<210> SEQ ID NO 40
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: oligonucleotide primer

<400> SEQUENCE: 40
ctggagccct ggtaatgg 18

<210> SEQ ID NO 41
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: oligonucleotide primer

<400> SEQUENCE: 41
gacgggaatg ggttca 16

<210> SEQ ID NO 42
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: oligonucleotide primer

<400> SEQUENCE: 42
taggtgcttc ttattggtat 20

<210> SEQ ID NO 43
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 43
catgcccata gtaggac 17

<210> SEQ ID NO 44
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 8
<223> OTHER INFORMATION: r = g or a
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 14
<223> OTHER INFORMATION: m = a or c

<400> SEQUENCE: 44
accagtttca ccamccat 18

```

-continued

<210> SEQ ID NO 45
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 45

agggtctctca catggttgctc 20

<210> SEQ ID NO 46
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 46

ccattaccag ggctccag 18

<210> SEQ ID NO 47
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 47

cacatctagc agcagactat ga 22

<210> SEQ ID NO 48
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 48

taggtgcttc ttattggtat 20

<210> SEQ ID NO 49
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 49

cgttggettt actggttcat tg 22

<210> SEQ ID NO 50
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 50

tccccgaagc ttggtttaat 20

<210> SEQ ID NO 51
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 51

gtcaggcctg cctatctttg 20

<210> SEQ ID NO 52
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 52

tccccgaagc ttggtttaat 20

<210> SEQ ID NO 53
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 53

cgggaccatt aaaccaagc 19

<210> SEQ ID NO 54
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 54

cagggggttc caagaataca 20

<210> SEQ ID NO 55
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 55

ggtgtactca cegcttagcc 20

<210> SEQ ID NO 56
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 56

ttgctacaat cgcccttctt 20

<210> SEQ ID NO 57
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 57

-continued

agggagaatg acagggtctg 20

<210> SEQ ID NO 58
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 58

acaaaggagc aaaaccaag 20

<210> SEQ ID NO 59
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 59

gtcacgttgg tggaccctac 20

<210> SEQ ID NO 60
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 60

agccagaaat gccacagc 18

<210> SEQ ID NO 61
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 61

acctgtgtgg gtgctaacat 20

<210> SEQ ID NO 62
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 62

ttactttgtc ttcccgttgc 20

<210> SEQ ID NO 63
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 63

ccaagaaact tcccatacg 20

-continued

<210> SEQ ID NO 64
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 64

ttccacatcc tctttcttct ttt 23

<210> SEQ ID NO 65
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 65

gctggccctc gaatgatcca 20

<210> SEQ ID NO 66
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 66

gttcctgtg tccttgctga 20

<210> SEQ ID NO 67
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 67

tgttttgtc ttggcactgg 20

<210> SEQ ID NO 68
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 68

gagcacaaca gggcagaaat 20

<210> SEQ ID NO 69
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 69

ccatcttct ttaggcaca 20

<210> SEQ ID NO 70
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 70

gtcaggcctg cctatctttg 20

<210> SEQ ID NO 71
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 71

ggagaagtca ctgacgcaca 20

<210> SEQ ID NO 72
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 72

gccatttcaa tcccagtatg 20

<210> SEQ ID NO 73
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 73

ggggtccaca cagcattgta 20

<210> SEQ ID NO 74
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 74

cccttgatac tcacgcctgt 20

<210> SEQ ID NO 75
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 75

gccgactcaa aatggagaaa 20

<210> SEQ ID NO 76
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 76

-continued

gccaccctat tcttgatct c 21

<210> SEQ ID NO 77
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 77

aatgagaag agggcagtgg 20

<210> SEQ ID NO 78
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 78

aaggccacca ctcaaatcac 20

<210> SEQ ID NO 79
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 79

aggcttctgc ttgaccagt 20

<210> SEQ ID NO 80
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 80

tccccgaagc ttggtttaat 20

<210> SEQ ID NO 81
<211> LENGTH: 45
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 81

ctaatacgac tcactatagg gcaagcagtg gtatcaacgc agagt 45

<210> SEQ ID NO 82
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 82

ctaatacgac tcactatagg gc 22

-continued

<210> SEQ ID NO 83
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 83

aagcagtgg atcaacgcag at 22

<210> SEQ ID NO 84
<211> LENGTH: 45
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 84

ctaatacgac tcactatagg gcaagcagtg gtatcaacgc agagt 45

<210> SEQ ID NO 85
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 85

ctaatacgac tcactatagg gc 22

<210> SEQ ID NO 86
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 86

aagcagtgg atcaacgcag at 22

<210> SEQ ID NO 87
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 87

cagttggtg gatccatgat cct 23

<210> SEQ ID NO 88
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 88

ggcctcacc tgcaacttt 19

<210> SEQ ID NO 89
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
 <223> OTHER INFORMATION: Oligonucleotide primer

<400> SEQUENCE: 89
 aagtcttcag cagttaact

19

What is claimed is:

1. An isolated RNA or DNA nucleotide sequence comprising:

- a) SEQ ID NO:1, wherein when the isolated RNA or DNA nucleotide sequence is an RNA nucleotide sequence, thymidine (t) nucleotides are substituted with uridine (u) nucleotides;
- b) an RNA or DNA sequence substantially homologous to the nucleotide sequence of (a);
- c) an RNA or DNA sequence comprising the complement of the nucleotide sequence of (a);
- d) a fragment of any one of (a), (b) or (c), wherein said fragment is at least 15 nucleotides in length;
- e) any one of SEQ ID NOs:3-10 and 12-15; or
- f) a variant of any one of (a)-(e).

2. The sequence fragment of claim 1 selected from the group consisting of SEQ ID NOs: 3-10 and 12-15.

3. An isolated amino acid sequence comprising:

- a) SEQ ID NO:2;
- b) polypeptide encoded by the nucleotide of claim 1;
- c) any one of SEQ ID NOs:16-27;
- d) fragments of (a) or (b);
- e) variants of any one of (a)-(d).

4. The sequence of claim 3 selected from the group consisting of the following locations in SEQ ID NO:2: 1-167, 168-267, 268-489, 490-685, 686-1062, 1063-1134, 1135-1602, 1603-2278, 2279-2341, 2342-2688, 2689-3193 and 3194-3886.

5. A method for detecting the presence of a PMC virus amino acid sequence according to claim 3 in a sample, comprising the steps of:

- a) contacting a sample suspected of containing a PMC virus amino acid sequence with an antibody that specifically binds to the PMC virus amino acid sequence under conditions which allow for the formation of reaction complexes comprising the antibody and the PMC virus amino acid sequence; and
- b) detecting the formation of reaction complexes comprising the antibody and PMC virus amino acid sequence in the sample, wherein detection of the formation of reaction complexes indicates the presence of PMC virus amino acid sequence in the sample.

6. A method for detecting the presence of an anti-PMC virus antibody in a sample, comprising the steps of:

- a) contacting a sample suspected of containing an anti-PMC virus antibody with an amino acid sequence according to claim 3 under conditions which allow for the formation of reaction complexes comprising the PMC virus antibody and the amino acid sequence; and
- b) detecting the formation of reaction complexes comprising the antibody and amino acid sequence in the sample, wherein detection of the formation of reaction complexes indicates the presence of PMC virus antibody in the sample.

7. A method for the detection and evaluating the levels of anti-PMC virus antibodies in a subject, comprising the steps of:

- a) depositing a predetermined amount of one or several PMC virus antigens comprising an amino acid sequence according to claim 3 onto a solid support such as a microplate;
- b) introducing increasing dilutions of a biological fluid onto the antigens and incubating;
- c) washing the solid support with an appropriate buffer;
- d) adding specific labelled antibodies directed against the antibodies of the subject;
- e) detecting the antigen-antibody-antibody complex formed, which is then indicative of the presence of anti-PMC virus antibodies in the biological fluid; and
- f) evaluating the amount of reaction complexes formed, which amount of reaction complexes corresponds to the level of PMC virus antibodies in the biological sample.

8. The method of claim 7 wherein the levels of PMC virus antibodies are determined in a series of biological samples obtained at different time points from an animal host undergoing therapeutic treatment.

9. A method for detecting the presence or absence of PMC virus in a biological sample, comprising the steps of:

- a) bringing the biological sample into contact with a polynucleotide probe or primer comprising an isolated RNA or DNA nucleotide sequence according to claim 1 under suitable hybridizing conditions; and
- b) detecting any duplex formed between the probe or primer and nucleic acid sequences in the sample.

10. A method for the detection of PMC virus nucleic acids present in a biological sample, comprising:

- a) amplifying the RNA or DNA nucleotide sequence of claim 1 with at least one primer;
- b) detecting the amplified nucleic acids.

11. A method for the detection of PMC virus nucleic acids present in a biological sample, comprising:

- a) hybridizing the nucleic acids of the biological sample at appropriate conditions with one or more probes comprising an isolated RNA or DNA nucleotide sequence according to claim 1,
- b) washing under appropriate conditions, and
- c) detecting the hybrids formed.

12. A method for detecting viral RNA or DNA comprising the steps of:

- a) immobilizing PMC virus on a support;
- b) disrupting the virion; and
- c) hybridizing the nucleic acids of the virion with a probe comprising an isolated RNA or DNA nucleotide sequence according to claim 1.

13. A method for screening the tissue of subjects for PMC virus comprising the steps of:

- a) extracting DNA from tissue;
- b) restriction enzyme cleavage of said DNA;

- c) electrophoresis of the fragments; and
d) Southern blotting of genomic DNA from tissues and subsequent hybridization with a labelled cloned PMC virus DNA sequence according to claim 1.
- 14.** A method for the generation of antibodies comprising the steps of:
a) providing a PMC virus polypeptide sequence comprising an amino acid sequence of claim 3 to a subject; and
b) collecting the antibodies generated in the subject against the polypeptide.
- 15.** The method of claim 14 wherein the polypeptide is further coupled or covalently conjugated to a physiologically acceptable carrier molecule.
- 16.** A vaccine composition comprising a PMC virus polypeptide that comprises an amino acid sequence according to claim 3
- 17.** A vaccine composition comprising an isolated RNA or DNA nucleotide sequence according to claim 1.
- 18.** The composition of claim 16 wherein the composition further comprises a pharmaceutically acceptable carrier or diluent and/or an adjuvant.
- 19.** A method to vaccinate an animal against PMC comprising the steps of: providing a vaccine according to claim 16 to the animal in an amount effective for producing protection against a pestivirus infection.
- 20.** The method of claim 19 wherein the immunogenic composition is administered by a method selected from the list comprising: intravenously, subcutaneously, intramuscularly, intraorbitally, ophthalmically, intraventricularly, intracranially, intracapsularly, intraspinally, intracisternally, intraperitoneally, buccal, rectally, vaginally, intranasally, orally or aerosol administration.
- 21.** A pharmaceutical composition comprising a PMC virus amino acid sequence according to claim 3 in a therapeutically effective amount admixed with a pharmaceutically acceptable carrier, diluent, or excipient.
- 22.** A pharmaceutical composition comprising antibodies prepared against PMC polypeptides comprising an amino acid sequence of claim 3.
- 23.** A therapeutic composition comprising an isolated RNA or DNA nucleotide sequence according to claim 1 admixed with a pharmaceutically acceptable carrier, diluent, or excipient.
- 24.** A method of ameliorating a disease associated with PMC virus comprising administering to a subject a PMC virus amino acid sequence according to claim 3, wherein said PMC virus amino acid sequence ameliorates said disease associated with PMC virus.
- 25.** A method of ameliorating a disease associated with PMC virus comprising administering to a subject antibodies against the PMC virus, wherein said antibodies against the PMC virus ameliorate said disease associated with PMC virus.
- 26.** A method of ameliorating a disease associated with PMC virus comprising administering to a subject a PMC virus nucleic acid sequence, or an antisense or ribozyme polynucleotide sequence hybridizable to a polynucleotide sequence encoding a PMC virus amino acid sequence according to claim 3, wherein said a PMC virus nucleic acid sequence, or an antisense or ribozyme polynucleotide sequence hybridizable to a polynucleotide sequence encoding a PMC virus amino acid sequence ameliorates said disease associated with PMC virus.
- 27.** A method of inducing a protective immune response in an animal or human against a PMC virus comprising the step of:
a) administering to said animal or human an effective amount of a composition comprising anti-PMC virus antibodies that are specific to an amino acid sequence according to claim 3.
- 28.** A method for enhancing an animal's immunocompetence and the activity of its immune effector cells against a PMC virus comprising the step of administering a composition comprising a therapeutically effective amount of a PMC virus peptide or polypeptide that comprise an amino acid according to claim 3.
- 29.** A live vector comprising an isolated RNA or DNA nucleotide sequence according to claim 1 and a heterologous polynucleotide.
- 30.** The live vector of claim 29 wherein the heterologous polynucleotide is operably linked to the polynucleotide sequence of the PMC virus, such that expression of the polynucleotide sequence of the PMC virus also leads to expression of the heterologous polynucleotide sequence.
- 31.** The vector of claim 29 wherein one or more sections of autologous polynucleotide sequence are removed such that the live virus is rendered attenuated in pathogenicity in a host subject.
- 32.** A method of screening for drugs comprising the steps of:
a) contacting an agent with a PMC virus amino acid sequence according to claim 3 and
b) assaying for the presence of a complex between the agent and the PMC virus amino acid sequence.
- 33.** A method of screening for ligands of the proteins of the PMC virus comprising the steps of:
a) contacting a ligand with a PMC virus amino acid sequence according to claim 3; and
b) assaying for the presence of a complex between the PMC virus amino acid sequence or fragment and a ligand.
- 34.** A kit for the demonstration of the presence of PMC virus comprising:
(a) a predetermined amount of at least one labelled immunochemically reactive component obtained by the direct or indirect attachment of a PMC virus amino acid sequence according to claim 3 or a specific binding partner thereto, to a detectable label;
(b) other reagents; and
(c) directions for use of said kit.
- 35.** A kit for demonstrating the presence of PMC virus comprising:
(a) a predetermined amount of at least one labelled antibody specific for an amino acid sequence of claim 3;
(b) other reagents; and
(c) directions for use of said kit.
- 36.** A diagnostic kit for demonstrating the presence of PMC virus comprising:
(a) a predetermined amount of at least one labelled polypeptide comprising an amino acid sequence of claim 3 derived from the PMC virus;
(b) other reagents; and
(c) directions for use of said kit.
- 37.** A kit for demonstrating the presence of PMC virus comprising:
(a) a predetermined amount of at least one labelled nucleic acid sequence derived from the PMC virus, wherein said

nucleic acid sequence comprises an isolated RNA or DNA nucleotide sequence according to claim 1;

(b) other reagents; and

(c) directions for use of said kit.

38. A recombinant expression vector comprising a PMC virus nucleic acid sequence or a part thereof of claim 1, operably linked to prokaryotic, eukaryotic or viral transcription and translation control elements.

39. A host cell transformed by the vector of claim 38.

40. A method for preparing a PMC virus amino acid sequence encoded by an isolated RNA or DNA nucleotide sequence according to claim 1, comprising the steps of:

(a) culturing a host cell containing a vector according to claim 38 under conditions that provide for expression of the PMC virus amino acid sequence; and

(b) recovering the expressed PMC virus sequence.

41. The vaccine composition of claim 17 wherein the composition further comprises a pharmaceutically acceptable carrier or diluent and/or an adjuvant.

42. A method to vaccinate an animal against PMC comprising the steps of: providing a vaccine according to claim 17 to the animal in an amount effective for producing protection against a pestivirus infection.

43. The method of claim 42 wherein the immunogenic composition is administered by a method selected from the list comprising: intravenously, subcutaneously, intramuscularly, intraorbitally, ophthalmically, intraventricularly, intracranially, intracapsularly, intraspinally, intracisternally, intraperitoneally, buccal, rectally, vaginally, intranasally, orally or aerosol administration.

44. A recombinant expression vector comprising an isolated DNA sequence according to claim 1, operably linked to prokaryotic, eukaryotic or viral transcription and translation control elements.

45. A host cell transformed by the vector of claim 44.

46. A method for preparing a PMC virus amino acid sequence, comprising the steps of:

(a) culturing a host cell containing a vector according to claim 44 under conditions that provide for expression of the PMC virus amino acid sequence; and

(b) recovering the expressed PMC virus sequence.

47. The method of claim 7, wherein said biological fluid is selected from the group consisting of blood serum, blood plasma, milk, cerebrospinal fluid and lymphatic fluid.

* * * * *

专利名称(译)	寄生虫病种		
公开(公告)号	US20120237519A1	公开(公告)日	2012-09-20
申请号	US13/472818	申请日	2012-05-16
[标]申请(专利权)人(译)	MINIST初级IND FOR & ON新南威尔士州代表国家		
申请(专利权)人(译)	代表新南威尔士州的初级工业部长		
当前申请(专利权)人(译)	代表新南威尔士州的初级工业部长		
[标]发明人	FROST MELINDA JANE KIRKLAND PETER DANIEL FINLAISON DEBORAH SUSAN		
发明人	FROST, MELINDA JANE KIRKLAND, PETER DANIEL FINLAISON, DEBORAH SUSAN		
IPC分类号	C12N15/40 C12Q1/70 G01N33/53 A61K39/42 A61K39/12 C07K16/10 C12N15/63 C12P21/02 G01N33/569 A61P31/14 C12N1/19 C12N1/15 C12N5/10 C12N1/21 C07K14/08		
CPC分类号	A61K39/12 C07K14/005 C12N7/00 C12N2770/24321 G01N2469/20 C12Q1/701 G01N33/56983 G01N2333/18 C12N2770/24322 A61K39/00 A61P31/12 A61P31/14 A61K2039/53 C12N2770/24334 C12Q2600/136		
优先权	2006902089 2006-04-21 AU 12/298026 2009-01-15 US PCT/AU2007/000521 2007-04-20 WO		
其他公开文献	US8569473		
外部链接	Espacenet USPTO		

摘要(译)

本申请涉及与猪心肌炎综合征相关的瘟病毒（称为PMC病毒），以及由其衍生的基因和蛋白质序列。本申请还涉及使用PMC病毒或其衍生的基因/蛋白质序列的检测方法，疫苗治疗剂和诊断方法。

Figure 1

```

gctaaacgac agtattccaa gtgtcgttat gcatcattgg ccataacaaa ctctcttaatt 60
tggaaataggc accctccacc ttccacaggg ccgacgctctg gtagccattc cgcctcatttg 120
gactagtaaa aatagtcgaa ctggctgagc agtgagctct gctgcagcgg cttagcgggtg 180
atcacccctt attctccacc agttcttact gtaaaaggatc acccactggtt gctgctctctg 240
tggacggaggc ontgtccacc ccaatgctat cagtagcggg ggtcgttact gggaaagcttg 300
cccgatctgg gttattgccc ataccctctg atagaaagcc ggtgcagcgc ctctattcttg 360
accgtatata atattatccc ttgttaagca tctgatactt tctacttcta ataccatctg 420
aggagttgag gaagaaacaa tctctcttag aactgcacc acrcgcccac caaccttaca 480
agaaccggtt taccacagca caatagacc aatttttggc gaaccccctc caaccttaca 540
caaacaccgc acgtcaaat tcccacttgc gttggtttcc gaaacacata cagttcaagg 600
ggggaatttg cccaaagagg gogatctgag ccactcaaac acagctccca ctctgggggt 660
gtaccttgaa ttgggttgag tctctctata agattcaagg ggaacgggat accaaagatt 720
accgttgaaa ctcttgcaaa gccaaggg gtctgagggg tccaagcttg tagggaaatt 780
gacgggttct gtagggagtt aacacgctt cctgaaatcg atcccaacc ccttgacctc 840
tggagagcaac tttagaggtc aaacagctt cctgaaatcg atcccaacc ccttgacctc 900
aacactttgg gcccagatt gtctgacga caaaaggagc aaacaggggt tgaacccaaa 1020
agacagcaag cccacagatg cccacagatg gtttgaagg caaaagctc caaaagctc 1080
gagggggaaa gccaacccc agactcaagg cggcttatcc caaacagaa accaaagctc 1140
aggtccaaag agagagcttg ccaagctgac acaatgaaac ctatattag ataaagctc 1200
gggtgtaccg gtaggttcaa ccaactgac acaatgaaac ctatattag ataaagctc 1260
taccagcaaa atctgcaag gattctctac acattataga cggctcttc ataaagctc 1320
gcccacaaa atctgcaag gattctctac acattataga cggctcttc ataaagctc 1380
gattcaaggg atggtgagtg gtagcccat gcccacatc acattataga ggtcaggg 1440
acatgggttg aacagctcag ggtgtgaaa ctgtcaaat atctgtggt ggtcaactc 1500
cctgactaat acccaagga cttatcaac ttgagaaat tcaactggt ggtcagctc 1560
atctgggttg gtaggggaaa ctgtgtgaaa ctgtcaaat atctgtggt ggtcaactc 1620
tctctgactt ggtgtgaaa aggggcaaa ctctctctc tcaagggagg tcaagggctc 1680
accctgaaac cttaggttaa cgtctgaaa ctgtgtgagg atctagattg acccaactg 1740
cggaggattt accactctg ggaagaaat cgttgaggct tacaacagag tagtaggaaa 1800
ggctgagttc agtagtttca ggtctcacc ctgtgtatcg atctagattg acccaactg 1860
gaaaaaaata tctggagctg agccagctcc ttaactgcca gttgtagaaa ggttctcna 1920
catatttct acccaactg gacaccggtc tgaattgaaa gtttagtcaa aattcaagg 1980
accagaaac tctgacctca gttgagggga tgaattgaaa tttccaaac tcccttaca 2040
agtataatc taccctggtt tggatcact aatgccaagt aatgcaaca gggactctct 2100
cgttagttg tcaatctccc tggatctaat tggatctctc gttatgctc caaggtggt 2160
cccacactg gtaattgtgt taagtgaatg ggttgcctc aaaccaagt ggtcggctta 2220
tctccggaaa atctcaaac tggctcaact gttctcaac ggtcagctg taactgttca 2280
gacctatgaa gaattgctaa atttctgac cgaagcaaca gctctggcat tctctgctg 2340
tctatgaaa atctctagg gctctgcat ccaagggta gctctggtta tcaactgtt 2400
ggggagccca gcccacact gcaacctgaa atctcaactg gacttggga aaaaaccag 2460
catagtttca ttggagagc cctcaactg ggaacgggtc ggaacacac caactgttct 2520
caactcact gacagaccga ttgaattcac ctgtctggtt gctaacatga ggaatcactg 2580
aggtgccaac aggtgaagc actgctctc tggcttcaac ccaaggtgaa gactcagag 2640
aaaggcgttg tcaaggaaaa tccacactca gactgagta ccaaggtgaa gactcagag 2700
aaactcacc caactctca tctctacc cagcttctga ctgtaaccgc ctagggttgg 2760
gactgggact gtcactctca ccaactctca ggaacacac ccaactctca ctagggttgg 2820
caactcacc agcccacac caactctca tgaacactg ttgacagata cagttgttgg 2880
gactgggact gtcactctca ccaactctca ggaacacac ccaactctca ctagggttgg 2940
agttcaagg gaaagggaag caaaatlaag gtaactgaaa ttgtgtggtt atagttcag 3000
tcccacaaat tctgtgact tccatctgtg caacaacggc acttctcttg caaaagagg 3060
actcgggat tctgtgact tccatctgtg caacaacggc acttctcttg caaaagagg 3120
tactgccaac ttgcaactag agttcaaaa agtttaccgtt aactctcttg caaaagagg 3180
atgtgcccac atgcccctga accccactg gtataactcc caaggggccc caaggcctaa 3240
gactcactc tctaggttgg cctcaactc gtaacaaa tctctctgac tcaagcaaaa 3300
cactacccg caataccta taaxgtcagg gtaacaaat tggttctgac tcaagcaaaa 3360

```